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Parkinson’s Disease (PD) is the second most common neurodegenerative disease in
the Western world. It shows a high degree of genetic and phenotypic complexity with
many implicated factors, various disease manifestations but few clear causal links.
Ongoing research has identified a growing number of molecular alterations linked to
the disease.
Dopaminergic neurons in the substantia nigra, specifically their synapses, are the
key-affected region in PD. Therefore, this work focuses on understanding the disease
effects on the synapse, aiming to identify potential genetic triggers and synaptic PD
associated mechanisms. Currently, one of the main challenges in this area is data
quality and accessibility.
In order to study PD, publicly available data were systematically retrieved and
analysed. 418 PD associated genes could be identified, based on mutations and curated
annotations. I curated an up-to-date and complete synaptic proteome map containing a
total of 6,706 proteins. Region specific datasets describing the presynapse, postsynapse
and synaptosome were also delimited. These datasets were analysed, investigating
similarities and differences, including reproducibility and functional interpretations.
The use of Protein-Protein-Interaction Network (PPIN) analysis was chosen to gain
deeper knowledge regarding specific effects of PD on the synapse. Thus I generated
a customised, filtered, human specific Protein-Protein Interaction (PPI) dataset, con-
taining 211,824 direct interactions, from four public databases. Proteomics data and
PPI information allowed the construction of PPINs. These were analysed and a set
of low level statistics, including modularity, clustering coefficient and node degree,
explaining the network’s topology from a mathematical point of view were obtained.
Apart from low-level network statistics, high-level topology of the PPINs was stud-
ied. To identify functional network subgroups, different clustering algorithms were
investigated. In the context of biological networks, the underlying hypothesis is that
proteins in a structural community are more likely to share common functions. There-
fore I attempted to identify PD enriched communities of synaptic proteins. Once iden-
tified, they were compared amongst each other. Three community clusters could be
identified as containing largely overlapping gene sets. These contain 24 PD associ-
ated genes. Apart from the known disease associated genes in these communities, a
total of 322 genes was identified. Each of the three clusters is specifically enriched for
specific biological processes and cellular components, which include neurotransmitter
secretion, positive regulation of synapse assembly, pre- and post-synaptic membrane,
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scaffolding proteins, neuromuscular junction development and complement activation
(classical pathway) amongst others.
The presented approach combined a curated set of PD associated genes, filtered
PPI information and synaptic proteomes. Various small- and large-scale analytical
approaches, including PPIN topology analysis, clustering algorithms and enrichment
studies identified highly PD affected synaptic proteins and subregions. Specific disease
associated functions confirmed known research insights and allowed me to propose a
new list of so far unknown potential disease associated genes. Due to the open design,




Parkinson’s Disease is a brain disease with extreme consequences for patients, their
families and carers. Treatment only moderates the symptoms and the number of pa-
tients is growing on a daily basis.
Many research projects identified dysfunctioning intracellular processes mainly lo-
cated in a specific part of brain cells. This part, the synapse, is in charge of transport-
ing information and its dysfunction leads to known disease symptoms such as tremor,
shuffling gait and less known non-motor symptoms such as enhanced sweating. Parkin-
son’s can currently only be diagnosed at a stage when brain-cells are dying, making
it very hard to treat the disease effectively. Another challenge are the very individual
symptoms the disease provokes in patients. A number of dysfunctions are known to
appear in the brain cells of patients, but not all of them can be found in all individuals.
Therefore this thesis aims towards gaining better understanding of specific disease
causes. New knowledge could then help to develop better treatment or even a disease
cure. To work towards this aim different systems biological analytical steps were car-
ried out. 418 genes which have shown to be affected in Parkinson’s Disease patients
were identified. The synapse was analysed and around 6,500 genes were identified in
this brain-cell region.
To understand the disease influence on the synapse, so called large-scale approaches
are required. Protein-Protein-Interaction Networks were used to analyse how proteins
interact and allow to identify gene groups which are in charge of specific synaptic
functions. Parkinson’s Disease associated genes could be located in the network. By
doing so three gene groups with an unexpected, significantly high number of disease
associated genes were identified. Apart from the disease genes these contained a set
of other genes which were analysed in-depth. It was possible to determine their over-
all function which is affected under disease conditions. Amongst others the release of
neurotransmitters, the main component of information exchange between brain cells as
well as structural aspects, guaranteeing protein interactions and their full functionality
could be identified.
The set of around 150 specific genes can now be used to i) set up more targeted
experiments, ii) help to identify different disease types and iii) develop new treatments.
Overall it would not have been possible to obtain these results without the use of large-
scale analytical approaches. Hence this work highlights their potential and promising
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Parkinson’s Disease (PD) is the second most common neurodegenerative disease in the
Western world (De Lau and Breteler, 2006) and its underlying causes are far from un-
derstood. Due to the growing improvement in the treatment of cancer and other lethal
diseases, neuronal disease is becoming more prevalent and currently about ten million
people worldwide suffer from the condition (European Parkinson’s Disease Associa-
tion1). In the US 0.01% of the population under the age of 45 and 1.2 - 4.38% over
the age of 65 are diagnosed with PD (numbers consider regional variability) (Kowal
et al., 2013). Usually symptoms appear between the age of 62 and 70 (Muangpaisan
et al., 2011). Apart from the impact on personal health and well being the estimated
financial burden in the US in 2010 was around eight million USD medical cost directly
attributed to PD and another 14 million social cost incurred by the PD affected popula-
tion. Additionally about six million USD were associated with reduced employment,
lost work days due to illness, formal care and others (Kowal et al., 2013). Numbers in
Europe are expected to be proportionally similar.
As presented in the World Health Organisation report, “Neurological Disorders:
Public Health Challenges”2 (2006), one of the dangers associated with neurodegener-
ative disease is the lack of communicable conditions and diagnosis. The main known
cause of PD and its symptoms is the degeneration of dopaminergic neurons in the sub-





2 Chapter 1. Introduction
largely unnoticed by the patient and can not yet be specifically detected. Hence di-
agnosis is only possible at a very advanced disease stage, when neurons are already
irreversibly destroyed.
Recent evidence is accumulating and indicates that synapses play a key role in
the degenerative process (Lüscher and Isaac, 2009). Neuronal connectivity, based on
synapses, was identified to be fundamental for a healthy brain. Hence, the gradual loss
of synapses and deteriorated synaptic plasticity precede neuronal dysfunction and cell
death, implying neurodegeneration (Knight and Verkhratsky, 2010).
This leads to motor and non-motor symptoms. Motor dysfunctions include bradyki-
nesia (decreased movement), rest tremor and rigidity. Non-motor functions are depres-
sion, cognitive impairment sleep disturbances and failure of cognitive abilities such as
memory and decision making (Magrinelli et al., 2016). Overall, disease development
and symptoms are very patient specific and depend highly on underlying causes. A
cure is currently not available and medication only moderates and alleviates symptoms
allowing for improved quality of life (Chen and Pan, 2014; Bredesen et al., 2006).
In order to find better treatment it is crucial to know disease causing dysfunctions
and have a better disease understanding. The following section introduces known de-
tails about the PD pathology.
1.1.1 Pathology
PD is considered a complex disease, with a number of dysfunctions associated with it,
all of which lead to the degeneration of dopaminergic neurons in the substantia nigra,
pars compacta (Dexter and Jenner, 2013). Recent years allowed to identify more and
more molecular alterations significantly associated with the development of PD. These
can be found in different patients and distinct combinations.
The familial (inherited) form of PD (~10% of the cases) made it possible to identify
genetic alterations associated with the disease (Spatola and Wider, 2014). These ex-
plain about 30% of the familial and between 3-5% of sporadically occurring PD cases
(Klein and Westenberger, 2012). Even though these numbers seem relatively small
they are a great source for research (Bonifati, 2014).
Additionally, a large number of non-genetic cases exist. These can occur due to
random genetic variants or other molecular dysfunctions. Figure 1.1 shows the central
dogma of molecular biology, indicating different molecular levels that can be affected
and lead to disease manifestation. Part A shows different cellular units and part B
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describes the union of those. Genetic modifications are reflected on the DNA. Changes
in RNA expression or altered protein levels are noticed on exome, transcriptome or
proteome level. The latter can also lead to disease manifestation but are more difficult
to detect. Since alterations on one level are not always directly propagated to the next
level (e.g. from genome to exome), RNA and protein level changes are not apparent























Figure 1.1: The Central Dogma of Molecular Biology. Individual constitutive units are
visualized (part A) as well as the union of all the units (part B). Part C shows examples
of experimental tools that can be used to study the different levels of information.
As indicated in Figure 1.1 C GWAS studies supply information regarding heritabil-
ity in genetic regions (also not completely correctly referred to as mutations), address-
ing alterations in the genome. Microarray studies identify disease associated changes
in the exome, transcriptome and proteome. These modifications can be detected with
a combination of pull-down analysis and mass spectrometry amongst others.
Compared to more traditionally used techniques, these all cover a large part or
all of the genome, transcriptome or proteome. This is specifically beneficial for un-
covering unsuspected disease associated alterations without targeting them based on
prior knowledge which was often the case in previously available, small-scale studies
focusing on individual proteins.
To gain an overall insight of the disease, large-scale analysis of results covering all
levels of the molecular machinery need to be considered and combined. Generally the
number of large-scale studies is increasing but results are most frequently considered
individually. Combining knowledge covering information describing distinct disease
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aspects is necessary and crucial to shed light over unknown connections amongst dys-
functions and the complete disease picture.
1.1.1.1 Affected Subsystems and Pathways
Even though there has not been any large-scale combinatorial study systematically
analysing similarities and differences between PD related results, individual studies
identified a number of PD affected molecular functions, also referred to as pathways.
All of them can contribute to the PD complexity. Based on current knowledge dys-
functions appear in different combinations, leading to the complex set of PD geno-
and phenotypes (Thenganatt and Jankovic, 2014). A major effort has been made and
a PD map3 was created, being under constant curation and expansion (Fujita et al.,
2014). It presents a great source highlighting affected pathways and Figure 1.2 shows
the published visualization of the interactive tool. Based on this overview and addi-
tional studies the following paragraphs briefly introduce affected systems.
Figure 1.2: The concept of PD map and its visualization (taken from Fujita et al. (2014)).
3http://minerva.uni.lu/MapViewer/
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Alpha-synuclein misfolding leads to the appearance of Lewy Bodies, a major com-
ponent of PD. Although a lot of research has been carried out, the exact function
of alpha-synuclein remains unknown (Breydo et al., 2012). Previously, links
between the presence of Lewy Bodies and neuronal plasticity responses, en-
zyme regulation, transporters, and neurotransmitter vesicles and others were
established (Uversky, 2008). Overall, Lewy Bodies are found in the major-
ity of PD affected brains (Wakabayashi et al., 2007), but can also be an indi-
cator for other types of Lewy Body dementia. Environmental factors, oxida-
tive stress, mitochondrial dysfunction, genetic factors and dysfunction of the
ubiquitin-proteasome system have been proposed to trigger the misfolding of
alpha-synuclein leading to the Lewy Body formation. Initially it was proposed
that alpha-synuclein and Lewy Bodies are cytotoxic, nevertheless a direct link
with neuronal cell death could not be shown (Wakabayashi et al., 2007). Hence
the real impact of alpha-synuclein misfolding is still elusive even though a link
to PD is widely accepted. Understanding the role of Lewy Bodies in disease
development could help to target them during disease treatment.
Apoptosis is specifically associated with PD in late stages of the disease development.
It has been proposed that a proapoptotic environment in the nigrostriatal region
of PD patients induces neuronal cell death (Lev et al., 2003). Neuronal cell death
has also been classified as an active processed referred to as a programmed cell
death. Compared with induced cell death it seems to involve slightly different
pathways than traditional apoptotic ones. Some affected functions are shared
by both processes, but programmed cell death also requires ATP and shows a
number of associated molecular alterations (Venderova and Park, 2012). Some
of these can explain the link to PD. Hence, more detailed insight into the pro-
cess could help to reduce the speed of neurodegeneration and overall disease
progression.
Calcium homeostasis has been shown to be dysregulated in PD patients. Since cal-
cium plays a ubiquitous role in cells it influences different PD associated path-
ways. Within dopaminergic neurons calcium is related to mitochondrial func-
tionality, oxidative stress and lysosomal activity (Schapira, 2013). Furthermore,
its role is key in the transmission of depolarizing signal and contributes to synap-
tic activity (Calì et al., 2014). All of these effects show major disease links and
further knowledge might help to counteract energy dysregulation.
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Failure of the protein degradation system can be a cause for protein accumulation
within cells. This characteristic is specifically associated with age-related dis-
eases, including PD. Under healthy conditions misfolded or not required pro-
teins are degraded. One of the main systems in charge of such processes is the
ubiquitin-proteasome system (Cook et al., 2012). In cases of disruption, mis-
folded proteins accumulate, potentially leading to cell death. Additionally, a di-
rect link with the accumulation of alpha-synuclein (Martins-Branco et al., 2012)
has been proposed. Unravelling concrete dysfunctions in the system can help to
better understand links to PD.
Mitochondrial dysfunction can influence brain cells in PD patients in different ways.
It can affect the cells through mitochondrion dependent programmed cell death
or necrosis (Perier et al., 2012). Additionally it was possible to link complex 1 of
the mammalian electron transfer chain to the PD pathology (Greenamyre et al.,
2001). Its dysfunction leads to depressed rates of ATP synthesis possibly induc-
ing graded mitochondrial depolarization and causing a decrease in intracellular
ATP/energy levels. This lack of cellular energy will ultimately lead to cell death.
Avoiding these processes could counteract the manifestation of PD.
Neuroinflammation has been linked to PD in several occasions. Distinct triggers for
the inflammatory process are known and range from immunological challenges
through bacterial or viral infections to injury such as stroke and others (Tansey
and Goldberg, 2010). All of these alterations lead to an increase in the blood
brain barrier permeability allowing filtration of lymphocytes and macrophages
into the brain. Identifying substructures related to the immune response in af-
fected brain regions of PD patients is another direct link of neuroinflammation
with neuronal cell death (Hirsch et al., 2012). Such a pathway could be classi-
fied as an “autoimmune” response. A better understanding could help to prevent
emergence of these processes.
Synaptic Vesicle Cycling and recycling has been linked to PD in several occasions.
Failing to transport information, in form of neurotransmitters e.g. to the synaptic
membrane can lead to a lack of information and postsynaptic triggers. This leads
to a synaptic dysfunction inducing cell death (Esposito et al., 2012).
Although it remains questionable whether the presented processes are direct PD causes
or consequences of dopaminergic cell loss, knowing about them can help to identify the
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disease causing ones amongst them. This raises hope to be able to identify and diag-
nose PD in earlier disease stages. Gaining this knowledge might also allow to establish
more specific “disease-subtypes”, depending on dysfunctioning systems, reflecting the
underlying disease pathology. Some of the traditionally known PD subtypes are intro-
duced in the next section.
1.1.1.2 PD-Subtypes
Traditionally PD is divided into a familial and sporadic form. This division depends
mainly on the family history (and possibly traceable mutations) which can provide
evidence for the familial form. Amongst familial cases around 30% are known to
be based on genetic dysfunctions. This number decreases to 3-5% in sporadic cases.
Some of the most well known genetic causes are linked to genes such as LRRK2 and
SNCA (Li et al., 2014; Siddiqui et al., 2016).
Furthermore, classic subtypes are described based on the disease phenotype and
distinguish between either akinetic-rigid or tremor-dominant. Other research identified
differently defined large clusters of symptoms. These specify patients with “old-” ver-
sus “young-age-at-onset” and “rapid-” versus “slow-disease-progression” (van Rooden
et al., 2011; Eggers et al., 2014). Based on the variety of affected pathways further dis-
ease subtypes may emerge in the future.
Additionally, recent findings lead to the hypothesis that PD should be considered
a syndrome rather than a single disease (Caligiore et al., 2016). As such, “PD” cur-
rently describes the “ultimate” disease phenotype, caused by a wide range of affected
underlying subsystems (Fujita et al., 2014). Individually or jointly affected subsystems
could be classified as PD subtypes. Given the diversity of subsystems it is also very
likely that those could be referred to as different diseases, especially when earlier di-
agnosis becomes possible. Hence this reflects additional support for the importance of
identifying, classifying and separating causes which can trigger the disease outbreak
individually. Apart from identifying subtypes this would also allow earlier diagnosis
and more specific treatment.
Overall, many individual PD associated pathways are relatively well understood.
Major efforts have been made to understand these individually. However, few studies
have been carried out to capture the complete disease picture.
Systems biological approaches are the tool of choice to tackle the presented prob-
lem. For best results data quality is of highest importance. The next sections covers
respective details.
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1.2 The Synapse
Synapses are part of neurons. As such they make up a large part of the (mammalian)
brain. The synapse is key to cell-cell communication, allowing to transmit informa-
tion from one cell to another. Chemical synapses (Yuste, 2015) can be split into three
main compartments. These are the presynapse, postsynapse and synaptic cleft (Figure
1.3). More recently glial cells (astrocytes amongst others) are considered as part of the
synapse as well. These surround presynapse, synaptic cleft and postsynapse, generat-
ing a micro-environment. Their specific role is not yet understood, but the concept of
the “tetrapartite synapse” is gaining growing recognition with a large body of litera-
ture showing a role of glial cells in all essential brain functions (Dieterich and Kreutz,
2016). Nevertheless, glial cells are beyond the scope of this study.
Figure 1.3: The tetrapartite synapse of principal neurons, consisting of the pre- and
postsynaptic compartment, synaptic cleft, astrocytic endfeet, and extracellular matrix.
The tightly regulated protein composition in the different regions can be seen. SV
stands for synaptic vesicle (taken from Dieterich and Kreutz (2016)).
Reflected by the anatomical composition of a synapse, signals are transmitted from
the presynapse to the postsynapse. An incoming presynaptic electric signal triggers
synaptic vesicles to locate on the presynaptic membrane. In the following step they
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release specific neurotransmitters and spread these into the synaptic cleft. There, they
bind to receptors, integrated in the postsynaptic membrane of the receiving neuron.
These binding reactions trigger signalling cascades inside the postsynapse, translating
the incoming signal into a variety of processes. This “two-component” interaction has
a vast number of regulatory points (Di Maio, 2008). Many aspects of the information
transmission process can be altered and adjusted, making the synapse a highly adapt-
able system which is reflected in its cell type specificities. Apart from its versatility
this complexity makes the synapse very hard to study and susceptible to disease with
dysfunctions which are hard to identify.
Apart from the purely anatomical description, the term synaptosome is widely used
when considering synapses. This is mainly due to experimental tissue preparation tech-
niques (Laßek et al., 2015) which established the term as the unit of extracted tissue. It
summarises the synapse as introduced earlier as well as additional components in the
presynaptic terminal, such as mitochondria and synaptic vesicles as well as extracellu-
lar matrix proteins (Laßek et al., 2015).
Recent advances in experimental techniques, such as high throughput proteomic
studies, gave access to extended synaptic datasets. The next section describes how to
obtain and and process such datasets.
1.2.1 The Synaptic Proteome
Proteomic studies aim towards identifying all proteins transcribed and translated in a
tissue or region. Thus one of the initial challenges in such an experimental setup is to
obtain the material of interest. Tissue preparation for a synaptic sample is challeng-
ing and initially based on the synaptosome. It is the key structure, isolated from brain
tissue (Sokolow et al., 2012; Dieterich and Kreutz, 2016). A number of experimental
protocols are available to obtain proteomic data, all starting with tissue homogenate
as the raw material. If desired, density centrifugation is used to separate pre- from
postsynaptic material and other cells. Optionally antibodies or other tags can be used
to specifically target proteins from one of the synaptic regions. Once proteins are ex-
tracted, these are purified and mass-spectrometric analysis is used to identify them.
Analytical data analysis is carried out and generates information of the entire analysed
proteome. Depending on centrifugation steps and the purpose of the analysis, some
studies analyse the full synaptosome, consisting of the entire synaptic region (Whit-
taker et al., 1964; Sokolow et al., 2012; Dieterich and Kreutz, 2016) or focus on the
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presynaptic (Boyken et al., 2013; Grønborg et al., 2010) and/or postsynaptic proteome
(Fernández et al., 2009; Bayés et al., 2012) individually.
One needs to keep in mind that results might not be fully complete and always
only reflect the set of proteins present in the extracted sample at the point of tissue
extraction. Therefore proteomic datasets are specific to a certain developmental state
and time.
Even though experimentally identified units are proteins, it is more convenient to
work with gene identifiers. This facilitates to exchange information coming from dif-
ferent species and avoids bias towards specific protein isoforms. This is specifically
the case since mass spectrometry and analytical steps are not yet detailed enough to
separate protein isoforms with high precision when reading large samples.
1.3 Systems Biology
Systems biology is a still relatively young field, but has been growing rapidly in recent
years. Very often it is associated with large-scale analysis which is not intrinsically
true. In general, systems biology addresses any topic on a “systems level” including
experimental and/or theoretical approaches. The field aims towards gaining a high-
level overview of a given system, considering data availability (Kitano, 2002b,a) and
combining suitable approaches.
Often such approaches have proven to be challenging since data are supplied in
different formats and certain analytical tests require very specific information and data
input. Several initiatives have been put in place to assist endeavours towards facilitating
data accessibility, usage and interpretation. One of them is the “FAIR” data-use prin-
cipal (Wilkinson et al., 2016). FAIR stands for: Findable, Accessible, Interoperable
and Reusable and aims towards generating more easily exchangeable data to allow the
whole scientific community to benefit from it.
In the presented study differences in data annotation presented recurring chal-
lenges. Depending on the situation they were solved in different ways, largely working
towards the use of accepted standards. Some of the mapping steps could not be com-
pletely automatised and required additional manual steps. This thorough approach lead
to results following accepted standards, making the data more valuable. Their use in
further experiments, a wide range of analyses, and amongst the research community is
highly beneficial.
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1.4 Protein-Protein-Interaction Networks
Network analysis, also network theory or graph analysis studies structures emerging
in directed or undirected networks. Such networks can be defined as graphs consisting
of “nodes”, also referred to as “vertices”, and “edges” connecting those nodes. Nodes
and edges can have attributes such as names and weights adding further information to
the network. The Euler’s solution to the “Seven Bridges of Koenigsberg problem” is
seen as the first proof in network theory (Newman, 2003). Since then amongst others
physics, computer science, engineering, biology, economics and sociology apply net-
work approaches to unravel insights into e.g. the World Wide Web, social, epistemo-
logical or gene regulatory and metabolic networks through the use of various analytical
approaches.
In this work nodes are proteins and edges their interactions. These are specifically
referred to as Protein-Protein Interactions (PPIs) and a growing amount is available in
publicly accessible databases. A detailed introduction can be found in Chapter 4.
Given a biological context network analysis shows growing impact in a number of
areas. Protein-Protein-Interaction Networks (PPINs) visualize complex biological in-
teraction patterns and aim to identify molecularly similar subgroups (Xia et al., 2014;
Wang et al., 2010; Pizzuti and Rombo, 2014). Neuronal networks (Paliwal and Kumar,
2009) strive towards describing processes such as memory formation and signal trans-
mission. Gene regulatory networks highlight regulatory and control relationships be-
tween proteins and genes or vice versa (Emmert-Streib et al., 2014). Other approaches
are available and more will likely be added in the coming years.
With the increase in data availability the number of analytical approaches is con-
stantly growing. This points towards the power of network analysis, if correctly ap-
plied.
For the purpose of this work the focus is on PPINs. Proteins are the functional
units of cells and synapses. To carry our their functions they need to interact between
each other. Some proteins undergo interactions with many others, whereas others with
very few. This means that a protein can have a central, connective position or play a
highly specific role involved in one function. This is just one example when PPINs are
an attractive analytical tool to unravel and point out such properties.
Various network measures exist to describe distinct network properties. Some of
these cover general measures referring to the entire network, and others focus on node
or edge specific properties, characterising these individually. These can be referred
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to as low-level statistics. Additionally high-level network statistics address aspects
on a more general network level such as its division into communities. A network’s
structure is often referred to as topology (Davis et al., 2015), reflecting properties of
the presented data. In general, all the presented measures can be used to characterise
and compare networks between each other. The following two sections focus on the
low- and high-level concepts and respective analytical approaches.
1.4.1 Statistical Network Analysis
Different types of low-level network analytical approaches exist. These range from val-
ues describing overall network properties to information specific to individual nodes or
edges (Bliss et al., 2014). Both types have different advantages and disadvantages and
serve distinct purposes. Overall, these measurements give a general idea of the net-
work structure, whereas node or edge specific values can supply information regarding
their individual role in the network.
For a general overview the underlying principles behind the statistical approaches
are introduced:
Clustering Coefficient is a measure describing the degree to which nodes in a net-
work tend to cluster together (Soffer and Vázquez, 2005). This gives a first
insight into the possibility of finding clearly defined network substructures and
reflects a property of the entire network.
(Network) Density “D” is defined as the ratio of the number of edges (“E”) that ap-
pear in the network of interest, compared to the number of possible edges be-
tween all nodes (Pavlopoulos et al., 2011). This measure indicates how densely
connected networks are, pointing towards the connectivity of its components.
Node Degree is a measure describing the number of connections a node has with other
nodes. In other words, it is the number of edges adjacent to a node. Nodes with
a large number of connections (relative to the connectivity in the network and
the total number of nodes) are hubs. In biological networks they often play a
role as key connectors and regulators between different pathways. Hubs are of-
ten multi-domain proteins, likely involved in a versatile set of functions (Patil
et al., 2010). Generally two types of hubs exist, and can appear with different
references in literature. Transient or date hubs participate in single interactions
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at a time whereas obligate or party hubs undergo multiple interactions simulta-
neously (Ran et al., 2013; Han et al., 2004). Depending on the type of hub, their
removal implies different consequences, but overall it leads to crucial changes in
the network structure. Hence hub nodes play important roles and are generally
located very centrally in the network. On the contrary, the low degree nodes
are found in the network periphery and their removal does not normally cause
drastic effects on the network itself.
Apart from identifying prominent positions in the network the node degree dis-
tribution can give insights into the heterogeneity of a network. If the node de-
gree distribution can be fit to a power law distribution the network is considered
“scale-free”. This implies a long tail, power-law distribution of the node de-
gree with few highly connected nodes and an exponentially larger number of
weakly connected nodes. In biological terms this means that the probability of
a substrate to react with x other substrates decays as a power law (Ravasz et al.,
2002; Barabási and Albert, 1999). Based on these properties scale-free analysis
reflects network topology regarding the connectedness between network nodes.
This analysis can help to confirm if a network has a topology generally known
for biological networks.
Betweenness (Centrality) is a centrality measure based on the number of shortest
paths passing through a node (Freeman, 1977; Brandes, 2001). It describes the
control a node has over a network, based on the “amount” of information that
passes through it. This can also be described as the amount of information that
“flows” over a certain node. Higher betweenness scores stand for higher central-
ity, monitoring communications between other nodes in the network. Consider-
ing PPINs such insight is specifically useful, since nodes with a high between-
ness value are highly frequented and can assist in information exchange between
different pathways (Vidal et al., 2011). On the contrary, nodes with a low be-
tweenness score, are also referred to as “bottlenecks” or “gate-keepers” since
information can get “stuck” or is purposefully delayed, by not being forwarded
rapidly to other nodes in the network. Such detail helps to better characterise
individual network nodes.
Using the introduced measures to classify and analyse networks often allows one to
draw further conclusions which are based on certain combinations of the network
statistics. For example, the scale-free nature of many biological networks (Barabási
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and Albert, 1999) refers to properties such as high degree nodes, indicating hubs,
sometimes linked to disease related genes. Overall, most of the measures can be used
to draw biological and functional conclusions and provide tools assisting the compari-
son of networks against each other.
1.4.2 Network Clustering
After having analysed the PPINs as they emerge based on the PPI pattern, further in-
terest lies in identifying network substructures. So called clustering algorithms divide
networks into communities, aiming towards identifying the “best”, most realistic di-
vision of network nodes. To do so, a number of approaches are available, all aiming
towards grouping more closely connected nodes together by separating them from less
closely connected ones. Given a biological context, these communities consist of genes
likely sharing similar functions or being “jointly” affected by the same disease.
Identifying “close connectedness” between a set of genes compared to others is
one of the main challenges in the field of network analysis and the number of available
techniques is constantly growing. Such techniques are referred to as network clus-
tering and use so called clustering algorithms. Some of the approaches are based on
node betweenness scores, the shortest walk between nodes and other measures such
as modularity scores of the network (Brandes et al., 2008). Modularity “Q” is a mea-
sure describing the number of edges falling within a given gene group less than the
expected fraction if genes were allocated at random or alternatively in an equivalent
network (Newman, 2006b; Ravasz et al., 2002).
Apart from the spinglass approach (introduced later on), clustering algorithms used
in this work are modularity based. An overview, as well as underlying computational
principles, can be found in Table 1.1.
1.4.2.1 Analysis of clustered PPINs
Once networks are clustered their structures can be compared. Due to the large datasets
and complex emerging community constellations it remains a major challenge to com-
pare network clustering results amongst each other. This makes it hard to identify the
right or best algorithm to represent a dataset, since it might not even exist. Certain sta-
tistical tests are available to e.g. test for the robustness of a clustering result, supporting
emerging network structures. Overall, it is necessary to be aware of the remaining gaps
and drawbacks PPIN clustering analysis contains.
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Table 1.1: Community clustering algorithms used to divide networks into communities.
Algorithm
Name
Reference Principle Additional Comments
Fast-greedy Clauset et al. (2004) hierarchical agglomerative algorithm with
greedy optimization approach
one of the first algorithms for large networks




information theory approach - minimizes the
expected description length of a random
walker trajectory
seeks optimal community structure by com-
pressing a descriptive “information flow” be-
tween nodes in the network
Louvain Blondel et al. (2008) heuristic algorithm , based on modularity op-
timization in a hierarchical way
reassigns community to nodes in an iterative
manner, works with very large networks and
short computation times
Spectral Mclean et al. (2016);
Newman and Girvan
(2004)
spectral based modularity clustering with
fine-tuning step
eigenvectors and eigenvalues are used to de-
scribe the network.; only available in C++
and as a cytoscape app; especially powerful
in detecting network communities that are en-
riched in similar biological functions




community detection is equivalent to identi-
fying the ground state of a infinite range spin
glass
minimization of the spin glass with the spin
state representing the community indices; al-
lows to detect overlap and hierarchy in com-
munity structure
Nevertheless, the use of PPINs greatly supports the identification of patterns and
biologically similar subgroups amongst larger datasets. Depending on the research
question, adjustments can be made to fine-tune analytical steps and to best benefit
from the results.
1.5 Functional Gene Set Analysis
Very often genes are not analysed individually, but as a group, since gene sets can show
common properties. To identify these properties, information regarding the property of
interest needs to be available for all genes in the set of interest as well as a background
set.
Gene sets as well as properties of interest can vary largely. Examples include
genes specifically expressed in a tissue or cell type of choice compared to all protein
coding genes in the human genome or a subgroup of expressed genes in a tissue of
interest, compared to all genes expressed in the same. Properties range from previously
identified gene-disease associations, functional descriptions of genes or their spatial
expression within a cell and many others (Fury et al., 2006).
In any given scenario the main question is to identify if a given number of genes
with a certain property found in a gene set of interest is higher than expected by chance.
Such a situation can be described as an over-representation or enrichment of a property
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amongst genes in a set. To calculate this probability a number of factors need to be
taken into account and statistical tests are available to carry out exactly this analysis.
The next section introduces the details.
1.5.1 Testing for Enrichment
To confirm over-representation of genes with a certain property, Fisher’s exact test or a
hypergeometric test are commonly used. Since both are known to be equivalent (Rivals
et al., 2007), a detailed example and description of the hypergeometric enrichment test
is given.
To identify a non-random accumulation of genes associated with a specific property
in a gene set four key numbers need to be considered. These are:
1. The number of genes in a full dataset, also considered as the background dataset,
N. Given the interest in a specific group of proteins, the background could either
contain all human protein coding genes or a specific gene set of interest, e.g.
all genes expressed in the synaptic proteome, also referred to as the synaptic
proteome.
2. The number of genes n in the subset of the full dataset which is tested for enrich-
ment. This is referred to as the “gene set of interest” and could be any subset of
the background set N. Examples are all genes in the presynapse, or a specific set
of proteins expressed in the synapse, e.g. a network community.
3. The number of genes associated with a certain property in the full dataset, T .
This can either be the number of genes associated with a specific disease, func-
tion or spatial component amongst others.
4. The number of genes t which represent a subset of T found in n. This refers
to the number of genes associated with the studied property (T ) that are also
present in the gene list of interest (n).
Based on these numbers a 2×2 contingency table can be constructed and the proba-
bility of encountering the exact number of hits t of interest in a set of genes n associated
with a property T , given a background N, can be calculated. Section 2.3.1 introduces
the formula and further details.
If this probability is less than a certain threshold (e.g. p < 0.05), the dataset is
regarded as enriched for the tested property (Rivals et al., 2007), or alternatively genes
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with the property of interest are considered as over-represented in the gene set of in-
terest.
1.5.2 Functional Annotations
Based on the introduced principle, the property of interest can be a specific function,
a process, a spatial component, a disease, etc. Over recent years large initiatives have
curated functional annotations for human protein coding genes.
The Reactome (Croft et al., 2014; Fabregat et al., 2016) database for example is
a “free, open-source, curated and peer reviewed pathway database”4. It associates
genes to molecular pathways also supplying a full overview of dependencies between
involved proteins.
As previously mentioned, gene-disease association information is of considerable
interest for this study. Several databases such as ClinVar (Landrum et al., 2014) and the
Human Gene Mutation Database (HGMD) (Stenson et al., 2014) amongst others store
such information. Standardised disease identifiers are supplied by the Disease Ontol-
ogy consortium (Schriml et al., 2011) which aims towards developing a “standardized
ontology for human disease with the purpose of providing the biomedical community
with consistent, reusable and sustainable descriptions of human disease terms, pheno-
type characteristics and related medical vocabulary disease concepts”5. Further details
are addressed in Chapter 3. Even though databases exist, in theory any (self-generated)
disease-gene-association dataset can be used as a source of information.
Another initiative is Gene Ontology (GO) focusing on functional terms. Consider-
ing GO (Ashburner et al., 2000), gene associated properties are also referred to as traits.
GO aims towards developing an “up-to-date, comprehensive, computational model of
biological systems”6. Therefore it covers three key areas: (i) Biological Processes
(ii) Molecular Functions and (iii) Cellular Components. Data in all of those ontologies
are publicly accessible and follow a directed acyclic graph (DAG) structure. It means
that terms relate to each other in a tree structure, moving from very generic terms de-
scribing functions such as “metabolic process” (GO:0008152) to more specific ones
like “positive regulation of L-dopa biosynthetic process” (GO:1903197).
Depending on the analytical questions a study can address a specific level of detail
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databases, gene annotations of interest can be easily obtained and used for analysis on
a large scale. Their combination with above mentioned enrichment tests can be used
to classify gene sets regarding their overall function.
A number of tools have become available to test for enrichment given a gene and
background as well as trait dataset of interest. The next section introduces two avail-
able tools.
1.5.3 topGO and topONTO
topGO and topONTO are computational environments (both available in R) allowing to
carry out enrichment studies. The first developed topGO package (Alexa et al., 2006)
introduces a way to directly work with gene-trait association information from GO.
Based on this, the R package topONTO (He and Simpson, 2017b) was developed. It
provides a more flexible environment which allows to work with ontologies other than
GO. Both packages facilitate functional enrichment analysis for gene sets of interest
given a self defined background gene set. The Fisher Exact test is used to identify
enrichment and tested traits can be retrieved directly from GO.
To benefit from the hierarchical tree structure of ontologies, topGO implemented a
number of more advanced analytical approaches. For best results specific algorithms,
considering the ontology structure, are put in place. topONTO inherits these algorithms
making them available for the use with other ontologies as well. The next section in-
troduces the technique and specific algorithm which was chosen in the work presented.
1.5.3.1 The topGO elim algorithm
Enrichment results depend on different aspects of available annotation information.
Based on the ontology structure the analysis can be adjusted to a desired level of detail
along the ontology tree. For example, a gene can be tagged with the term “transmission
across chemical synapses” which is a relatively broad description. But more specific
tags such as “trafficking of AMPA receptors” are also available. The higher the term
is located in the hierarchy, the more genes are associated with it. For example, 212
genes are associated with “transmission across chemical synapses”, but only 31 genes
are specifically described as related to “trafficking of AMPA receptors”. Consider-
ing the relationship between those numbers the 31 genes associated with “trafficking
of AMPA receptors” are also amongst the 212 genes specified in the “transmission
across chemical synapses” category. Hence, different levels in annotation detail are an
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important feature to be considered during enrichment analysis.
To retrieve most specific and refined terms among significantly enriched ones, the
elim algorithm proposed by (Alexa et al., 2006) was used. Through consideration of
the ontology tree structure it is possible to target the enrichment analysis towards a
desired information specificity. Since a child term is potentially more interesting than
its more generic ancestors, the elim algorithm computes significance of a term de-
pending on its child terms. More specifically functional enrichment analysis is carried
out starting from the lowest level traits in the ontology tree. If the lowest leaf terms
of a branch are not significantly enriched in the gene set of interest traits on the next
up-stream level are tested. Once the gene set of interest is significantly enriched based
on a certain ontology term, genes associated with the enriched term are deleted from
all gene-trait sets upstream of the enriched one. In other words, genes associated to a
child term of a trait of interest are disregarded in future enrichment tests. Hence, once
a gene trait association contributed to an enriched term of a gene set that gene is no
longer considered for additional contribution to enrichment of a functional parent term.
In summary, this approach guarantees to identify the most specific enriched functional
term for the gene set tested.
It is also advantageous that the elim algorithm keeps track of the number of enrich-
ment tests that are carried out while analysing the whole ontology tree. This informa-
tion is crucial to correct for multiple testing which is explained in the next section.
Before moving on, it should be pointed out that the ONTO-Suite Miner, underly-
ing the topONTO package (He and Simpson, 2017a) is also a great tool to extract e.g.
gene-disease association information retrieved from distinct databases in an automated
manner. Specific disease identifiers (“DOIDs”) can be used to screen loaded datasets
e.g. from Ensembl Variation (EnsVar), Gene Reference into Function (GeneRIF) and
Online Mendelian Inheritance in Man (OMIM), all providing a link between gene al-
terations and disease (see Section 3.2.2 above for more details).
1.5.3.2 Correction for Multiple Testing
A common challenge when carrying out large-scale analytical tests is correction for
multiple testing. The main interest in using such a correction is to ensure that obtained
significance values were not influenced by the number of comparisons made through-
out the repetitive testing process (Shaffer, 1995; Al-Shahrour et al., 2004).
Therefore different, more or less stringent approaches are available. One of the
most traditional and very strict correction approaches is referred to as Bonferroni cor-
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rection (Bonferroni, 1935). It considers the exact number of elements in the tested
dataset to correct the initial p-value.
An alternative less stringent and well studied approach was published by Benjamini
and Yekutieli (Benjamini and Yekutieli, 2001). Instead of considering the exact num-
ber of elements, the number of comparisons, also representing number of “degrees of
freedom” are used for correction. Additionally the method controls for the false discov-
ery rate, describing the expected proportion of false discoveries amongst the rejected
tests. This makes it less stringent than the family-wise error rate, giving increased
sensitive to detect enriched traits.
This work concentrates on the second, less strict approach which was proven to be
sufficient enough to correct initial p-values, without being overly strict and could lead
to the loss of interesting results.
1.6 Objectives
It is of great interest to gain further understanding of the complexity behind PD. Hav-
ing a more detailed overview would be highly beneficial to better diagnose the disease,
identify biomarkers and develop more targeted treatment. Therefore this study in-
cludes data from several sources addressing distinct molecular details. PPINs were
chosen to shed light over the data structure and gain detailed gene specific, as well as
more general, functional insights to the data and disease.
Data quality and an open development of the analytical workflow are of highest im-
portance and propose open approaches to be used to answer similar research questions
in the future.
More specifically, it has been widely suspected that PD, as it is diagnosed today,
can be the result of different causal dysfunctions which might be considered disease
subtypes or even represent individual diseases. Hence dividing affected genes into
groups is of great interest and might represent disease types which are associated with
crucial dysfunctions in distinct cellular regions and affect diverse molecular functions.
Hence the main interest of the presented analysis is to gain more in-depth func-
tional information about genes associated with PD and detect highly affected gene
groups acting together. Since these are often triggering the disease manifestation in
the synapse they indicate likely promising areas for further detailed research in the PD
field. The identification of their overall function can contribute more insight pining
down largely affected functional areas.
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Finally, this work aims towards presenting a set of known and new PD associated
genes, as well as synaptic dysfunctions.


























New set of PD 
associated genes
Figure 1.4: Work presented in this thesis. Blue boxes refer to data, orange boxes





This chapter introduces methods of general relevance to the work presented and used
in more than one occasion. Methods used only in a specific chapter are introduced
there.
2.1 General Programming
Most of the analytical work presented in this work was carried out with one of the
programming languages: Python (2.7.13) (van Rossum, 1995)1 or R (3.4.1) (R Core
Team, 2017)2. A number of different packages were used, these are listed in the spe-
cific sections.
2.1.1 Venn Diagrams
Venn diagrams were generated using either the python package matplotlib-venn3
or the R library Vennerable (Swinton, 2013). Most of the four way diagrams were
generated with R, but generally the tool of choice was defined based on where the data
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2.1.2 Computing Environment
The Edinburgh Compute and Data Facility (ECDF), eddie4 supplies a high-performance
computing facility which was used for computationally heavier processes. It also al-
lowed to parallelise computations if required.
2.2 Annotations and Mappings
Traditionally the discovery of a new gene or protein allowed researchers to name those.
Over the years this lead to genes and proteins with multiple names used in different
publications not always being connected. In 1957 an international committee pub-
lished recommendations for genetics symbols and their nomenclature (Tanaka, 1957).
The Edinburgh Human Genome Meeting formalised those in 1979 publishing “full
guidelines for human genome nomenclature” (HGNC, 1979). Now every known gene
is specifically identified through a name, symbol and ID. Protein nomenclature under-
lies similar efforts and is closely linked to gene nomenclature. Human genes can be
mapped to human proteins and vice versa, allowing the use of one single identifier (ID)
for analysis. Due to variability in gene to protein transcription and translation, map-
pings are not always direct, one-to-one. Hence, one gene can encode several proteins.
Additionally one protein can be encoded by several genes, which can be explained by
having several copies of the same gene in the genome, all leading to the same protein
product.
Genes and proteins can also be mapped across species. All species tend to follow
a similar annotation structure, and structural and sequential similarities are reflected
in gene and protein names. This allows mapping of e.g. mouse gene IDs to human
gene IDs which is especially beneficial when experiments are carried out in different
species.
It is also possible to use databases such as Ensembl when evolutionary relationship
is not evident. These rely on more advanced methods to ensure gene correspondence
across species (Herrero et al., 2016).
4http://www.ed.ac.uk/information-services/research-support/research-computing/
ecdf/high-performance-computing
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2.2.1 Mapping File Generation
Due to variability in data and experimental procedures not all used sources present re-
sults using the same gene or protein ID. To allow working with unique IDs, a mapping
table was generated to map GeneSymbols (Uniprot Gene IDs) to Entrez Gene IDs
and vice versa. Data to generate the mapping were obtained from UniProt (UniProt
Consortium et al., 2017) and National Center for Biotechnology Information (NCBI)
(NCBI, 2016). Three annotation files were used. The used Uniprot idmapping (se-
lected tab file5 was obtained from the ftp server6 which can be accessed via the “pre-
vious release” repository7 in the moment of writing the thesis. NCBI data were also
downloaded via an ftp server8. Two files were used to include an intermediate mapping
step. The gene2accession file9 supplies a number of mappings, including the “NCBI
protein accession” which is mapped to the “Uniprot Accession” which can be used in
combination with a further mapping file10. Figure 2.1 shows an overview of data, map-
ping steps and the outcome. Inter-species mapping was carried out using NCBI and
UniProt homology mapping flat-files11 12. In the cases where no results were found
homology mappings from the Mouse Genome Database13 were consulted. Homology
mapping was mainly carried out by Colin Mclean.
All three datasets were downloaded on March 24th 2017 and analysis was spe-
cific for human gene taxID (9606) associated genes. For best mapping outcome the
two NCBI mapping files were combined based on the “NCBI protein accession”. The
columns “Entrez ID”, “NCBI Protein Accession”, “EntrezGeneName” and “Unipro-
tAccession” were extracted from the raw files and kept for further analysis. Based
on the NCBI mapping the data were merged with the Uniprot mapping file to obtain
Uniprot IDs. This mapping step was possible through cross-linking the Entrez ID as
well as the Uniprot Accession.
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Mapping between 
Gene / Protein 
IDs
NCBI Protein Accession *
Uniprot Accession
NCBI Entrez Gene ID to
Uniprot Protein Accession/ID









NCBI Protein Accession (*)
Human: 
NCBI Entrez Gene ID **
NCBI Protein Accession *








Figure 2.1: Overview of the mapping approach, showing input data and the obtained
output. Dark blue boxes indicate raw data, light blue highlights the columns of interest
in the respective files. Green boxes refer to processes and the magenta box highlights
the outcome. */** highlight the information that was cross-linked between the files.
IDs (also referred to as “Uniprot entry name”). 19,377 Entrez Gene IDs and 32,879
Uniprot IDs are part of that dataset. An additional mapping file was obtained, including
57,606 Entrez Gene IDs, being mapped to 57,557 Entrez gene names.
Depending on the dataset size a manual mapping step followed the automatised
mapping, to identify outstanding hits. Most of these used gene aliases as the reference
gene name and could not be mapped automatically.
For the purpose of this work the Entrez Gene ID is used as the unique gene identi-
fier. It will be referred to as Entrez ID.
2.3 Enrichment Analysis
2.3.1 Hypergeometric Testing
Hypergeometric testing is a statistical approach that calculates the probability of over-
representation of a “trait” of interest in a subgroup of a larger group (Fury et al., 2006).
Thus statistical testing has been extensively used in large-scale studies to identify over-
represented or underrepresented “traits” such as specific genes and/or functions. To be
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able to calculate potential over-representation a background gene set is required. Trait
information for all genes needs to be available. Given the context of this work, the
groups consist of varying numbers of genes. Traits can vary widely from genes previ-
ously associated to a disease, genes associated to a specific biological process, molec-
ular function or cellular component. They can also be manually defined or retrieved
from databases.
A number of different scenarios can require enrichment testing. Understanding
numbers larger than expected at random e.g. disease associated genes in a gene subset
(e.g. in a specific tissue, given a genome background), identifying a significant overlap
between two gene lists or detecting general over-representation of a functional term
amongst genes in a set are just some examples.
The hypergeometric probability h(t;N,n,T ) describes the probability of encounter-
ing the exact number of hits of interest in the data subset, given a defined background
set as well as a set of trait-associated genes.
Four numbers are required to compute the probability:
1. the number of elements in the full dataset, also considered as the background
dataset (“N”),
2. the number of elements in the subset of the full dataset which shall be tested for
enrichment (“n”),
3. the number of elements of interest, e.g. associated with a certain trait, in the full
dataset (“T ”) and
4. the number of elements of interest in the data subset of interest (“t”).
This information allows to compute a probability (p-value) of how likely it is to observe










To describe the probability of finding the exact number of items of interest (“t”) in the
subset (“n”) or more, the cumulative hypergeometric probability is used. It is the sum
over the hypergeometric probabilities:
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Since one is interested in over-representation of a certain trait, relative to the total
number of of elements of interest the probabilities of seeing between “t” and “T ” hits
needs to be calculated. This is done as follows:












Predefined functions to compute the (cumulative) hypergeometric probability are avail-
able in R. The dhyper function (Johnson et al., 2005) was selected for calculations in
this work. Depending on the research question and analytical setup the one-tailed Fish-
ers exact test is commonly applied. It is known to be equivalent to the hypergeometric
test (Rivals et al., 2007).
2.3.2 Gene Set Enrichment: topGO and topONTO
Functional enrichment analysis is one of the examples where hypergeometric testing
is required. topGO (Alexa et al., 2006) supplies an environment to carry out a number
of enrichment test. Apart from the enrichment testing itself, it contains a range of al-
gorithms guiding the testing approach. Since functional enrichment information used
in these setups relies on data structured in form of directed acyclic graphs enrichment
testing can be adjusted to consider this information. Since topGO is only able to ac-
cess information from the Gene Ontology (GO) database, topONTO (He and Simpson,
2017b) was built to load ontologies and use the tools provided by topGO for the anal-
ysis of other gene-trait information sets. Thus topONTO has been used for the analysis
in this work, also allowing to specify desired GO versions.
The presented work uses the one-tailed Fisher exact test, equivalent to the hyper-
geometric test. Section 1.5.1 explains the underlying test principle and Section 2.3.1
introduces technical details. As outlined in Section 1.5.3.1 the elim algorithm was
used.
For a detailed overview of the full topGO and topONTO analysis, a step by step
protocol is presented.
1. All available trait-gene mappings are retrieved from the source database. In the
presented case, traits were GO terms associated with human Entrez IDs.
2. Once the database content was retrieved, lists of all Entrez IDs with an associ-
ated GO term of the specific subclasses (Biological Process, Molecular Function,
Cellular Component) were generated.
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3. Depending on the defined enrichment background, genes with an associated GO
term were selected.
4. The gene subset to be tested for enrichment was imported and genes present in
the background dataset were identified.
5. Once all data was prepared in the correct format, GO-data objects were gener-
ated. At this stage, the specific GO subclass is defined and according datasets
are used.
6. The generated GO-data object is used to perform desired enrichment testing. At
this stage enrichment test and algorithm are chosen.
7. Results can be accessed and visualized in data tables, as GO-graphs and word
clouds amongst others.
A number of steps require specific data formats, and details can be found in the
topGO14/topONTO15 documentation. These documents also include installation details.
Apart from being a great tool to carry out functional enrichment studies, topONTO
can be used to extract sets of gene associated to terms in the loaded ontology. Hence
genes associated to a specific disease (based on human Disease Ontology Identifiers
(DOIDs)) can be automatically obtained.
2.3.3 Multiple Testing Correction
Different programming languages implement functions to carry out multiple testing
correction. Since topGO/topONTO are run in R the p.adjust function from the R-stats
package was used. Corrected p-values were calculated for all originally obtained ones.
When using the p.adjust function, the correction test type can be selected. The
Benjamini and Yekutieli correction was used (Benjamini and Yekutieli, 2001). Apart
from having medium stringency, it is relatively accessible regarding the specification of
the number of tests that need to be corrected for. Given the use of the elim algorithm,
it was possible to extract that number and integrate it for multiple testing correction.
Other available correction alternatives include the classical, very stringent Bonfer-
roni correction, the Benjamini & Hochberg approach (also referred to as “fdr”/“false
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2.4 Protein-Protein-Interaction Network Analysis
A number of visualization and analysis tools are available to generate and work with
Protein-Protein-Interaction Networks (PPINs). igraph (Csardi and Nepusz, 2006)16
was chosen for network generation, clustering and analysis. This work uses the R im-
plementation of igraph. Some of the final visualizations were obtained with cytoscape
(Shannon et al., 2003)17.
All networks presented in this work are based on Protein-Protein Interaction (PPI)
lists, so called edge-lists or edge-tables. These are generated based on a gene list of
interest and contain information of two interacting genes (using a gene ID of choice).
The curated, direct, human PPIs list (Chapter 4) was used to extract internal PPIs.
This means that interactions are only considered if both interactors are present in the
supplied gene list of interest. The Entrez ID was used as the unique identifier.
The edge list is the minimum requirement to build a network. For further detailed
information a node list or node table can be supplied. This table contains information
regarding (all) nodes (genes) in the network. The additional information can include
gene names, disease association or other values of interest.
Based on this information, igraph can generate PPINs. Additionally, it provides
a number of tools to directly compute statistical network measures. The following
section describes concepts of global and local parameters and statistics which are used
in this work.
Betweenness (Centrality) CB reflects the number of shortest paths passing through
a node. High betweenness centrality scores indicate that a lot of information
passes by and/or is processed by a node (Freeman, 1977; Brandes, 2001). This
highlights a node’s centrality and often means that it is a form of communication
centre between different network regions. To obtain the betweenness centrality
of a node V in a graph G : (V,E) with V nodes and E edges the following steps
need to be taken: (i) the shortest path between each pair of nodes (xy) is com-
puted; (ii) the fraction of shortest paths passing through the node in question (V )
is determined; (iii) the final value is the sum over all the fraction values for all
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σxy refers to the total number of shortest paths from nodes x to y and σxy(v) is the
number of those passing through node V . The betweenness can be normalised if
required.
Closeness Centrality CC quantifies the normalized average length of the shortest paths
(geodesics) through a given node of interest. It is calculated by dividing the num-
ber of all nodes in the network by the sum of the shortest paths through all nodes





d(x,y) is the distance between nodes x and y and N is the total number of nodes in
the graph. This formula applies to large networks, where the difference between
N and N − 1 is inconsequential. Nodes with a low value are separated from
others by short geodesics. This might highlight better access to information or
more direct influence at other vertices.
(Network) Density describes how dense a graph is based on the number of edges that
are appearing in the graph. It is defined as the proportion of edges in the graph
compared to all possible edges between any two nodes in the network. More
formally this means:
Network Density =
actual edges in graph
potential edges in graph
(2.6)





n refers to the number of nodes in the network. The measure is proportional to
the maximum amount of all possible edges appearing between any two nodes in
the graph (Wasserman and Faust, 1994).
Diameter describes the longest geodesic in a graph. It is basically the “longest short-
est path” which can be found in the network, connecting two nodes amongst
each other. It is identified through comparison of all geodesics in a graph.
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Global Transitivity/Clustering coefficient are two terms, used equivalently. In an
undirected graph, they describe the ratio of closed triangles appearing in a net-
work, compared to connected triangles in the graph (the direction of the edges is
ignored). In other words, it is a measure of probability that the adjacent vertices
of a vertex are connected (Barrat et al., 2004).
A triangle can be described as a sequence of nodes x,y,z,x which are connected
as follows: (x,y), (y,z) and (z,x). Global Transitivity is then calculated as fol-
lows:
T =
number o f closed triangles
total number o f possible triangles
(2.8)
Node Degree is the number of connections a node shows. In other words it can be
referred to as the number of edges connected to a node. The maximum node
degree is the largest node degree appearing in a network. Generally nodes with
a large degree are referred to as hubs.
Scale Free Network Analysis requires information regarding the node degree of all
nodes in a network. Based on that, an alpha value describing the exponent of
a fitted power-law distribution of the node degree can be obtained. A long tail,
power-law distribution of the node degree points towards a so called scale-free
network which is commonly seen in a biological context (Ravasz et al., 2002;
Barabási and Albert, 1999).
Depending on the required insights different values were computed and analysed. For
further higher-level analysis the next section outlines required steps.
2.4.1 Network Clustering Algorithms
Once PPINs are generated (Section 2.4), clustering algorithms can be applied to divide
the network into communities. Many clustering algorithms are included in igraph.
The ones used in this study include:
• fastgreedy (Clauset et al., 2004),
• infomap (Rosvall and Bergstrom, 2008),
• louvain (Blondel et al., 2008) and
• spinglass (Reichardt and Bornholdt, 2006; Newman and Girvan, 2004; Traag
and Bruggeman, 2009).
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However other algorithms are not implemented and need to be used separately. One of
them is the
• spectral clustering algorithm (Newman, 2006a; Mclean et al., 2016).
A C++ and cytoscape implementation is deposited on sourceforge18 and can be directly
downloaded19. The README files includes installation and usage instructions.
Since most of the above algorithms are based on modularity optimisation the un-
derlying mathematical calculation is introduced. As a measure, describing the number
of edges falling within a given gene group less than the expected fraction if genes
were allocated at random, modularity Q is usually defined via a symmetric modularity
matrix. Elements of this matrix can be represented as follows:




Ai j refers to the number of edges between nodes i and j, ki and k j is the number of
edges of these nodes and m = 12 −∑i ki. Based on this the modularity Q is calculated





with s being the column vector of elements si in the matrix which indicates if node i





Finding a Parkinson’s Disease Core
Dataset
3.1 Objective
Parkinson’s Disease (PD) is considered a complex disease affecting a number of path-
ways and showing large diversity in phenotypes. To gain better understanding of how
PD affects the human cellular machinery, a core dataset covering genes significantly
associated with the disease is needed. This chapter analyses published datasets de-
scribing PD, all of which address different disease aspects. Available sources were
identified to extract PD associated genes and proteins. The raw data included informa-
tion describing i) direct and indirect influences of mutations on genes and ii) effects of
protein expression changes on the cellular machinery.
An additional aim was to understand the impact of a gene or protein alteration on
the disease picture itself. This could help to classify alterations as 1) disease causal or
2) “consequential”. The two aspects can be linked to the disease genotype or pheno-
type. Identifying links between underlying dysfunctions would allow classification of
PD into different types.
Hence, this chapter aims to define a key set of genes associated with PD. An
overview of the workflow including aims, analytical approaches and conclusions can
be seen in Figure 3.1.
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Figure 3.1: Work presented in Chapter 3, focusing on the workflow used to analyse
data and generate a combined PD dataset. Dark blue boxes refer to published data,
light blue boxes are generated datasets, green boxes describe processes and magenta
boxes show outcomes.
3.2 Material
Over the years many researchers dedicated time and effort towards shedding light on
the cause of PD. Significant effort has been put into collecting data which was made
available to the research community mostly via databases. A number of (bioinformat-
ics) approaches were used to retrieve desired information such as genes and proteins
significantly associated with PD.
For the purpose of this study the unique identifier was chosen to be the human
(gene) Entrez ID (further referred to as Entrez ID). In cases where only protein symbols
or alternative identifiers were used, these were mapped to the respective Entrez ID.
3.2. Material 37
3.2.1 Data Types
Figure 1.1 C shows different experimental approaches facilitating insight into distinct
levels of the cellular machinery. These tools are designed to obtain large-scale data
sets. Nevertheless results can also contain false positive hits. Due to our interest in the
effects of PD on the genome as well as the exome, transcriptome (and proteome) data
obtained via the following approaches were used.
Genome Wide Association Study (GWAS) are the most commonly used large-scale
tool to obtain information regarding Single Nucleotide Polymorphisms (SNPs)
associated to e.g. a disease. They are applied to analyse genetic alterations found
in a given population as compared to a reference one. Once SNPs are identified
these can be associated to nearby genes.
Microarray Studies can be used to identify differences in RNA and protein expres-
sion in a specific tissues between samples of interest and control. Statistical
methods are used to define significant changes between the two datasets. Re-
sults include protein expression levels that change significantly under e.g. dis-
ease conditions. This study uses transcriptomic microarray study results as a
data source.
Manually Curated Data Individual publications identify a number of protein- and
gene-disease associations. The experimental objective can vary, but usually a
small number of proteins are addressed. Through the screening of individual
publications a further gene-disease set can be obtained. A number of databases
collect such expert curated information and are publicly available.
3.2.2 Data Sources
The National Center for Biotechnology Information (NCBI) (NCBI, 2016) offers ac-
cess to a large amount of information using publicly available publications and datasets.
For the purpose of identifying PD associated genes a literature search, followed by
manual curation was carried out. Papers published roughly in the last 10 years, based
on personal recommendations and NCBI searches including: “(Parkinson’s Disease
[Title]) AND (“2006/01/01” [Date - Publication] : “2014/01/01” [Date - Publication])”
helped to identify such studies.
Manual publication search also allowed the identification of key studies focusing
on PD associated genes identified based on transcriptomic changes (see the 2nd level of
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detail in Figure 1.1 B). Most of those have deposited raw data in the Gene Expression
Omnibus (GEO). Directly querying GEO helped to identify further deposited studies
of interest.
GEO is a public repository with functional genomics data1, accepting array and se-
quence based results (Edgar et al., 2002). Many publications share their data
by publishing it on a platform such as GEO. Functional genomics data includes
microarray and sequence-based technologies, both high-throughput approaches.
Data can be accessed by specific accession numbers and can be cited in publi-
cations. Publication title, authors and keywords are accepted as search terms to
query the database and obtain studies of interest.
Compared to information based on transcriptomic changes a larger number of re-
sources hosting mutation-based gene-disease alterations are available. These either
associate mutations to diseases and establish a mutation to gene relationship after-
wards or directly associate genes to diseases. The former are widely based on GWAS
or other mutational studies, whereas the latter rely on (manually curated) text anno-
tation. The topONTO R package, allows mutation- and gene-disease information to be
extracted from a number of databases. This highly facilitates their use and accessibility
(more details in Section 1.5.3). The following databases can be queried via topONTO
and were used in this study:
Ensembl Variation (EnsVar) contains information regarding genetic differences be-
tween individuals (Chen et al., 2010)2. Available data describe sequence and
structural variance, including SNPs (specific to one single nucleotide in the
genome), insertions or deletions (of one or several nucleotides) as well as copy
number variations (indicating the in- or decrease in the copy number of a given
genomic region). Mutations are annotated, depending on their position on the
genome. To understand potential links with gene coding or regulatory regions
altered positions are mapped to gene location. EnsVar obtains data for hu-
man genetic information from six different sources (see entries type “variant”
in the table at the online source3). These are: (i) “ClinVar”4 (Landrum et al.,








(iv) “ESP”7 (Exome Variant Server, 2012) (v) “HGMD-PUBLIC”8 (Stenson
et al., 2014) and (vi) “PhenCode”9 (Giardine et al., 2007). Detailed informa-
tion describing the six reference databases can be found in Table 3.1.
Table 3.1: Databases which EnsVar retrieves its data from.





ClinVar aggregates information about genomic varia-
tion and its relationship to human health; fo-
cus on medically important variants and phe-
notypes
Landrum et al. (2014)
Catalogue Of Somatic
Mutations in Cancer
COSMIC information about somatic mutations in human
cancer
Forbes et al. (2015)
Database of Short Ge-
netic Variations
dbSNP hosted by NCBI; contains small genetic varia-
tions < 50 base pairs (bp)
Sherry et al. (2001)
NHLBI Exome
Sequencing Project
ESP focus on heart, lung and blood disorders; next-
generation sequencing data of human pro-








free and public version (slightly less up-to-
date); supplies information about (published)
gene lesions underlying and/or causing human
inherited disease
Stenson et al. (2014)
PhenCode PhenCode aims towards better understanding of relation-
ships between genotype and phenotype in hu-
mans, specifically focusing on clinical data;
information combination from various locus-
specific mutation databases with genome se-
quence data and evolutionary history
Giardine et al. (2007)
Gene Reference into Function (GeneRIF) (Jimeno-Yepes et al., 2013)10 provides a
simple mechanism for researchers to integrate functional annotations of genes
to genes listed in the NCBI EntrezGene “Gene” database (Maglott et al., 2005).
Thereby it enriches available information, through e.g. functional terms or dis-
ease association. It is based around an open system where scientists can submit
information for the wider community. A peer-reviewed publication is required to
support any description which requires experimental and not only computational
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obtain genes with descriptions of interest.
Online Mendelian Inheritance in Man (OMIM) , the Online Catalogue of Human
Genes and Genetic Disorders11 (McKusick, 1998; Amberger et al., 2009) con-
tains text based annotations regarding all known Mendelian disorders for more
than 15,000 human genes. OMIM focuses on the relationship between pheno-
type and genotype. Text-mining approaches can be used to extract information
such as gene-disease links of interest.
Raw data containing information about PD associated genes is supplied as digital sup-
plementary material (folder: “PD-associated-data”, the README file contains de-
tailed information about the individual files).
3.3 Results
3.3.1 PD associated genes studied in literature
To obtain an overview of existing PD research, a manually curated dataset of genes
associated with the disease was generated. A representative, rather than exhaustive
list of publications, based on recommended papers and references, was gathered (see
NCBI search as specified in Section 3.2.2). Publications were considered individually
and a set of 52 Entrez IDs were extracted, several of them appearing in more than one
publication. The identified genes of interest are: ACMSD, ADORA2A, APP, ATP13A2,
BST1, CACNA1D, CALB1, CALM1, CALR, CCDC62, CCL5, CDH8, DGKQ, EIF4G1,
GAK, FGF20, GBA, GIGYF2, GPR37, HIP1R, HSPA4, HTRA2, ICAM1, ITGA8, MCC,
LAMP2, LAMP3, LRRK2, MAPT, MCCC1, NOS2, NR4A2, NSF, PANK2, PPARGC1A,
PARK2, PARK7, PARK12, PARK16, PINK1, RAB25, SLC25A48, SLCO3A1, SNCA,
SNCAIP, STK39, SYT11, TMEM163, UCHL1, UNC13B, VPS35, WNT3. Appendix
Table A.1 presents an overview, including human Entrez IDs and reference sources.
This set represents the in-house generated set of PD associated genes.
3.3.2 PD associated genes based on expression data
Altered gene expression, which is detected as changes in level of expression at the
transcriptome or exome level, may have a direct impact on the proteome or interfere
11https://www.omim.org/
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in intracellular regulatory processes. Such changes can influence both disease devel-
opment as well as the overall disease picture which are both of considerable interest to
the research community.
A first PD microarray meta-analysis was published by Chandrasekaran and Bonchev
(2013). Raw data is available via the GEO. Two years later a second statistical meta-
analysis of human brain transcriptome data by Glaab and Schneider (2015) analysed
a larger number of public microarray gene expression datasets to identify significantly
affected pathways in PD patients.
Three original case-control studies, as well as the first meta-analysis were consid-
ered as references for this work and details of the original studies can be seen in Table
3.2.
Table 3.2: Four gene expression microarray studies, used to obtain PD associated dif-
ferently expressed genes. “Publication” refers to the study, “Brain Region” describes the
tissue that was analysed, “Array Type” gives information about the array (all Affymetrix
human GeneChips covering the whole human genome). The significance threshold
shows p-value and fold-change information applied during original data analysis. “As-
sociated Genes” shows the number of genes identified in the study, “Additional Infor-
mation” contains further details, “Mapped Genes to Entrez ID” refers to the number of
genes which were extracted from the study and successfully mapped to a unique En-
trez ID and “Sample Size” refers to the number of samples (PD cases/controls) tested
in the study.

















p-value < 0.01 267 Entrez IDs and Gene Symbols full gene list was supplied
after contacting the author
267 30/24





fold change > 1 -
fold
570 differentially expressed genes - top 21
differently expressed genes, also confirmed in
a second study; top 25 records based on gene
sequences and mapping to regions of estab-
lished PD linkage were supplied
data (Gene Symbols) man-
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All samples were post mortem, and information regarding the tested brain region
from which human tissue was obtained, the used microarray chip (all Affymetrix hu-
man GeneChips covering the whole genome) as well as a summary of the findings are
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presented. The number of significantly differently expressed genes associated with PD
per study can be found in column “Mapped Genes to Entrez IDs”.
Based on the four studies, 667 unique genes (based on Entrez IDs) were identified
to be significantly differently expressed in PD patient’s brains compared to healthy
controls. As visualized in Figure 3.2 the majority of genes is only associated with PD
in one study. None of the records could be replicated in all four studies, and only 57
genes (~8.5% of all genes detected via microarray studies) are found in at least two
datasets.
Figure 3.2: Venn Diagram showing the overlap of genes significantly associated with
PD (based on Entrez ID count). The different coloured ellipses represent Entrez IDs
that have been associated with PD based on a microarray expression study. The four
compared studies are: Chandrasekaran and Bonchev (2013) (red), Simunovic et al.
(2009) (green), Zhang et al. (2005) (blue) and Moran et al. (2006) (turquoise). Numbers
in overlapping regions indicate genes found in one or more studies.
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3.3.3 PD associated genes with genetic and/or manually curated
evidence
The genome of many PD patients shows alterations. As outlined in Section 1.5.3,
topONTO was the tool of choice to retrieve PD associated genes. This decision was
based on the principle of retrieving reviewed, curated and high quality disease-gene
association data. The ability to retrieve information from several databases as well as
meta-data allowed for best possible data screening, filtering and curation. The coming
paragraphs explain required steps.
The Disease Ontology (DO)12 was developed to associate unique identifiers to hu-
man diseases (Schriml et al., 2012; Kibbe et al., 2014), referred to as Disease Ontology
Identifiers (DOIDs), and was used to obtain a list of genes associated with PD. The
unique DOID for PD is “14330”. It describes PD as a “synucleinopathy” which is
classified as a “neurodegenerative disease”. Seven child terms are associated to PD




























Figure 3.3: DO graph showing PD with its parent and child terms. DOIDs indicated in
brackets are the official disease identifiers, used to extract associated genes. PD as
well as all subtypes, indicated in boxes with blue borders are used in the analysis.
12http://disease-ontology.org/
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Since topONTO queries data from different sources: (i) EnsVar (ii) GeneRIF and
(iii) OMIM, these were considered separately and jointly. Depending on the source,
gene-disease associations are only made if the exact DOID is associated with the gene,
but not the parent term. This means that some genes associated with a disease subtype
are not associated with the parent disease term (PD) itself. To obtain a full gene set
individual searches were carried out for all PD subtype DOIDs, as identified in the DO
tree.
After obtaining the results, data was manually checked. A number of irregularities
were spotted. E.g. it was not possible to directly map the Entrez ID 401884 to a gene
symbol. Closer analysis showed that it refers to a discontinued NCBI entry which is
now Entrez ID: 147081 and included in the dataset. Therefore the discontinued record
was deleted from the list. All other entries identified by topONTO could be confirmed
and Table 3.3 shows that 635 genes were associated with at least one of the DOIDs.
Source database specific information is shown in different columns. As indicated by
the numbers in brackets, only two disease subtypes show genes specifically associated
with them, but not directly to PD. In both cases, autosomal recessive juvenile PD 2
and autosomal recessive early onset PD 7, all hits were retrieved from the GeneRIF
database.
Table 3.3: Number of genes associated with PD based on the topONTO query. Columns
refer to the different source databases and “Disease (Subtype)” refers to the different
PD subtypes (see Figure 3.3). Numbers in brackets refer to the number of genes asso-
ciated with only the disease subtype but not PD itself.
Disease (Subtype) Ensembl Variation GeneRIF OMIM All Sources (joint)
PD 290 372 19 620
autosomal dominant PD 1 0 5 0 5
autosomal recessive juvenile PD 2 0 22 (14) 0 22
early onset PD 6 0 3 1 3
autosomal recessive early onset PD 15 0 2 0 2
autosomal recessive early onset PD 7 0 7 (2) 1 7
autosomal dominant PD 8 0 3 0 3
Kufor Rakeb syndrome 0 0 0 0
All Disease Types (joint) 290 388 21 635
Databases follow distinct annotation approaches for generating the different gene
sets. To identify the overlap between PD associated genes depending on the reference
source which detected them, Figure 3.4 shows their overlap.
As illustrated, the number of genes appearing in all three databases is rather small,
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Figure 3.4: Venn Diagram showing the overlap of genes significantly associated with
PD based on data retrieved with topONTO; PD subtype term results are included.
containing only 18 records. This phenomena can be explained by the differences in na-
ture of the annotation mechanisms of the databases and distinct focus on the reference
data.
As outlined in the Section 3.2.2, OMIM is based on text information regarding
Mendelian disorders. OMIM genes are directly associated with PD or its respective
subtypes. Due to well curated expert annotation information the data is of highest
quality. With 21 PD associated genes based on OMIM data, this group makes the
smallest part of topONTO queried results. All identified genes are also found in at least
one of the other two databases, confirming the high annotation quality.
GeneRIF is also based on an open system, describing genes in terms of function
and gene-disease association. A total of 388 genes are associated with PD based on the
GeneRIF database. Compared to OMIM, annotation terms vary more widely. GeneRIF
uses the following “term_names” to retrieve PD associated genes: “park1”, “park15”,
“park2”, “park6”, “park7”, “park8”, “parkinson disease”, “parkinson disease (parkin-
son’s disease)” and “parkinson’s disease”. Manual curation showed that the “park-x”
terms refer more likely to the PARK genes and are often analysed in a different context.
In several cases text containing a “park-x” associated genes describes associations to
e.g. a cancer risk factor. For best data quality all genes associated with PD based on a
“park-x” term were excluded from the GeneRIF gene set. Additionally one discontin-
ued entry was identified (Entrez ID 23707) and removed. This reduces the GeneRIF
dataset from 388 to 372 genes, all of which are associated with either “parkinson dis-
ease” or “parkinson’s disease”.
As Figure 3.8 illustrates, those 15 “park-x” associated entries were only present in
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the GeneRIF database.
Overall, PD is a well defined term. Since it represents an unambiguous concept
text-mining approaches tend to be highly reliable, and errors are unlikely. Additionally
the above filtering step makes GeneRIF data more concise by only targeting PD as a
disease and not genes associated by name. Nevertheless negative associations can
be part of the descriptions. For example a text annotation such as: “gene A is NOT
related to PD” or “there is NO association of gene A to PD”. Hence GeneRIFs text
annotations were manually filtered, by reviewing all entries containing either “NOT”
or “NO”. Based on manual inspection of the descriptions, 10 genes were excluded due
to only negative association to PD (Entrez IDs: C1QA, C1QB, DRD4, GSTA4, HCRT,
HFE, IL10, PSMC1, STX6 and TLR9. All those were only referenced in the GeneRIF
database. Some more negative associations were identified, but they all showed at least
one positive association based on a different reference and were kept in the disease-
gene datasets.
This filtering step leaves a total of 362 genes retrieved from the GeneRIF data base.
The overlap with the other datasets and final numbers are addressed later on (Figure
3.8).
EnsVar is based on identifying genetic alteration, such as SNPs. In this case,
topONTO extracts SNP-disease associations. Based on the SNP location disease as-
sociated genes are identified.
This approach is required due to the raw data EnsVar supplies. Associating SNPs
to genes is not an easy task and topONTO uses a relatively straight forward approach.
EnsVar supplies the position of a SNP on the genome. That information is compared
with gene locations (gene coding sequences (CDSs)) were retrieved from Ensembl
gene, via biomart). Genes associated with a SNP are (i) overlapping with the SNP
position, (ii) the closest upstream or (iii) the closest downstream gene relative to the











Figure 3.5: SNP-gene association classification of SNPs extracted from the EnsVar
database, based on their position on the genome relative to the gene.
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Figure 3.6 shows that around one third of all previously identified genes contain at
least one SNP that is overlapping with the CDS (“overlapping SNP”). Another third of
the genes is associated with PD by virtue of being either the closest up- or downstream
one (“upstream SNP”, “downstream SNP”’). Four genes are identified with an over-
lapping as well as up- and downstream SNP linked to the them. These are: LRRK2:
leucine-rich repeat kinase 2 (120892), CRHR1: corticotropin releasing hormone recep-
tor 1 (1394), TMEM175: transmembrane protein 17 (84286) and MAPT: microtubule
associated protein tau (4137), all very well known to be associated with PD. Observing
three different SNPs associated with those genes might confirm their high impact on
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Figure 3.6: Venn diagram showing genes associated with PD based on a SNP (derived
from EnsVar). The different circles indicate the relative position of the SNP to the gene
(Figure 3.5). Numbers refer to gene numbers and one gene can be affected by several
SNPs.
Spatial information of the SNP relative to the gene is of interest since it can con-
tain more details about the potential effect on the affected gene. Figure 3.7 shows a
more detailed gene overview, visualizing the CDS. Based on the Ensembl glossary
definition the CDS only consists of protein coding sequences, exons. Nevertheless the
spatial comparison only considers start and stop position of the CDS meaning that an
overlapping SNP can also be located in an intronic, 5’ or 3’ UTR (untranslated) region.
The exact SNP location determines the effect on the protein. A genetic variant
(SNP) in an exon can directly affect the protein, through alteration of its DNA sequence
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and the produced protein. Alterations in an intronic or 5’ and 3’ UTR do not always
have to show a direct effect, but most likely do so. Overall SNPs lying in a gene coding
region are relatively well studied and their effect on the protein can be analysed more
easily compared to SNPs located elsewhere. In fact, it is almost impossible to screen
the effect of SNPs not overlapping with exons in the CDSs in an automated manner.
Mutations allocated in an intron might not show a direct effect on the protein but can
do so, e.g. through the generation of additional splicing sites, and hence modify the
gene product and transcribed protein. SNPs in the 5’ and 3’ UTR are more likely to
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Figure 3.7: Schematic illustration of gene components, highlighting the gene coding
sequence.
SNPs that are located up- or downstream of the associated gene can show a different
level of influence, or not influence the currently associated genes at all. Due to the
complexity of the genetic code it is possible that the up- and downstream regions of
a gene contain sensitive regulatory regions. If these are affected by the SNP, gene
expression levels can be influenced. This is true if e.g. the transcription factor binding
sites, such as a TATA-/CCAAT-box is affected (Figure 3.7). Since such details are
not widely annotated, they were not considered for further data filtering, but can be
considered in individual cases.
Based on this knowledge it was decided to currently only consider genes showing
mutations with at least one overlapping SNP for further studies. This means that 198
PD associated genes based on non-overlapping SNPs are excluded.
After analysing gene-disease associations separately, highly trustable datasets were
combined. These are:
• all 21 positive entries from the OMIM search,
• all 92 genes associated with overlapping SNPs (EnsVar) and
• the filtered list of 362 GeneRIF results.
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The joint set is constituted of a total of 418 genes. The core PD associated gene
set is highlighted in Figure 3.8. Numbers labelled with a * belong to the set of 418
genes. This will be the reference set of PD associated genes based on best possible

























Figure 3.8: Venn diagram summarising all the filtering steps of the data retrieved with
topONTO. Gene numbers with a star refer to gene sets that are part of the final PD
associated gene set.
3.3.4 Meta-analysis
After having identified, verified and cleaned all PD associated gene sets the overlap
between the datasets was analysed. Three gene sets were considered:
• the manually curated literature list with 52 PD associated genes (Section 3.3.1),
• the full list of 667 PD associated genes based on microarray studies (Section
3.3.2) and
• the fully filtered list of 418 genes associated with PD based on a filtered topONTO
query result (Section 3.3.3).
A total of 1055 unique genes were identified. As Figure 3.9 shows, different sources
lead to different results, showing a very small overlap between the datasets.
Only 10 genes appear in all three sources. These are: APP, ATP13A2, HTRA2,
MAPT, NSF, PARK7, PINK1, SNCA, UCHL1, WNT3. Table 3.4 shows an overview









Figure 3.9: Venn diagram showing the overlap of PD associated gene sets retrieved
from different sources.
of these with additional detailed information. Regarding the genetic evidence, all but
one gene are found in EnsVar, with an overlapping SNP. APP is the one gene not
to be found in EnsVar, but showing a very strong disease link based on its GeneRIF
annotation. Four genes are also found in the OMIM database, further confirming the
high disease association and genetic link.
Genes associated with PD based on expression differences show that NSF was
found in three out of the four considered studies. Seven records were found by Simunovic
et al. (2009) and four by Chandrasekaran and Bonchev (2013). Genes MAPT, SNCA,
PARK7 and PINK1 have also been identified in more than one manually annotated
study.
11 genes appear only in the PD literature dataset. These are (in alphabetical or-
der of gene name): ACMSD (reference pubmed ID: 22438815, 21812969), CACNA1D
(23771339), CALR (23771339), HIP1R (22438815, 22786590), ICAM1 (18044695),
MCC (22438815), RAB25 (22438815), PANK2 (22806825), SLCO3A1 (21812969),
SLC25A48 (21812969), TMEM163 (22438815). Another two PD literature based as-
sociated genes only overlapped with genes showing PD association based on altered
transcription. These are: CALM1 (23771339) and CDH8 (21812969).
Due to the large differences between the PD associated gene sets the significance
of their overlap was analysed. A hypergeometric test was used to identify significance
in the overlap of PD associated genes based on the filtered topONTO query, compared
to the PD associated genes based on the four microarray studies. A p-value was calcu-
lated, as described in Section 2.3.1. The background dataset contained 20,000 genes
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Table 3.4: PD associated genes referenced in all three sources (ordered numerically
by Entrez ID). “Genetic Evidence” can be “E” for EnsVar, “G” for GeneRIF or “O” for
OMIM“; “Microarray Study” is “C’ (Chandrasekaran and Bonchev, 2013), “M” (Moran
et al., 2006), “S” (Simunovic et al., 2009) or “Z” (Zhang et al., 2005). “Literature Refer-
ence” lists the pubmedID of the paper(s) where the PD link was recorded.
Entrez ID Gene Symbol Genetic Evidence Microarray Study Literature Reference
351 APP G S 22438815
4137 MAPT E, G, O S 22438815, 22806825
4905 NSF E M, S, Z 21812969
6622 SNCA E, G, O C, S 23380027, 20495568, 22438815, 21812969, 22786590,
21412835
7345 UCHL1 E, G, O S 23380027
7473 WNT3 E C 21812969
11315 PARK7 E, G S 23418303, 23380027, 20495568, 22581678, 21812969
23400 ATP13A2 E, G C, M 23380027
27429 HTRA2 E, G, O C 20495568
65018 PINK1 E, G S 23380027, 20495568, 22581678, 21812969
(all human protein coding genes, (Ezkurdia et al., 2014)) and the dataset of interest
with 418 PD associated genes (core PD associated gene list). The sub-sample consid-
ered contains 667 PD associated genes based on microarray studies. 37 genes were
found in both datasets. The hypergeometric test showed that the probability of finding
37 successes or more in the sub-sample given the indicated background and dataset
size is: P(X >= 37) = 2.30∗10−08. This is a highly significant overlap, indicating that
the PD associated datasets are not unspecific, but potentially cover different disease
aspects.
3.3.5 Summary
Important differences in the PD associated datasets, obtained depending on input data
and applied methods, were identified. A decision regarding which datasets to take
forward as a reference was needed. As stated previously, the objective of this part of
the study was to obtain the most concise PD gene set possible.
The results presented highlight the differences between available datasets. This
variety reflects the complexity of PD and confirms what was outlined in the Central
Dogma of Molecular Biology (Figure 1.1 A).
Since the datasets presented may cover distinct disease aspects, disease states, dis-
ease types or others a core PD datasets of interest needed to be selected. Genomic al-
terations are generally associated with underlying disease causes and triggers, whereas
changes in the transcriptome and subsequently proteome most likely reflect the dis-
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ease phenotype. Additionally, manually reviewed and annotated data is more secure
and linked to a direct disease association. Based on this understanding, the most reli-
able dataset describing directly disease associated PD genes was selected.
The PD associated genes based on literature search nicely coincide with parts of
the other datasets, with a tendency towards genes retrieved through the topONTO query.
Eleven genes have not been identified in other studies. This gives an interesting insight
and shows that several individually identified genes seem to have a disease link that
has not yet been discovered in any large-scale study. This phenomena might be ex-
plained by the very detailed focus of experimental studies addressing pathways very
specifically. Such studies are also able to detect genes/proteins with a rather minimal
influence on the disease which can not be picked up in more generic settings.
Raw data from microarray studies was available, but time was too short to repro-
duce the published findings and confirm consistency in significance of the detection
levels. Due to the variability in the published results, especially regarding the signifi-
cance thresholds (Table 3.2), it was decided to use this dataset as a “wider” description
of the disease picture, with a tendency towards capturing the disease phenotype and
pathology. The fact that its overlap with the genes obtained via topONTO is signifi-
cant, based on hypergeometric testing, proves a clear link of both datasets with PD.
Hence, the possible indirect relationship between the two datasets that might emerge
based on molecular regulatory mechanisms, adds great comparative value to the gene
set obtained through microarray experiments. It could be considered a great source for
comparison with new hypothesized PD associated genes later on in this study. Fur-
thermore the minimal overlap of results between datasets was surprising. This finding
can be caused by different aspects. Tissue extraction, preparation, experimental setups,
and data analysis can be some of them. Additionally the results might cover different
disease types or stages. Therefore all identified genes might play a role in PD but more
studies are required to confirm these links. To maintain a general focus on disease
causative genes and given the low coverage for most of the records identified in the
microarray studies, this dataset was excluded from the key PD associated genes.
In summary, the key PD associated gene set includes PD associated genes deposited
in curated databases and the ones with an overlapping SNP in their CDS. Regarding
data retrieved from EnsVar, GeneRIF and OMIM (all obtained via topONTO a number
of filtering steps were taken to obtain the “best possible” dataset (Section 3.3.3)). This
leads to a core gene set which will be considered for further analysis in the following
chapters. The “key PD associated gene set” contains 418 PD associated genes. 37
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and 12 genes in the set overlap with the PD microarray evidence dataset and the PD
literature dataset respectively. 10 genes can be found in all three datasets (Figure 3.9).
For comparative purposes, the set of 1055 PD associated genes is relatively broad
but of good value to be used to gain a more general PD overview. It also represents
a valuable reference source, especially with regard to the microarray records. These
might likely capture PD associated genes having the potential to explaining the disease
“phenotype”, supporting functional conclusions at a later stage of this study.
3.4 Discussion
A lot of effort has been put into identifying and understanding underlying causes of PD.
A growing number of publications use large-scale approaches to gain wide understand-
ing of this complex, neurodegenerative disease. Experimentalists mainly ask specific
questions and analyse individual candidate processes in detail. This study aimed to
identify a key set of genes describing the genetic and molecular PD complexity on a
large scale. The endeavour was addressed through integration of PD associated data
from different databases, covering specific disease aspects.
Data was retrieved and filtered to obtain the most concise and comprehensive
dataset covering different aspects of the disease. Even though datasets seem quite dif-
ferent a small, but significant overlap between datasets capturing PD associated genes
based on genetic and curated information versus gene expression alterations was iden-
tified. This indicates that datasets are specifically describing common aspects of the
disease, but very likely mutations are not directly reflected on the gene expression level.
Different approaches are possibly capturing distinct disease aspects and are biased to-
wards the detection sensitivity they have towards a certain set of disease associated
genes.
Different insights can also emerge due to differences in experimental material and
analysed tissue. Extraction, preparation and further conditions such as post-mortem
tissue processing, biopsy techniques and the use of specific tissue parts can highly
influence results. This can also be considered a positive point, since it might capture
a wide range of PD subtypes covering a large variety of factors to be considered to
capture the full disease picture. Nevertheless this means that current datasets can show
biased results, depending on their strengths and weaknesses of the underlying detection
approach, leading to the encountered differences.
Overall differences between topONTO and microarray results are likely to reflect
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the influence of the genes on the PD genotype and phenotype.
The literature based dataset only supplies very superficial insights and one would
suspect a bias towards genes and proteins that are more easily studied and experimen-
tally analysed. They might also show a longer detection history and/or well known
disease links. This dataset is far from complete but shows higher overlap with genes
with a genetic and manually curated link to PD. It is difficult to judge if genes are anal-
ysed based on previous experimental findings, their appearance in large GWAS studies
or based on therapeutic potential. In any case this approach gave a good first insight to
the field and could suggest experimental approaches, mostly addressing genes showing
mutations and possibly triggering the disease without directly influencing the disease
phenotype.
Considering the vast differences between the results obtained in the different mi-
croarray studies, obtaining experimental material is a crucial step to ensure data qual-
ity. When working with human brain tissue, this is specifically challenging, since it
involves collecting post-mortem samples. Depending on tissue extraction procedures
and timing, certain intracellular degradation processes might have become active in
brain cells and influence the results. Nevertheless this is a phenomena that affects all
studies of this type and can be counteracted by guaranteeing a maximum time between
death and obtaining the tissue. Differences in the dataset size reported in the distinct
studies can be partly explained by individual significance thresholds, the material, de-
tection and analytical sensitivity. Further aspects influencing microarray expression
study analysis are analytical procedures and thresholds. Since these highly influence
the results they introduce bias and complicate cross comparison of results amongst
studies. Sample and data quality differences can emerge at various levels also consid-
ering technical setups. The selection of test samples and controls is specifically chal-
lenging considering complex diseases, such as PD. The joint consideration of patients
with potentially distinct disease types might lead to confusion of disease associated
gene expression differences. Similar effects can happen in case controls are affected
by undetectable alterations highly specific to individuals and modifying significance in
obtained results.
All these challenges represent limitations of the use of microarray expression study
results in other projects, not diminishing the information it can contribute to the dis-
ease understanding as an additional reference and/or as support to distinct research
questions. They reflect an additional point why this data was excluded in the final PD
associated gene set
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In the curated datasets, the annotation specificity of GeneRIF adds an additional
level of information, but also a source of error. Human annotation and interpretation
error can lead to false positive records in databases. Mapping genes only to PD sub-
types but not to the parent PD term might lead to their exclusion. This is also reflects
the properties of the GeneRIF database, where associations between gene and diseases
are not automatically propagated to parent nodes in the ontology tree. Nevertheless,
in-depth detailed insight and associations considering disease subtypes can be very
valuable and need to be considered when carrying out large-scale studies. To counter-
act these phenomena the presented study explicitly included information covering all
disease subtypes.
Using data with a genetic link retrieved from EnsVar is the most secure approach to
use when drawing conclusions regarding the PD genotype. The further filtering step,
screening results for genes with CDS overlapping SNPs additionally support this link
and should be considered before drawing conclusive decisions. For further certainty a
number of other aspects could be considered. The aforementioned (in-) direct effect of
SNPs and their effect on the affected gene, apart from the SNP position, can be influ-
enced by the number of alterations found in one gene. This number would also need to
be interpreted depending on the gene length. This is just one additional example of the
drawbacks in using relatively direct gene-disease association approaches. A number of
approaches are being developed to describe the effect of genetic alterations on a gene
in a score based system. Such an approach can further support gene-disease links and
improve data quality which could be considered in future studies.
As far as can be ascertained, this is the first study directly comparing disease as-
sociated data retrieved from different sources and capturing distinct PD aspects on a
large scale and in this level of detail.
The PD map (Fujita et al., 2014)13 is a joint effort addressing a similar question
and trying to build a set of “all” genes associated with PD. The data is publicly avail-
able and accessible in a very interactive way. Nevertheless included genes are not all
evidence based, or evidence is not shared with the user, making it very hard to under-
stand the strength of a gene-PD link in depth. As this chapter shows, such information
can have a large influence in the reproducibility of results and likely the type of gene-
disease-link. Therefore the presented manually curated gene set was preferred for the
available details.
The findings also illustrate that in the case of PD, as probably with any other com-
13http://minerva.uni.lu/MapViewer/
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plex neurodegenerative disease, datasets should be treated individually when required
(which is not possible in the case of the PD map). Doing so will avoid wrong con-
clusions being drawn, and allows detection of “real patterns”, focusing on e.g. the
genotype or phenotype of a disease.
Overall, a key advance presented in this chapter is the combination and thorough
analysis of data from multiple data sources and different levels in the biological ma-
chinery, defining the disease picture. More importantly manual curation steps were
performed to confirm and/or discard initially detected gene associations to PD, leading
to a high quality set of PD associated genes.
Even though a gene set was obtained, further detailed disease insights are missing.
The complex disease pattern suggests that a range of different PD subsystems are af-
fected by several genes in the dataset. Those are very likely to be connected and/or
influencing each other, making the picture even more complex. Since individual gene
analysis does not allow such links to be detected, these need to be analysed and under-
stood on a large scale. For this purpose Protein-Protein Interactions are of most inter-
est, as they allow cross-links to be established between affected genes, likely involved
in the disease. The coming chapter introduces the concepts behind such an approach
and following chapters introduce their effective use in Protein-Protein-Interaction Net-




Even though an increasing number of databases supply Protein-Protein Interaction
(PPI) information in a standardised format, most researchers obtain their PPI data
from just one of the available ones, running the risk of ignoring crucial information
deposited in other repositories. In order to avoid such loss of information this chap-
ter merges content from multiple databases. This endeavour allows differences and
similarities among datasets used, to be identified. These insights can then be used to
set adequate filters to obtain a clean, human-only unified reference PPI dataset. Pro-
cesses such as mapping of gene and protein identifiers as well as joining datasets are
performed using available bioinformatics tools and methods.
Hence, this effort aims towards obtaining a clean, curated, human-only PPI set,
which is a valuable source for further analysis, guaranteeing highest quality of results
and bridging the gap between data deposited in different databases. Figure 4.1 shows
an overview of sources, techniques and the outcomes of this chapter.
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Figure 4.1: Overview of work presented in Chapter 4. Input databases are shown
in dark blue boxes (turquoise represents a special case addressed in the text and ex-
cluded in the final PPI set). Light blue stands for newly generated and curated datasets.
A yellow box refers to processes, leading to an analytical result (pink boxes). Green
boxes represent outputs of this chapters analysis or future results.
4.2 Introduction and Data Processing
4.2.1 Protein-Protein Interactions
Interactions of proteins as well as interactions between proteins and other biomolecules,
are crucial for any process happening within and between cells. Only interactions can
trigger signals, initiate enzymatic processes and release interaction cascades, through
activation, inhibition, or other processes. Some of the most common ones appear be-
tween e.g. enzyme and inhibitor or antibody and antigen but a large number of other
interactions are required for cells to fully function.
Two types of PPI interactions can be easily distinguished: transient or stable ones
(Perkins et al., 2010). Transient interactions lead to specific effects in a short time
width, whereas stable ones usually lead to more permanent multiprotein complex for-
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mation. For example, the formation of a clathrin cage, involved in endocytosis, as well
as most reactions in signalling pathways are transient interactions (Ozbabacan et al.,
2011). In the clathrin case cages build up, carry out their function and disassemble.
Since this is not a permanent state, interactions are considered as transient. In contrast
the ribosome, a large macromolecular complex and the gamma-aminobutyric acid type
A receptor (GABAA) rely on highly stable and permanent PPIs. In both cases it is the
joint protein complex that carries out a function and can only do so as a fully assem-
bled union. Such complexes can vary in size and most often act as molecular machines
in living systems. Their constitution is referred to as quaternary structure, describing
interacting domains and structural relationships between individual proteins (Yu et al.,
2006).
The transition between the two types is difficult to define and it is relatively hard
to experimentally identify the interaction type. Nevertheless depending on detection
approach used, physical interactions between protein pairs can be classified based on
standardised interaction types. This point is addressed and discussed later on in this
chapter (Section 4.3.1).
An additional challenge is the specific identification of binary interactions, based
on only two elements, as opposed to the presence of two elements in one complex, not
undergoing a direct interaction. Some databases maintain information including this
distinction, but the majority do not. Often, if experiments supply data based on com-
plexes these are “spoke expanded”, meaning that all possible protein pairs in a complex
are considered as PPIs (Gingras and Raught, 2012). In particular this is specifically
the case when retrieving data through so-called pull-down experiments. This practice
might not be the best approach but is widely accepted and frequently used on a large
scale.
Various high-throughput techniques exist to extract PPIs on a large scale. Amongst
these are yeast-two-hybrid, pull-down and co-localization studies (Berggård et al.,
2007). Experiments can be carried out with proteins from different species and even
cross species, meaning that for example human proteins are expressed in a mouse cell
line (in-vitro). Different approaches are more suited to identify certain types of PPIs.
An exhaustive, recent review explains the different techniques (Wetie et al., 2013).
Additionally, computational approaches can predict human PPIs based on structural
similarities or occurrence in other species such as mouse and rat. These rely on ho-
mology and interolog mapping (Folador et al., 2014).
Nowadays most published PPI studies submit their data to at least one of the major
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databases, or databases identify new publications and include PPIs in their repositories.
To combine data from multiple sources additional analysis is required. The following
section explains the most commonly used, current standard format put in place to store
data and facilitate its analysis.
4.2.2 Data Format
The mitab25 format (following PSI-MI standards) allows researchers to access pub-
lished PPI data in an easy and automated way, allowing direct integration into work-
flows. HUPO, the Proteomics Standards Initiative introduced the PSI-MI TAB format
for data storage and interchange in a tab delimited format (Hermjakob et al., 2004a;
Kerrien et al., 2007)12. As such it is under constant review to serve the scientific
community as required. To follow the format’s standards a minimum of 15 standard
columns are required with each of them containing predefined content. An overview
is given in Table 4.1. Further columns can be added but are not required.
Table 4.1: 15 standard mitab columns together with their content, including an example
(randomly selected, not consistent between different columns).
Column Content Example
1 & 2 interactors entrez gene/locuslink:84665; uniprotkb:P49418
3 & 4 alternative IDs biogrid:124185; entrez gene/locuslink:MYPN; intact:EBI-
7121510; uniprotkb:Q75MK5; intact:MINT-109264
5 & 6 interactor aliases entrez gene/locuslink:CMD1DD(gene name synonym);
psi-mi:amph_human(display_long); uniprotkb:AMPH(gene
name); psi-mi:synj1_human(display_long); uniprotkb:Synaptic
inositol 1,4,5-trisphosphate 5-phosphatase 1(gene name
synonym)
7 interaction detection method psi-mi:"MI:0018"(two hybrid); psi-mi:"MI:0084"(phage dis-
play)
8 first author, reference publication "Bang ML (2001)"; Cestra et al. (1999)
9 publication identifier pubmed:11309420; mint:MINT-5211933
10 & 11 taxon ID of interactors taxid:9606; taxid:9606(human); taxid:9606(Homo sapiens)
12 interaction type psi-mi:"MI:0407"(direct interaction)
13 source database psi-mi:"MI:0463"(biogrid); psi-mi:"MI:0471"(MINT)
14 interaction identifier biogrid:117; intact:EBI-7121552; mint:MINT-16056
15 confidence score (if available) -; intact-miscore:0.56
Some of the meta-data can be standardised through the use of MI-IDs. MI-IDs
1http://www.psidev.info/molecular-interactions
2https://psicquic.github.io/MITAB25Format.html
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are widely used identifiers, defined in different ontologies, specific to the column con-
tent and available for information supplied in mitab25 file columns 7 and 12-14. The
“source database” for example can be referred to with a (standardised) name or an MI-
ID. Many of such mappings can be retrieved from the Ontology lookup service3 (Jupp
et al., 2015).
This meta-data can be used to filter interactions based on their properties which can
lead to a more specific set of PPIs of interest. Based on the standard mitab25 format
these filtering steps can extract interactions, which are e.g.
(i) detected in one specific species (through the use of taxIDs, columns 10 and 11),
(ii) obtained via the use of a specific experimental approach (defined by interaction
detection method, column 7),
(iii) described with a specific interaction type (specified in column 12) and/or
(iv) extracted from a specific source database (listed in column 13).
These steps allow the level of data “cleanliness” and “certainty” to be increased and
enable users to set personal PPI data filters based on their needs and research purpose.
4.2.3 Databases
Based on the growing amount of data, major databases gather published PPIs and make
the data accessible. Five major PPI databases are, in alphabetical order (i) BioGRID
(Stark et al., 2006; Chatr-aryamontri et al., 2016) (ii) Database of Interacting Proteins
(DIP) (Xenarios et al., 2000; Salwinski et al., 2004) (iii) HIPPIE (Schaefer et al., 2012;
Alanis-Lobato et al., 2016) (iv) Human Protein Reference Database (HPRD) (Prasad
et al., 2009) and (v) IntAct (Hermjakob et al., 2004b; Orchard et al., 2013). Table
4.2 introduces them in more detail, including references, primary protein identifiers
and first and most recent release dates. It can be seen that all sources, apart from
HPRD supply data following mitab25 standards (see above) (Hermjakob et al., 2004a;
Kerrien et al., 2007). Unfortunately the HPRD data format is incompatible with the
mitab25 standards. Furthermore the last release was updated in 2010, meaning that the
information contain is outdated and all entries are now most likely covered by other
databases. HIPPIE lacks two mitab25 standard columns (describing the “interaction
type” and “interaction identifiers”) but the data can still be combined with the other
sources.
3http://www.ebi.ac.uk/ols/index
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Table 4.2: Five of the most commonly used PPI databases. “Main Identifier” refers
to the identifier used for the interactors (given in columns one and two of the psimi25
standard format files). Most recent release refers to the point of writing (May 2017).
Database
Name
Reference First available Most recent
release
Main Identifier (data format)
BioGRID Stark et al. (2006); Chatr-
aryamontri et al. (2016)
2002 (monthly
release)
May 2017 Entrez ID (mitab 25 format)
DIP Xenarios et al. (2000);





Uniprot ID / Uniprot Accession
ID (mitab 25 format)





June 2016 Entrez ID (mitab 25, but missing
two columns: “Interaction Type”
and “Interaction Identifiers”)
HPRD Prasad et al. (2009) 2003 (irregular
releases)
April 2010 Uniprot ID / Entrez ID (tab de-
limited xml format)
IntAct Hermjakob et al. (2004b);
Orchard et al. (2013)
2002 (monthly
release)
April 2017 Uniprot ID / Uniprot Accession
ID (mitab 25 format)
Hence for the purpose of this study HPRD was excluded. Based on the selected
databases Table 4.3 shows the exact data releases that were used in this work. Links
to the online data repositories, specifying the datasets and releases used are listed. To
analyse the development of database content and its consistency, data belonging to
two different releases was considered. Data were downloaded directly from the online
repositories, and are accessible via FTP servers. Since the previous HIPPIE release
was published more than 18 months earlier only one HIPPIE dataset was considered.
In summary, a number of PPI databases gather protein interaction information and
make it publicly available to the wider research community. The use of a uniform data
format allows information to be compared and combined, while maintaining highest
quality.
Based on those efforts it became easier to access and use the data in a solitary and
joint manner. Nevertheless content in different repositories still varies. Cross analysis
and strict filtering can help to obtain the most concise PPI dataset possible. Based on
available resources and including only a minimum of false positive interactions, this
chapter aims to obtain such a dataset. Details regarding the data cleaning and joining
process can be found in the next section.
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Table 4.3: Overview of the four databases of choice. All supply data in the mitab25
format. Two different, recent releases, per database are listed together with the data-
file names.





















The use of datasets from different sources made it necessary to merge information.
One of the key challenges was the mapping between gene and protein IDs that were
used as primary identifiers by the different databases (see Table 4.2). This discrepancy
might be one of the main reasons why most other researchers limit themselves to using
data retrieved from only one of the listed resources. Nevertheless using information
from all different sources broadens the insight and allows a more complete dataset to
be obtained.
Therefore a number of mapping and merging approaches were carried out. Bi-
oGRID and HIPPIE use Entrez IDs as their primary interactor identifier, but DIP and
IntAct base their primary interactor identifiers on Uniprot IDs or Uniprot Accession
IDs. To obtain consistency, the following steps were taken after having downloaded
the data:
1. Raw data files from each database were considered individually. All files were
read and headers were checked to confirm the mitab25 format. Data were filtered
for the taxID of interest (“9606” for human). 15 standard mitab25 columns were
printed in database specific output files, using official mitab25 headers. This step
was also used to extract some statistical insights (e.g. the percentage of human
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PPIs compared to the full dataset).
2. Each of the preprocessed files was considered individually. Columns 1 and 2,
containing the interactors, were read. Columns were checked individually. If
the column content was identified as an Entrez ID, it was kept (based on an
internal comparison with the mapping table, see Section 2.2.1 for more details).
If the supplied interactor was not an Entrez ID it was first checked against a
list of UniprotIDs. In case of successful mapping, the Entrez ID was obtained
and used. Alternatively the supplied interactor ID was checked against Uniprot
Accession IDs and mapped to the corresponding Entrez ID (for mapping tables
see Section 2.2.1). In some cases a UniprotID mapped to a number of different
human Entrez IDs, meaning that the same protein is encoded by different genes.
In those cases all possible Entrez IDs were added to the PPI set. This phenomena
can influence the number of total PPIs before and after the mapping step.
In case one of the two, or both, interactor identifiers could not be mapped to an
Entrez ID the interaction was not included. If mapping was required, the “origi-
nal” identifier was moved to columns 3 or 4 (“alternative IDs”) respectively.
In an additional step, other columns were processed simultaneously to reflect the
following standards:
(a) Columns 7 and 12, the “interaction detection method” and “interaction
type” were standardised to identifiers in the “MI:number” format.
(b) Columns 9, 10 and 11, containing pubmed IDs as well as taxIDs of both
interactors were cleaned to contain only respective numeric identifiers.
(c) Column 13, containing information about the source database was trans-
lated to the database’s MI-ID. Database name to ID mappings were ob-
tained from the Ontology lookup service (Jupp et al., 2015) and an overview
table can be seen in Appendix Table B.2.
Depending on the database additional filtering steps were applied and will be
introduced in more detail later on, since these are based on intermediate results.
In summary, this step generated database specific mitab25 files with unified iden-
tifiers, Entrez IDs, and standardised column content. In columns with multiple
entries, the pipe (“|”) separator was used as a divider. If protein IDs were used
and mapped to several Entrez IDs these were added to the dataset as new rows,
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maintaining information in the additional columns. These data can be used to
identify similarities and differences between the repositories, and allow for fur-
ther data processing.
3. Having translated all data to unique identifiers, data from different sets were
joined. During this data merge interactors were first kept in the original column
order, but later sorted by ascending Entrez ID (Entrez ID interactor 1 < Entrez ID
interactor 2). Where an interaction occurred multiple times information in any
of the other columns was joined and separated by “|”. Ordering of the identifiers
results in a file with unique PPIs, excluding mirrored duplicates (a-b and b-a are
merged to one interaction, where “ID-a < ID-b”).
4. Based on further intermediate results, other filtering steps were undertaken. These
addressed certain columns and extracted full rows depending on the filtering cri-
teria. Details are covered in the Results section (Section 4.3).
The joint dataset was analysed to understand and identify similarities and differences
between data sources and to detect potential bias and underlying patterns in the data.
4.3 Results
To gain a deeper understanding of published PPIs, individual datasets obtained from
four distinct databases (Section 4.2.3) were processed and analysed. Through specific
data filtering a joint set was obtained. This chapter shows intermediate results, outlines
filter settings and introduces the “final” PPI set further used in this study. Statistical
analysis is also presented.
4.3.1 Data Analysis and Cross-Comparison
Individual datasets were analysed regarding the number of PPIs they contain. A first
filter was set to consider only human PPIs. Two different data releases were consid-
ered to track development over time. Table 4.4 and Table 4.5 show source-specific
overviews regarding the number of PPIs contained in the different databases. Table
4.4 refers to the most up-to-date data as of August 2016, whereas Table 4.5 presents
most up-to-date datasets available in May 2017. Numbers increase slightly with the
newer release, but relative proportions of data in the different databases remain the
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same. Overall both tables show that the number of deposited PPIs varies widely be-
tween databases. If not further specified this chapter refers to numbers based on the
most up-to-date data in March 2017 (Table 4.5).
In terms of numbers, BioGRID contains the largest amount of total entries: ~1.4
million. It is followed by IntAct with ~0.7 million entries, HIPPIE with ~ 0.27 million
PPIs and DIP with ~76 thousand interactions.
Table 4.4: Overview of PPIs obtained from four databases (August 2016). Numbers
represent PPI counts based on the row count in the file. Some PPIs may occur multiple
times and duplicates such as (a-b and b-a are counted separately). “Human” means
that both interactors were associated with the human taxid (9606). “Unique” PPIs rep-
resents the unique number of PPIs (filtered for mirrored duplicates). Direct interactions
were obtained by filtering for direct-only interaction types.
BioGRID DIP HIPPIE IntAct
Rows in file (PPIs) 1,030,500 76,796 273,927 650,097
Human PPIs 298,823 5,537 273,927 122,049
+ 49,005 (unassigned pubmedID - rows)
+ 73,999 (spoke expansion - rows)
Percent human PPIs 28.99 7.21 100 18.77
PPIs mapped to human Entrez ID 298,745 6,010 272,431 117,571
Unique PPIs mapped to human Entrez ID 216,887 5,967 271,815 61,627
Unique, direct PPIs mapped to human Entrez ID 184,648 5,957 0 60,959
Table 4.5: Overview of PPIs obtained from four databases (March 2017). See caption
Table 4.4.
BioGRID DIP HIPPIE IntAct
Rows in file (PPIs) 1,381,962 76,881 273,927 718,180
Human PPIs 305,924 5,569 273,927 125,147
+ 81,256 (unassigned pubmedID - rows)
+ 76,939 (spoke expansion - rows)
Percent human PPIs 22.13 7.24 100 17.42
PPIs mapped to human Entrez ID 305,847 6,041 272,431 120,224
Unique PPIs mapped to human Entrez ID 221,419 5,998 271,815 62,136
Unique, direct PPIs mapped to human Entrez ID 188,945 5,988 0 61,458
After filtering the data for human-only interactions, with both interactors associ-
ated with the human taxID (9606), it was confirmed that HIPPIE only contains human
specific interactions. Considering the other databases (see Table 4.5), BioGRID con-
tains the highest proportion of human-only PPIs (~22%), followed by IntAct (~17.5%)
and DIP (~7%). The number of human IntAct PPIs splits up into: (i) 81,256 inter-
actions which lack an associated pubmed ID, (ii) 67,939 spoke expanded interaction,
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leaving (iii) 125,147 interactions following this study’s requirements. Studies without
a pubmed ID referenced an IMEx4 number instead. It is a joint effort across molecular
data databases to provide curated information, e.g. from PPI databases. All 81,256
interactions were retrieved from two studies. These were published in 2016 and 2017
with IMexx identifiers “IM-25054” and primary pubmedID “unassigned1312”5 as well
as “IM-25472” and “unassigned1304”6 respectively. It was surprising that the PPI
records did not show an associated pubmedID. Detailed investigation showed that the
study published in 2016 was associated with a pubmedID (27173435) (Boldt et al.,
2016), based on the data description qualifier “see-also”. Such a link was not available
for the study published in 2017. To maintain reproducibility, consistency and allow for
automated and controlled data curation, PPIs retrieved from those references were not
considered.
Furthermore, spoke expanded PPIs are likely to include a high percentage of false
positive entries. These were identified and excluded from the PPI set to maintain best
possible data quality. After identifying those “special” cases IntAct data were filtered
accordingly.
In the next step, and to obtain comparable datasets all “interactor identifiers” were
mapped to human Entrez IDs. BioGRID and HIPPIE entries were already supplied as
such. Nevertheless all entries were compared with records in the mapping file and only
kept if both interactor Entrez IDs could be confirmed. In the case of IntAct and DIP,
Uniprot IDs or Uniprot Accession IDs were mapped to Entrez IDs. As Table 4.4 and
Table 4.5 illustrate most of the entries could be mapped to human Entrez IDs. Consid-
ering data in DIP it can be seen that the number of “PPIs mapped to human Entrez IDs”
is higher than the number of “human PPIs”. This is due to multiple mappings of single
UniprotIDs to several Entrez IDs. One example is uniprotkb Q13748, representing the
Tubulin alpha-3C/D chain, which maps to two Entrez IDs: 7278 (tubulin alpha 3c),
and 113457 (tubulin alpha 3d). Similarly uniprotkb P86479, proline-rich protein 20C
maps to six different Entrez IDs, all being different forms of the proline rich 20 genes.
This intermediate step allowed further analysis carried out in subsequent steps.
Directionality in PPIs is very hard to measure and will not be considered in this
work. Some PPIs are listed in both directions (a-b and b-a). In some cases this is
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so called “mirrored duplicates” were filtered and equal PPIs were joined, keeping all
meta-data. Table 4.4 and Table 4.5 show the consequences on PPI numbers after this
filtering step. Remaining PPIs are referred to as “unique”. All further statistical anal-
ysis reflects only uni-directional (“unique”) interactions.
A further crucial aspect when considering PPIs and using information for data anal-
ysis is the fact that interactions can be direct or indirect. Considering the use of PPI
information in this study, and since most analytical approaches rely on physical protein
interactions, these should be direct. Therefore direct experimental evidence is crucial
to guarantee a minimum certainty of an interaction happening under in vivo condi-
tions. To obtain such information the “interaction type” was considered (column 12 of
the psimi25 PPI file). Figure 4.2 shows details about interaction types associated with










































































































































































































































































































































































Interaction type and PPI numbers
Figure 4.2: PPIs based on a certain “interaction type”. Data from all four source
databases, not filtered for direct interactions is visualized (“unique PPIs mapped to
human IDs” in Table 4.5). The x-axis shows the interaction type in alphabetical order.
It can be seen that a number of PPIs are considered interactions, based on protein
‘colocalization” as well as “genetic interaction”. These interaction types, classified
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as non-physical, contain a high probability of not being direct, instead proteins were
detected in a shared cellular location or via “genetic interaction”. Therefore these
classifiers were considered as “non-direct” interactions.
After having excluded these two interaction terms an interaction type ontology
(Jupp et al., 2015) was used to identify a set of “direct” interaction type identifiers.
Figure 4.3 shows an overview of interaction types part of the ontology tree. This
confirmed that “colocalization” (MI:0403), “genetic interaction” (MI:0208) (including
“suppression” (MI:0796) and “synthetic” (MI:0794) amongst others) and “predicted
interaction” (MI:1110) were classified as being very likely to refer to non-direct inter-

























Total of 63 children terms
Figure 4.3: Tree structure of the interaction type ontology branch and respective MI-ID.
The term “molecular association” (MI:2232) was considered as indicating direct
interactions and addressed in more detail. With respect to the ontology it is followed
by the interaction types “association” (MI:0914), “physical association” (“MI:0915”)
and “direct interaction” (“MI:0407”). The “direct interaction” term contains 63 spe-
cific child-terms, all indicating different subtypes of direct interactions. It was also
discovered that some of the source data references the obsolete interaction type “phys-
ical interaction” (MI:0218), which was updated to “association” and “physical asso-
ciation”. After checking all the individual child terms referring to specific “direct
interaction” types it was decided to include them all to the final list classifying direct
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interactions. Hence a final set of 67 MI-IDs specifically describing direct PPI inter-
action types was obtained and used to filter PPI data for direct interactions only. An
overview of the direct MI-IDs can be seen in Appendix Table B.1 and was used to filter
the database-specific PPI sets.
Remaining PPI numbers can be seen in the last row of Table 4.4 and Table 4.5
(“unique, direct PPIs mapped to human EnterzIDs”). Hence the number of unique,
direct, human PPIs which are deposited in the databases and could be mapped to En-
trez IDs are 188,945 (BioGRID), 61,458 (IntAct) and 5,998 (DIP). Due to a lack of
information none of the interactions retrieved from the HIPPIE database remained part
of the set. Numbers are based on data from May 2017 (Table 4.5).
The datasets obtained were re-analysed regarding the distribution of different inter-
action types. An overview can be seen in Figure 4.4. “Physical association” remains
the main type, followed by “direct interaction” and “association”. “Phosphorylation
reactions” are the fourth most common type. Another 25 terms appear describing at



















































































































































































































































































































Interaction type and PPI numbers
Figure 4.4: PPIs in the dataset based on a certain “interaction type”. Data from all
four source databases filtered for direct interactions is visualized. The x-axis shows the
interaction type in alphabetical order.
Since the HIPPIE database does not supply information regarding the “interaction
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type”, the overlap of unique PPIs deposited in HIPPIE and the other databases was
investigated. Figure 4.5 shows that 44,547 out of 271,815 PPIs are only found in
HIPPIE. On the contrary, the remaining ~84% (227,268) of the HIPPIE PPIs appear
in at least one of the other databases. Hence interaction type information and other
meta-data can be obtained from there. Given the interest of eliminating as many false
positive PPIs as possible it is preferred to not consider PPI records without “interaction
type” information. This lead to the exclusion of PPIs unique to the HIPPIE database.
Figure 4.5: Overlap of PPIs supplied by the different databases.
To understand the development of available data, two of the most recent releases
for each database were compared. Table 4.4 and Table 4.5 show that all databases
but HIPPIE exhibit an increase in the number of stored PPIs. HIPPIE data were not
updated between August 2016 and March 2017. Since the data were not included in the
final dataset this was not further investigated. Numbers of PPIs obtained from other
sources increased by varying numbers of interactions, depending on the annotation
methods used by the source databases. This insight highlights the need of constant
data-updating to maintain best data quality.
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4.3.2 The final, joint, human PPI dataset
Based on the above insights a final PPI dataset was generated and can be found in the
digital supplementary material (folder: “PPI-data”). Examples showing the raw data
format as well as the final, human, unique, direct PPI lists and a README file are
available. Table 4.6 shows a total of 353,294 PPIs, available with Entrez IDs. 288,958
of those are unique, and again, 211,824 are unique and direct. A number of other
statistics are included in the table.
Table 4.6: PPI count depending on different filter settings.
Joint PPI set number of PPIs (August 2016) number of PPIs (May 2017)
Human PPIs 347,898 353,294
Human unique PPIs 284,169 288,958
Human unique direct PPIs 207,175 211,824
Number of pubmed-id references 31,386 32,271
Number of interaction detection methods 160 161
Number of interaction types 32 33
Number of source types 14 14
Hence, after applying all outlined filtering steps, the final PPI set only contains
interactions with a pubmed reference and, when information was available, excludes
any spoke expanded interactions. As far as can be ascertained this is the currently
in existence most concise and complete PPI dataset excluding as many false positive
records as possible, with a low removal rate of real PPIs. This is a major step forward
towards highest data quality. The dataset was further analysed and the results are as
follows.
Figure 4.6 shows the overlap of PPIs appearing in the three remaining sources.
This figure also highlights the data diversity in the different databases, with only 1,264
PPIs appearing in all three source databases.
Based on that insight information listed in the “source database(s)” column of the
final PPI dataset was analysed. All original sources are shown in Figure 4.7, with
BioGRID and IntAct as the main references. Mint, DIP and the Uniprot knowledge
base follow, together with 9 additional sources appearing with small numbers of PPIs
associated with them. These additional PPI databases are mostly smaller efforts con-
centrating on subsets of available data. They were not considered individually since
the selected databases integrate information deposited in those smaller ones. A poten-
tial explanation for the high numbers of PPIs provided by BioGRID is their relabelling



















Figure 4.6: Overlap of PPIs between the three main databases that were kept to retrieve
the final (human, unique, direct PPI dataset).
Based on this insight Figure 4.8 shows in how many “source database(s)” a PPI
appears. The majority, almost 170,000 (~80%) PPIs are only listed in one source
database, with a maximum of six (out of 14 possible databases, see Figure 4.7).
To further test PPI detection coverage, PPIs are checked for the number of different
publications they appear in. As indicated in Table 4.6, 32,271 different pubmed IDs
describe 211,824 PPIs. Figure 4.9 highlights that most of the PPIs are found in only
one publication (~190,000 PPIs, corresponding to ~90%), with the remaining ~10%
confirmed in two or more. This percentage is higher when considering PPIs that ap-
pear in multiple source databases. Around 20% of the PPIs appear in two databases or
more, showing that databases pick up interactions from the same publications. Regard-
ing the coverage based on publications, a maximum of 389 references for one single
PPI can be detected. The interaction between MDM2, the MDM2 proto-oncogene (En-
trez ID: 4139) and TP53, tumor protein p53 (Entrez ID: 7157), has been described in
389 publications. This might highlighting a key role and ubiquitous presence of the
interaction, but also points towards a very highly studied interaction, leading to the
high, observed value.






















































Source Database of PPIs
Figure 4.7: Human, unique, direct PPIs found in different source databases (based on
information in the “source database” column of the mitab25 files). The x-axis shows the
source database in alphabetical order.
In conclusion, the analysis presented leads to a high confidence dataset which can
be used for future studies. Source and interaction type of PPIs offer a good understand-
ing of data quality. Furthermore additional filtering can be applied depending on the
user’s needs and requirements.
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PPIs and their database source coverage
Figure 4.8: Human, unique, direct PPI coverage in different source databases (based
on “source database” count).











PPIs and their pubmedID coverage
Figure 4.9: Human, unique, direct PPI coverage in different publications (based on
“publication identifier” count).
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4.4 Discussion
A growing number of databases supply PPI information. However their content varies
widely and most often individual studies use data from only one resource.
Based on the use of the accepted PSI-MI XML 2.5 standard, the mitab25 for-
mat allows combination and comparison of data from different sources. Nevertheless
databases use different primary identifiers for interactors. The human Entrez ID was
chosen as the main identifier in this study and two mapping files (Entrez IDs to Uniprot
IDs as well as Entrez ID to Uniprot Accession IDs) were used to make the mapping
process as complete as possible. Checking all Entrez IDs for their presence in the
mapping file guaranteed the exclusion of outdated or replaced records.
The use of Entrez IDs unique to genes is debatable, since it does not reflect post-
translational modifications such as splicing and other events. These can lead to protein
isoforms which are not reflected in Entrez IDs. Nevertheless they were considered the
best option guaranteeing consistency and avoiding divergent results due to different
protein isoforms. Detecting specific PPIs based on exact protein variants is almost
impossible given current technologies. For consistency between data and annotation
methods the use of gene IDs seemed to be more precise and avoided biases towards
more easily detectable transcription variants of a protein.
Considering the PPI type and defining a set of direct interaction types reduced
the number of total interactions, generating the final, best possible interaction dataset,
given the defined interests. Depending on data use, this step seems crucial and avoids
including too many false negative records, possibly leading to wrong conclusions.
The large differences between data deposited in different databases demands atten-
tion. Therefore combining information from distinct sources is important and allows
complete PPI datasets to be assembled to the best of current knowledge. It also exposes
how different data gathering, extraction and annotation strategies used by the different
databases are, none of which can be considered as the only right or wrong approach.
The information combination hence enriches the final PPI dataset, a more complete
one, compared to ones considering only single sources.
These are just some aspects highlighting the improved quality of the presented
dataset. Considering and including as much (high-quality) data as possible allows
for optimal and most reliable results. Since the presented dataset is straight-forward
to generate and shared with the scientific community it could help other researchers to
easily benefit from the full range of available PPI data for their studies , without having
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to personally join information from different sources.
A similar effort was made by the IMEx consortium (Orchard et al., 2012). It aims
to supply a non-redundant PPI set spanning a range of organisms. In some cases data
are still repetitive and a number of primary resources have not yet been integrated. Fur-
thermore BioGRID data are not included and contain a large part of the analysed data,
since it does not overlap with information available via DIP and IntAct. Additionally
psicquic, which is compatible with IMEx supplies a data query interface which allows
to retrieve interactions from IMEx associated databases. An R package supplying an
interface to psicquic is available via bioconductor7 and linked to the HUPO Proteomics
Standard Initiative (HUPO-PSI). A list of linked PPI databases can be found online8.
During the exploration of options of this project, there were times when some of the
advertised linked source databases were not reachable via psicquic. Furthermore com-
putation times to obtain the desired datasets were very long, given the large size of the
full human PPI set. Additionally it was preferred to have direct access to the meta-data
instead of having the psicquic tool act as the intermediate filter. Working with raw
data also allowed its in-depth analysis, such as cleaning and standardising meta-data.
This highlights the increased quality and interoperability of the presented PPI dataset.
Nevertheless psicquic is a good tool, especially when working with smaller datasets.
It allows researchers to obtain PPI information deposited in different sources making
their datasets more complete.
Overall the implemented approach allowed for higher flexibility in updating data,
obtaining statistics and being able to access all meta-data at any point. It was possible
to generate the best possible and most up-to-date PPI dataset for human, unique, direct
interactions. The ease of rerunning the data extraction and combination pipeline al-
lows constant use of most up-to-date data, directly supplying statistics describing most
recent changes to the database content. This again illustrates the quality of the dataset
as well as its maintain- and traceability including all available meta-data. Extending or
modifying existing studies based on updated PPI data gets easier since the presented
process is more transparent and PPI source relationships can be easily obtained, which
is not the case using for example the psicquic tool. Furthermore the flexibility of fil-
tering options and ease of use makes the pipeline and PPI set a valuable source for the
wider research community.
As more studies become available it seems that not all PPIs have been discov-
7https://bioconductor.org/packages/release/bioc/html/PSICQUIC.html
8http://www.ebi.ac.uk/Tools/webservices/psicquic/view/main.xhtml
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ered yet. Coverage is still low with new studies identifying additional PPIs instead
of rediscovering already known ones. Hence the (human) PPI set still appears to be
incomplete. The increase in PPIs between August 2016 and May 2017 confirms this
phenomenon. Future studies will show if the total number of PPIs stagnates, indicating
a saturated PPI dataset. More targeted PPI analysis could also show that the full set of
interactions occurring in certain cell types or tissues, at specific developmental stages
is already completely understood, but remains challenging to be identified.
When using PPI data, given a specific background, it has to constantly be consid-
ered that none of the databases supply information regarding the tissue, cell type, cell
compartment, or developmental stage in which an interaction occurs or was recorded.
In addition many interactions have been detected based on experiments carried out
under artificial, experimental conditions, using varying setups. Even though human
proteins were used, interactions might have been discovered in-vitro and not in-vivo,
and partially in cells derived from different organisms (Rao et al., 2014). Other chal-
lenges are presented when considering the definition of a direct interaction and the
way they can be identified in experiments. For example pull-down experiments do not
only detect direct interactions, but include first and second order interactors if they
are part of interaction complexes (Zhang et al., 2008). First order interactions are di-
rect whereas second order interactions are indirect, with additional proteins between
the two proteins identified. Only the IntAct database includes information of those so
called “spoke expanded” interactions. Other databases do not supply such information
but include PPIs derived from pull-down experiments. Excluding all records retrieved
from pull-down experiments seemed too strict, since they represent a reliable, well
studied and high quality source. Nevertheless specifically labelled records (from the
IntAct database) were excluded to maintain data quality. New technologies may be
able to produce and confirm this information in the future, allowing for more precise
filtering and leading to even more concise PPI datasets.
Notwithstanding the uncertainty of confirming the presence of an interaction in a
given tissue, or during a specific developmental stage, the use of proteomic data are of
high value. Knowing the set of expressed genes in a tissue of interest allows a more
precise PPI set to be generated. This does still not eliminate the problem of temporal
expression patterns, but excludes proteins and their interactions that are not expected to
occur in the tissue at all. With improving proteomic experimental setups this challenge
might be counteracted and data could be retrieved capturing different developmental
stages, enabling the comparison between the proteomes as well as their interaction
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patterns e.g. at different developmental stages. Some first efforts have been made,
including multi-scale modelling. However to gain confidence in the results, detection
limits for proteomics still need to improve.
The growing availability of PPI data also led to an increase in analytical tools for
large-scale study. The potential of PPI data, is to unravel patterns among connected
proteins on a large scale, which is of high value and part of an expanding field.
Therefore the next two chapters focus on the identification of a proteomic dataset
and the use of PPI data. Chapter 5 identifies and introduces the proteomic datasets of
interest and Chapter 6 combines the proteomes with PPIs and uses network analysis
approaches, including clustering techniques, to gain a deeper insight into the data. This
can help to find answers to various scientific questions. This work focuses specifically
on the effects of Parkinson’s Disease (PD) in the synapse.

Chapter 5
The Synaptic Proteome and
Parkinson’s Disease
This chapter covers work that was part of a joint project. All analytical results pre-
sented in this chapter were obtained by myself. Screening and annotating of published
synaptic proteomic studies was carried out by Colin Mclean and Oksana Sorokina,
both from Douglas Armstrong’s research group at the University of Edinburgh. This
work is currently in preparation to be published with above mentioned co-authors and
will be submitted shortly.
5.1 Objective
This chapter aims to identify the most up-to-date proteomic datasets describing the
presynapse, postsynapse, synaptosome and the entire synapse. Once required mapping
steps were carried out, individual datasets were joined to generate “regional” synaptic
reference proteomes, specific to the presynapse, postsynapse, synaptosome as well as
the synapse. Extracted data were compared to identify reference datasets containing
all expressed proteins in the synapse.
Since the regional datasets emerged through data-fusion, based on different publi-
cations, protein detection coverage relative to the year of first detection is presented.
This helped to determine data quality and allowed to carry out meta-analysis of the
final proteomic datasets. In this way similarities and differences between protein-sets
expressed in distinct synaptic regions were identified.
To understand synaptic region specific and overall functions, enrichment analy-
sis was used. Through the use of gene-trait annotation information it aims to identify
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over-represented specific traits in a subset of a given dataset. These traits can be molec-
ular functions, biological processes and cellular components common amongst genes
uniquely expressed in a region of choice. This approach helps to gain region specific
insights as well as identify common synaptic specific functions.
Furthermore Parkinson’s Disease (PD) associated genes were compared with the
synaptic proteome. By doing so a set of synaptic PD associated genes was identi-
fied. Consequentially this also leads to a set of PD associated genes not expressed in
the synapse. It was of interest to extract common properties of genes in the two PD
gene lists, as this new knowledge can then help identify main disease-affected cellular
functions, pathways and components in the synapse and other tissues.
Figure 5.1 shows an overview of described approaches, including data input, ap-

















































Figure 5.1: Overview of used data, analytical processes and outcomes of Chapter 5.
Dark blue boxes refer to published data, light blue boxes are generated datasets, yellow
boxes refer to analytical steps, green boxes describe processes and magenta boxes
show outcomes.
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5.2 Introduction and Material
A cell’s phenotype and characteristics are defined by the expressed genes and conse-
quently transcribed proteins. The set of expressed proteins in a cell is referred to as
its proteome (Figure 1.1 B). In recent years a number of tissue and cell type specific
proteomes have been identified, analysed and published. Thanks to the increase in
large-scale experimental approaches the number of published studies rises constantly.
This leads to larger, very likely more complete proteomic datasets resulting in higher
statistical power to draw significant data-based conclusions.
Since the synapse is thought to be the main cellular region affected by PD, hosting
disease-causing alterations it was addressed in this study. These alterations can pro-
voke a number of dysfunctions, ultimately triggering the degeneration of dopaminergic
neurons leading to the disease manifestation.
5.2.1 Proteomic Studies
The selection of proteomic studies was carried out in a joint effort and based on the
research groups expertise in the field. Individual publications were studied and sup-
plied protein identifiers were retrieved. Therefore data were extracted from a variety
of file-types, such as .txt, .csv and .pdf. To obtain consistent identifiers these needed
to be mapped between the different species mouse, rat and human. Mappings between
protein and gene or gene and gene identifiers were carried out as specified in Section
2.2.1.
5.3 Results
5.3.1 Synaptic Proteome Datasets
Nine presynaptic, 22 postsynaptic and six synaptosome proteomic studies were iden-
tified. Two studies contain two datasets each: Distler et al. (2014) in the postsynaptic
set and Cohen et al. (2013) in the synaptosome set. These were considered separately,
leading to 23 postsynaptic and seven synaptosome datasets.
Data were extracted and all identified genes were mapped to human Entrez IDs.
Homology information from published annotation files was used and verified through
manual checks. If an entry could not be mapped it was discarded. For all the studies,
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Table 5.1 contains further information such as the organism the data were obtained
from as well as the number of identified genes (mapped to human Entrez IDs).
Table 5.1: Synpatic proteome publications and respective datasets used in this study.
“# genes” refers to the number of proteins, mapped to human Entrez IDs identified in
the study. Studies are sorted based on presynapse, postsynapse, synaptosome and
ascending depending on the year of publication. Studies highlighted with * contain two
datasets. More details can be found in the Appendices C.1, C.2, C.3.
Study Year Reference Region Species # genes
MORCIANO 2005 Morciano et al. (2005) presynapse rat 85
BURRE 2006 Burré et al. (2006) presynapse rat 157
MORCIANO 2009 Morciano et al. (2009) presynapse rat 308
GORINI 2010 Gorini et al. (2010) presynapse mouse 49
GRONBORG 2010 Grønborg et al. (2010) presynapse rat 613
BOYKEN 2013 Boyken et al. (2013) presynapse rat 414
WILHELM 2014 Wilhelm et al. (2014) presynapse rat 1158
BRINKMALM 2014 Brinkmalm et al. (2014) presynapse mouse 68
WEINGARTEN 2014 Weingarten et al. (2014) presynapse mouse 467
WALIKONIS 2000 Walikonis et al. (2000) postsynapse rat 29
PENG 2004 Peng et al. (2004) postsynapse rat 325
SATOH 2002 Satoh et al. (2002) postsynapse mouse 45
YOSHIMURA 2004 Yoshimura et al. (2004) postsynapse rat 435
FARR 2004 Farr et al. (2004) postsynapse rat 71
JORDAN 2004 Jordan et al. (2004) postsynapse mouse and rat 390
LI 2004 wan Li et al. (2003) postsynapse rat 137
TRINIDAD 2005 Trinidad et al. (2005) postsynapse mouse 234
CHENG 2006 Cheng et al. (2006) postsynapse rat 288
COLLINS 2006 Collins et al. (2006) postsynapse mouse 717
DOSEMESI 2006 Dosemeci et al. (2006) postsynapse rat 113
DOSEMESI 2007 Dosemeci et al. (2007) postsynapse rat 548
TRINIDAD 2008 Trinidad et al. (2008) postsynapse mouse 2150
SELIMI 2009 Selimi et al. (2009) postsynapse mouse 61
FERNANDEZ 2009 Fernández et al. (2009) postsynapse mouse 292
BAYES 2010 Bayés et al. (2011) postsynapse human 1441
BAYES 2012 Bayés et al. (2012) postsynapse mouse 1545
SCHWENK 2012 Schwenk et al. (2012) postsynapse unknown 34
DISTLER PSD1* 2014 Distler et al. (2014) postsynapse mouse 3545
DISTLER PSD2* 2014 Distler et al. (2014) postsynapse mouse 2092
BAYES 2014 Bayés et al. (2014) postsynapse human 1141
UEZU 2016 Uezu et al. (2016) postsynapse mouse 1111
FOCKING 2016 Föcking et al. (2016) postsynapse human 2026
FILIOU 2010 Filiou et al. (2010) synaptosome mouse 2778
DAHLHAUS 2011 Dahlhaus et al. (2011) synaptosome mouse 638
ZIV synapse* 2013 Cohen et al. (2013) synaptosome rat 185
ZIV full* 2013 Cohen et al. (2013) synaptosome rat 2447
BIESEMANN 2014 Biesemann et al. (2014) synaptosome mouse 157
CHANG 2015 Chang et al. (2015) synaptosome human 2076
DISTLER 2014 Distler et al. (2014) synaptosome mouse 4475
Further details, including an extended description of the datasets, can be seen in
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Appendices C.1 (presynapse), C.2 (postsynapse) and C.3 (synaptosome). The ap-
pendix tables also include details regarding experimental approaches used in the orig-
inal studies. Distler et al. (2014) is the only study supplying data for more than one
region. The publication contains data describing the synaptosome as well as the post-
synapse.
Data was retrieved from the individual publications and can be found in the digital
supplementary material (folder: “synaptic-proteome-data”). It contains one file for
the presynaptic, postsynaptic and synaptosome proteome. These specify the different
studies and respective proteins in the set.
Having a unique identifier (human Entrez IDs) for all genes is of great value and
allows efficient comparison of datasets amongst each other. Based on the growing
number of available studies, the increase in detected proteins was analysed. Figure 5.2
visualizes the increase in identified presynaptic (5.2a), postsynaptic (5.2c) and synap-
tosome (5.2b) proteins over the time since the first proteomic study was published.
Those different datasets will be referred to as region specific synaptic datasets or pro-
teomes. Figure 5.2d shows the dataset growth considering the union of all proteins
in the three regional datasets. This dataset will be referred to as the joint synaptic
proteome.
All four plots show an increase in the number of proteins. Presynaptic data started
to be published in the early 2000’s and show three peaks in protein numbers, one when
first published (2004), a second around 2010 and an additional increase in recent years,
leading to a current total of 1,867 presynaptic proteins (Figure 5.2a). Studies address-
ing the synaptosome have only been published starting from around 2010. Based on
available experimental approaches, those already contained more than 2,500 proteins.
By 2016 the number of identified synaptosome proteins grew to 5,862 proteins (Figure
5.2b).
The postsynaptic proteome in comparison has been studied for almost 20 years.
Initially smaller datasets were identified and a first significant increase in identified
protein numbers can be seen in the early 2000’s. This is followed by another peak
leading to around 2,500 identified proteins which stabilises nicely around 2010. More
recent studies lead to another rise in protein numbers leading to a current total of 5,053
postsynaptic proteins (Figure 5.2c).
Considering the synaptosome as an individual unit might be subject to discussion,
since, by definition, it contains all presynaptic and postsynaptic proteins. Hence the
union of all three datasets was also considered. It shows constant data growth up to the

































































































































































(d) Synapse (joint set)
Figure 5.2: Increase in unique synaptic proteins, identified in different studies over the
indicated years. Years without a bar reflect that no new data were added in those years.
current number of 6,706 proteins. The increase in identified proteins follows roughly
the steps indicated for the postsynaptic proteome (increasing in the early 2000’s, 2010’s
and in recent years (Figure 5.2d).
The time-frames of dataset growth are similar in all cases. The clear steps might
reflect advances in experimental setups and analytical approaches which allowed de-
tection of by then undiscovered proteins.
The postsynaptic and synaptic datasets show relatively clear plateaus in protein
growth. This stagnation might indicate that the full datasets for those regions are al-
most identified. Regarding the presynapse and synaptosome no plateaus can be ob-
served. Hence it is likely that an additional number of proteins, possibly already in-
cluded in the current synaptic proteome will be associated with the presynapse based
on future studies.
The next section addresses the presence of proteins found in different studies as
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well as their functions.
5.3.2 Protein Coverage and Data Consistency
To test whether newer studies lead to a stabilization of total protein numbers in the
regional sets their coverage amongst different studies was analysed. Due to improved
experimental setups, it is suspected that newer studies re-detect proteins which had
already been identified in previous analysis. Such findings would confirm synaptic
proteome sets quality and consistency. Coverage is referred to as the number of studies
in which a specific protein has been detected.
Figure 5.3 shows the number of genes detected with a certain coverage (blue bars).
Since the number of studies varies among different datasets, total numbers can be
misleading. Therefore Figure 5.3 also visualizes the coverage on a proportional scale
(red bars). Both visualizations show that the majority of proteins have a coverage of
1 (for all four datasets: presynapse, postsynapse, synaptosome and the total synapse).
This phenomenon is prominent in the presynaptic and synaptosome datasets, showing
a steep dip of protein numbers associated with coverage 1 and 2.
When considering the percentage bars a slightly different impression can be ob-
tained. The postsynaptic, as well as the joint synaptic dataset, contain a larger pro-
portion of proteins identified in two studies or more: 68% and 75% respectively. This
leaves 32% and 25% of the proteins identified in a single study. Considering the presy-
napse and synaptosome, slightly more than 60% and almost 45% of the proteins are
found in one study only which is likely due to the lower number of total published
studies addressing those regions.
Overall this approach does not consider the moment of first detection of a protein.
Figures 5.4, 5.5, 5.6 and 5.7 reflect this fact, as well as protein detection coverage in
studies published after first detection. Proteins are only associated with a year if they
were newly detected. Each protein is represented once and multiple detections in other
studies are visualized based on the coverage colour code. For example a postsynaptic
protein detected in 2004 is one of almost 800 others first detected in 2004 (Figure
5.5). It was detected in at least one of five studies (see Figure 5.5, “studies” in x-axis
label). Total studies indicates how many studies were published in the given year (here
2004) and thereafter (until 2016). Assuming the scenario that the protein of interest
was detected in two studies published in 2004 and another five thereafter it is one of
the proteins counted towards the “coverage seven” colour code in the barplot.
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(d) Synapse (joint set)
Figure 5.3: Number of proteins found in the regional proteomic studies and their cover-
age in a specific number of studies (blue bar). The red bar indicates the percentage of
proteins identified with the respective coverage relative to the studied dataset.
This approach helps to highlight proteins detected for the first time at a later point,
possibly due to advances in experimental technologies and not “penalising” their later
detection through lower coverage, compared to “long standing single coverage” pro-
teins that have not been re-detected in a large number of follow-up studies. An example
could be the almost 100 presynaptic proteins first published in 2009 (see lowest, com-
pletely transparent part of the bar, Figure 5.4). These have not been re-detected in any
of the following six studies published thereafter, whereas the remaining approximately
120 proteins were found in at least one more future study.
Hence Figures 5.4, 5.5, 5.6 and 5.7 confirm the peaks in dataset growth, indicat-
ing an increase in protein numbers in 2004, around 2010 and 2014. This supports
the hypothesis that more advanced, fine-grained experimental techniques lead to the






































































































































Figure 5.4: Coverage of presynaptic proteins, relative to year of first detection. X-axis
label contains the year, number of studies published in that year (“studies”) and the




























































































































































































































































































Figure 5.5: Coverage of postsynaptic proteins, relative to year of first detection. X-axis
label contains the year, number of studies published in that year (“studies”) and the
number of studies published in the year and all coming years (“total studies”).













































































































Figure 5.6: Coverage of synaptosome proteins, relative to year of first detection. X-axis
label contains the year, number of studies published in that year (“studies”) and the

















































































































































































































































































































































Figure 5.7: Coverage of joint synaptic proteome proteins, relative to year of first detec-
tion. X-axis label contains the year, number of studies published in that year (“studies”)
and the number of studies published in the year and all coming years (“total studies”).
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eral levels of the experimental pipeline, ranging from tissue extraction and preparation
(meaning the extraction of proteins) to mass-spectrometry accuracy and data analysis.
Hence 2008 seems to be a key year when first larger scale experiments were published.
Figure 5.5 shows more than 1,200 newly identified proteins and Figure 5.4 around 700
in 2009 and 2010. Further evidence for advanced technologies is the first large dataset
describing the synaptosome which contains more than 2,500 proteins (Figure 5.6).
Considering the plateau interpretation mentioned earlier and initially pointing to-
wards having identified all proteins specific to any of the regions it can be seen that
specifically studies in 2014 uncovered a number of new proteins for all the datasets.
It is therefore questionable if the total numbers of proteins expressed in the different
synaptic regions are already saturated or not.
The ongoing detection of additional synaptic proteins seems to reflect the contin-
uing growth and refinement of the synaptic proteome. It may be that a number of
presynaptic proteins remaining to be discovered, and/or rediscovered in future stud-
ies. Considering the synaptosome it seems reasonable to focus on the joint dataset
including more studies. Even though higher coverage is seen in postsynaptic proteins,
the joint synaptic proteome reflects the biological definition of the synaptosome and
summarises all currently available knowledge, ensuring best possible data quality.
This analysis allows to draw first conclusions considering protein coverage, relative
to the first detection of proteins. This is of considerable interest, since higher coverage
increases the probability that a protein is really expressed in a region of interest. This
adds certainty to a dataset, making it more credible. It also gives the opportunity to
delete false positive records amongst the data. Setting a fixed filter should nevertheless
consider when a protein was first discovered, allowing a certain number of equally po-
tent studies (considering experimental approaches) to re-discover the protein of interest
before excluding it from the set based on a fixed coverage threshold. Therefore having
a “relative” coverage measure would allow to set flexible filters to reflect experimental
advances and to obtain the best possible synaptic proteome datasets. Since there are
no clear cut-offs yet, this chapter assumes the risk of having false positive records in
the data, compared to discarding any of the real records.
Coverage information was subsequently used to gain insights into the functional
roles of key proteins in the regional datasets.
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5.3.3 Top Coverage Genes
Coverage does not only guarantee data quality, but can also give first hints towards cen-
tral proteins in a dataset. In contrary to low coverage, high coverage can point towards
highly expressed proteins, which are widely and easily detectable. These might have
key roles in the respective tissues, even though this is not guaranteed simply due to high
coverage. A list of these records can highlight similarities and differences between the
regional datasets. Therefore proteins with maximum coverage in the different datasets
were identified. The maximum coverage of proteins varies depending on the number
of available studies.
Table 5.2, Table 5.3 and Table 5.4 show the top coverage records in the presynapse,
postsynapse and synaptosome (second top coverage is included if only one top cover-
age record was found). Table 5.5 shows the top eleven proteins from the joint synaptic
dataset. These overlap partly with top coverage genes in regional proteomes. The
results do not consider the first detection year of proteins.
A close look at the top coverage genes in the joint synaptic proteome shows that
one presynaptic gene appears in the joint synaptic top records. This number increases
when considering postsynaptic and synaptosome top-coverage genes, with five and six
genes present among the top-coverage genes in the joint synaptic dataset. In three cases
synaptic top coverage genes are also amongst the top records in both, the postsynapse
and synaptosome. Only two of the joint synaptic top records are not amongst the top
coverage genes in any of the regional datasets.
The next paragraphs highlight some of the functions of the top coverage genes.
Such insight presents a first biological interpretation of likely dominating functions in
the distinct synaptic regions.
Three genes show top coverage in the presynaptic dataset (Table 5.2). The VAMP2
protein confirms the importance of presynaptic vesicle to membrane fusion which is
crucial for synaptic information transmission. ATP1A3 and GNAO1 might not intu-
itively associate to the presynapse, but are consistently detected. ATP1A, a sodium-
potassium-pump (member of the P-type cation transport ATPases), plays a role in
maintaining electrochemical concentration gradients. This is important for all neuron
related regions and other sources have confirmed associations between ATP1A and the
axon and synapse (Blom et al., 2016). Additionally links to PD have been previously
postulated (Blanco-Arias et al., 2009). GNA01 is a member of the signal-transducing
guanine nucleotide-binding (G) protein family (Murtagh et al., 1991) and was shown
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to be implicated in ion channel regulation. This functionality might be more likely
associated with the postsynapse but also contributes to maintain ion gradients across
the whole synapse.
Table 5.2: Genes detected with top coverage in the presynaptic proteome (ordered by
coverage and alphabetically by gene name).
Gene Name Gene Name long Entrez ID Coverage
ATP1A3 ATPase Na+/K+ transporting subunit alpha 3 478 9
GNAO1 G protein subunit alpha o1 2775 9
VAMP2 vesicle associated membrane protein 2 6844 9
Overall the three presynaptic top-coverage genes are involved in key functions in
the synapse. The mainly postsynaptic G-protein associated functionality as well as
the sodium-potassium-pump properties associated with the presynapse could highlight
the ubiquitous presence of some synaptic proteins amongst the different regions. This
is specifically true for GNA01 which is also amongst the top-coverage genes in the
joint synaptic dataset. Alternatively the detection of intuitively postsynaptic genes in
the presynaptic proteome highlights the difficulty of extracting tissue specific to either
the pre- or postsynapse. Nevertheless the identified results are of great interest, but
it should be considered that presynaptic and postsynaptic expression specificity might
diffuse between the synaptic regions.
In 22 out of the 23 postsynaptic datasets DLG4, a scaffolding protein was detected
(Table 5.3). This highlights the complex structure of the postsynapse and the neces-
sity to hold proteins in place and finely position them. Scaffolding proteins such as
DLG4 make this possible. Another six proteins have been identified in 21 datasets.
Two of them are the well studied CAMK2A and CAMK2B, both members of the ser-
ine/threonine protein kinase family as well as its Ca2+/calmodulin-dependent protein
kinase subfamily (Coultrap and Bayer, 2014). Calcium signalling is crucial for plas-
ticity, specifically in glutamatergic synapses and significantly linked to memory and
its formation including long-term potentiation (LTP) (Voglis and Tavernarakis, 2006).
This can explain the central role of those proteins in the (post-)synapse. Addition-
ally SYNII plays a role in synaptogenesis and neurotransmitter disease modulation
(Cruceanu et al., 2012). This gene might be more naturally associated with the presy-
napse. Nevertheless it seems to play a central role in the postsynapse or likely amongst
the whole synapse. This again underlines the hypothesis that tissue separation between
the pre- and postsynapse remains very challenging.
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Table 5.3: Genes detected with top coverage in the postsynaptic proteome (ordered by
coverage and alphabetically by gene name).
Gene Name Gene Name long Entrez ID Coverage
DLG4 discs large MAGUK scaffold protein 4 1742 22
CAMK2A calcium/calmodulin dependent protein kinase II alpha 815 21
CAMK2B calcium/calmodulin dependent protein kinase II beta 816 21
GAPDH glyceraldehyde-3-phosphate dehydrogenase 2597 21
INA internexin neuronal intermediate filament protein alpha 9118 21
SPTBN1 spectrin beta, non-erythrocytic 1 6711 21
SYN2 synapsin II 6854 21
Considering the synaptosome (Table 5.4), calcium related processes as well as vesi-
cle and synapse specific proteins are detected with a high coverage.
19 genes show the top coverage of seven in the synaptosome. CAMK2A and
CAMK2B are amongst the top coverage hits, as they are in the postsynapse. Similarly
DLG4 as well as DLG2 are found, confirming the necessity of distinct scaffolding pro-
teins. A number of the proteins seem to appear in pairs. This indicates that different
variants of the proteins are identified with a high coverage. Such a finding might high-
light that those form part of one complex, requiring both genes to be expressed for full
functionality. STXBP1 and STXBP5 are one example. Both of them are involved in the
synaptic vesicle cycle, specifically vesicle-membrane fusion and carry out their full
functionality by interacting with other proteins such as STX1. STXBP5 plays a (nega-
tive) regulatory role in exocytosis and neurotransmitter release (Joshi and Whiteheart,
2017) and STXBP1 might determine intracellular fusion specificity (Archbold et al.,
2014). It has been proposed that both proteins compete for STX1 binding1. SV2B
and SV2A are members of the synaptic vesicle proteins 2 family (SV2) associated with
the regulation of vesicle trafficking and exocytosis. Additionally SV2A interacts with
SYT1, enhancing low frequency neurotransmission in quiescent neurons (Bartholome
et al., 2017). Overall this shows the centrality of synaptic vesicle cycling which fea-
tures a prominent role in the synaptosome as well as the presynapse.
With regard to protein pairs these are either functionally dependent from each other
or reflect two protein variants. These may carry out similar functions in distinct brain
regions or cell types or actively compete with each other. Overall top coverage genes
detected in the synaptosome are involved in central synaptic processes. Similar find-
ings can be made in the joint synaptic proteome and are addressed below.
1http://www.uniprot.org/uniprot/Q5T5C0
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Table 5.4: Genes detected with top coverage in the synaptosome proteome (ordered
by coverage and alphabetically by gene name).
Gene Name Gene Name long Entrez ID Coverage
AP2M1 adaptor related protein complex 2 mu 1 subunit 1173 7
ATP6V1A ATPase H+ transporting V1 subunit A 523 7
CADPS calcium dependent secretion activator 8618 7
CAMK2A calcium/calmodulin dependent protein kinase II alpha 815 7
CAMK2B calcium/calmodulin dependent protein kinase II beta 816 7
CTNNA2 catenin alpha 2 1496 7
DLG4 discs large MAGUK scaffold protein 4 1742 7
DLG2 discs large MAGUK scaffold protein 2 1740 7
NSF N-ethylmaleimide sensitive factor, vesicle fusing ATPase 4905 7
PPFIA3 PTPRF interacting protein alpha 3 8541 7
SH3GL2 SH3 domain containing GRB2 like, endophilin A1 6456 7
SNAP25 synaptosome associated protein 25 6616 7
STXBP1 syntaxin binding protein 1 6812 7
STXBP5 syntaxin binding protein 5 34957 7
SV2A synaptic vesicle glycoprotein 2A 9900 7
SV2B synaptic vesicle glycoprotein 2B 9899 7
SYNGR3 synaptogyrin 3 9143 7
SYP synaptophysin 6855 7
SYT1 synaptotagmin 1 6857 7
The 11 top coverage proteins in the joint synaptic proteome are listed in Table 5.5.
The maximum coverage is 35 (out of 38 datasets) and more proteins are found with
a coverage of 32 and 31. The first six records in particular overlap with top coverage
proteins in the postsynapse or synaptosome. These proteins cover calcium/calmodulin
related functions as well as vesicle cycling and fusion related roles. SYN1 and SEPT5
are not amongst the top coverage genes in any of the regional datasets, but appears in
the joint synapse.
SYN1 forms part of synaptic vesicles. It has been shown to be involved in neu-
ral development, synaptic neurotransmission as well as plasticity (Fassio et al., 2011).
Its coverage in the regional datasets is relatively high, but is not amongst the top hits
(8, 26 and 6 in the presynapse, postsynapse and synaptosome). SYN1 together with
SYN2 additionally appear to be part of another protein pair encoding neuronal phos-
phoproteins, associated with the synaptic vesicle surface. Interactions between the two
proteins have been identified and point towards their complex formation (Hosaka and
Südhof, 1999). This finding can also be used to expand the identification of key genes,
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Table 5.5: Genes with top coverage, detected in the joint synaptic proteome (ordered
by coverage and alphabetically by gene name). “pre”, “post” and “synapt” refer to the
presynapse, postsynapse and synaptosome proteomes respectively.
Gene
Name
Gene Name long Entrez ID Coverage top enriched in other
dataset(s)
CAMK2A calcium/calmodulin dependent protein kinase II alpha 815 35 post, synapt
INA internexin neuronal intermediate filament protein alpha 9118 33 post
NSF N-ethylmaleimide sensitive factor, vesicle fusing ATPase 4905 33 synapt
SYN2 synapsin II 6854 32 post
SYT1 synaptotagmin 1 6857 32 synapt
DLG4 discs large MAGUK scaffold protein 4 1742 32 post, synapt
SYN1 synapsin I 6853 32 -
STXBP1 syntaxin binding protein 1 6812 31 synapt
GNAO1 G protein subunit alpha o1 2775 31 pre
CAMK2B calcium/calmodulin dependent protein kinase II beta 816 31 post, synapt
SEPT5 septin 5 5413 31 -
based on other proteins, likely forming part of the same reaction complex.
In general this illustrates how dataset comparison can confirm known principles
and lead to new insights of key genes in large datasets. The presented results show
that top coverage genes might not always be as region specific as expected, based
on their role, but give a notion of overall important and dominating functions in the
synapse and its specific regions. Therefore individual analysis and interpretation of
protein functions within the synapse can help to pin down central functions of synaptic
regions. This analysis considered all protein in the respective datasets. To understand
region specific properties the regional datasets were compared.
5.3.4 Regional Synaptic Properties
After having analysed the individual datasets as well as the joint synaptic proteome,
these were compared with each other. Figure 5.8 visualizes the overlap in terms of
common genes. A total of 6,706 synaptic proteins were identified in at least one study
(mapped to a human Entrez ID). This represents the size of the synaptic proteome as
introduced earlier (Section 5.3.1).
The intersection of the three sets contains 1,478 proteins, being 22% of all iden-
tified proteins. These are present in all three datasets and likely carrying out general
cellular functions.
Overall it can be seen that the synaptosome contains most of the proteins (5,862),











Figure 5.8: Overlap of unique, human Entrez IDs of the genes identified in the presy-
napse, postsynapse and synaptosome proteome. All genes are included (minimum
coverage = 1).
844 of the total number of synaptic proteins were not found in the synaptosome (~12%
of the joint synaptic set).
The postsynapse is the second largest set with 5,053 proteins in total, followed by
the presynapse, containing 1,867 proteins. The number of proteins uniquely expressed
in each of the three regions is relatively small. 1,296 (22%), 571 (11%) and 240 (12%)
proteins are specifically expressed in the synaptosome, postsynapse and presynapse
respectively (percentages are relative to the total number of proteins in the regional
dataset).
Since protein coverage in the different datasets may reflect data quality (Section
5.3.2) it was of interest to consider changes in overlap when only considering proteins
found in a minimum of two or three studies. Figures 5.9a and 5.9b show the respective
venn diagrams and Table 5.6 shows a numeric overview. It can be seen that remov-
ing low coverage genes does not automatically remove all region specific records. It
reduces the parts specific to the presynapse and synaptosome, whereas the postsynap-
tic proportion rises. This is due to the fact that far less presynapse and synaptosome
specific studies were available compared to postsynaptic ones. This phenomena re-
confirms that higher detection coverage can increase data quality and consistency, but
previously explained first-detection times should to be considered.
Even though region specific unique gene sets are small, they very likely contain





















(b) Minimum coverage = 3
Figure 5.9: Overlap of unique human Entrez IDs of the genes identified in the presy-
napse, postsynapse and synaptosome proteomes (minimum coverage of considered
proteins as indicated above).
Table 5.6: Number of genes in the synaptic regional proteomes, filtered for coverage.
Coverage Presynapse Postsynapse Synaptosome Joint synaptic set
1 1,867 5,053 5,862 6,706
2 696 3,439 3,266 5,452
3 361 2,346 1,997 2,850
genes associated primarily to functions, typical to the different synaptic regions. To
identify those, functional enrichment analysis was carried out. Gene Ontology (GO)
annotation terms were used to test gene sets uniquely expressed in the presynapse,
postsynapse, synaptosome and amongst all three datasets. Enrichment was carried out
for Biological Process, Molecular Function and Cellular Component associated terms
(retrieved from the GO database). The Fisher exact test, the topGO elim algorithm
and Benjamini and Yekutieli multiple testing correction were used. Results based on
different background datasets were compared and using the full synaptic proteome
as a reference background turned out to give most representative results which are
presented in this chapter.
Few functional terms were enriched for region-unique datasets. Table 5.7 sum-
marises the results and the following paragraphs interpret the findings.
Regarding uniquely presynaptic proteins “neurotransmitter biosynthetic process”
(GO:0042136) stands out as the one enriched Biological Process. Considering Molecu-
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Table 5.7: Significantly enriched functional GO terms of the gene sets specifically ex-
pressed in only one of the three regional synaptic proteome datasets. The gene sets
of interest were enriched compared to all genes expressed in the synapse. Results
were obtained using the Fisher exact test, elim algorithm and Benjamini and Yekutieli
multiple testing correction; significance p-value threshold was set to 0.05.
Gene Ontology Type Presynapse (p-value) Postsynapse (p-value) Synaptosome (p-value)





mRNA splicing, via spliceo-
some (6.2x10−03)





Cellular Component transcription elongation factor
complex (1.10x10−02)
integral component of peroxi-
somal membrane (5.51x10−03)
nucleoplasm (1.5x10−03)
lar Function terms, “serine-type endopeptidase activity” (GO:0004252) was identified,
and “transcription elongation factor complex” (GO:0008023) is the enriched Cellular
Component. All these terms overlap with well known presynaptic functions. Neu-
rotransmitters are crucial for cell-cell communication and as the top-coverage genes
indicate their transport in vesicles is also a highly central presynaptic function (Sec-
tion 5.3.2). Regarding the Molecular Function “serine-type endopeptidase activity” is a
specific form of a catalytic activity, assisting to initiate other interactions. This mostly
happens through the modification of a protein, converting it into its active form. Iden-
tifying the “transcription elongation factor complex” indicates the high activity of the
presynaptic region, requiring large amounts of newly generated protein to maintain its
functionality. The elevated need of proteins such as neurotransmitters and transport
related factors could explain the enrichment of proteins supporting protein production
specifically in the presynapse.
With regard to the postsynapse specific genes (Table 5.7), a common Biological
Process is “negative regulation of interleukin-10 production” (GO:0032693). Inter-
leukin-10 (IP-10), also referred to as C-X-C motif chemokine 10 (CXCL10) and is a
small cytokine belonging to the CXC chemokine family. Its expression is usually trig-
gered by IFN-gamma as a response to pathogens. Since this does not seem to be a brain
specific functionality, the expression pattern of IP-10 was reviewed. It could be seen
that IP-10 is highly expressed in the fetal brain2 which might explain its enriched ap-
pearance in the postsynapse. Another explanation is around the theory that pathogens
tend to affect synaptic vesicles or cytokines to enhance the pathogens reproduction.
2http://biogps.org/#goto=genereport&id=3627
100 Chapter 5. The Synaptic Proteome and Parkinson’s Disease
Therefore a range of (synaptic) vesicle proteins are associated to pathogenic and vi-
ral terms which appear amongst enrichment analysis results (Franco and Shuman,
2012). Regarding prominent Molecular Function, “protein heterodimerization activ-
ity” (GO:0046982) stands out. The dimerization of heterodimers is closely connected
with G-protein coupled receptors (GPCRs) which communicate external postsynaptic
signals into the cell to trigger downstream actions. The full functionality of a range
of GPCRs is only given when two of them dimerize which makes the heterodimeriza-
tion activity a crucial postsynaptic process. Furthermore the “integral component of
peroxisomal membrane” (GO:0005779) is the enriched cellular component amongst
proteins uniquely expressed in the postsynapse. Peroxisomes are cell organelles, in-
volved in the fatty acid catabolism and hosting highly important enzymes, participat-
ing in the energy metabolism (Wanders and Waterham, 2006). Additionally they have
been shown to synthesize ether phospholipids which are critical for normal mammalian
brain function. This role could explain their over-representation in the postsynapse.
The last region specific gene set describes the synaptosome. As Table 5.7 shows,
“mRNA splicing via spliceosome” (GO:0000398) stands out as the enriched Biological
Process. Splicing is crucial to generate mature mRNA which is consequentially trans-
lated into a protein. Through alternative splicing it can also lead to different mature
mRNA products. Since the synapse is a highly active region hosting many processes at
the same time, it requires well functioning protein production activity. Additionally it
might indicate that different synapses produce distinct protein splice variants, requir-
ing high spliceosome activity. No Molecular Function was identified as significantly
enriched and the “nucleoplasm” (GO:0005654) is the enriched Cellular Component
for the synaptosome specific proteins. The nucleoplasm comprises all nuclear proteins
other than the chromosomes. Again this could point towards highly elevated protein
production in the synapse which requires transcription of DNA as well as their trans-
port through the nuclear membrane. These are functions covered by proteins in the
nucleoplasm.
Alternatively to the established hypotheses the discovered terms might be artefacts
occurring due to contamination of analysed samples. Experimental spot-checks as well
as additional studies might help to find additional proof for the association or help to
discard it.
Apart from the dataset specific functions, common functions covered by all three
datasets were investigated. The 1,477 genes expressed in all three synaptic regions
were analysed. Figure 5.10 displays the enriched terms. Compared to the region unique
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datasets, the number of enriched terms is higher. This might be due to the fact that this
dataset is larger as well as an increase in processes specific to the synapse itself.
(a) Biological Process (b) Molecular Function
(c) Cellular Component
Figure 5.10: GO enrichment of the set of genes expressed in all three datasets (presy-
napse, postsynapse and synaptosome). Enrichment was tested compared to the whole
synapse as a background. Results for different GO ontologies are shown. Fisher test,
the elim algorithm and Benjamini and Yekutieli multiple testing correction were used.
Colour gradient (violet to blue) and size (small to large) reflect significance of the terms.
Some of the significantly enriched Biological Processes are “mitochondrial respira-
tory chain complex I assembly” (GO:0032981), “glutamate secretion” (GO:0014047),
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“neurotransmitter secretion” (GO:0007269) as well as “synaptic vesicle endocytosis”
(GO:0048488) and “synaptic vesicle exocytosis” (GO:0016079) (Figure 5.10a). Mito-
chondria generate intracellular energy which is ubiquitously required in the synapse.
The central role of energy production has been seen in several studies and links be-
tween a lack of energy to neurodegenerative diseases are getting more and more clear
(Beal, 1998). Synaptic vesicles are the main transport media involved in informa-
tion transmission and also amongst the top coverage genes in the synaptosome and
joint synaptic proteome (Tables 5.4 and 5.5). Their prominent functionality amongst
the joint synapse dataset shows their clear importance even though synaptic vesicles
might intuitively be associated with the presynapse.
Enriched Molecular Function terms contain “GTPase activity” (GO:0003924) and
“GTP” and “GDP binding” (GO:0005525, GO:0019003) as well as “NADH dehydro-
genase (ubiquinone) activity” (GO:0008137) and “structural constituent of cytoskele-
ton” (GO:0005200) (Figure 5.10b). These are processes mainly involved in energy
rich functions as well as protein generation and structural intracellular management.
Hence, the terms provide further evidence of the high energy consumption of the
synapse and indicate that energy related processes are very prominent amongst the
most prevalent ones in the region. To manage parallel processes the cytoskeleton has
a crucial role in assisting the transport of components in the synapse. Identifying en-
riched terms associated to the cytoskeleton and its structure confirms the importance
of spatial intra-synaptic organisation for full functionality.
The “extracellular exosome” (GO:0070062) as well as the “myelin sheath” (GO:
0043209) are two enriched cellular components, confirming that the genes found in
all three regional datasets are describing the synapse, or more generally neurons them-
selves (Figure 5.10c).
This shows that gene set enrichment analysis of heterogeneous datasets is a great
tool to obtain detailed and general functional descriptions of gene sets. Results should
always be cautiously analysed but reveal general patterns.
After having analysed the data from the synapse level they were used for further
studies in PD. Putting dataset completeness over the removal of possible false pos-
itives, the full dataset (coverage = 1) was used to locate PD associated genes in the
synapse.
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5.3.5 PD and the Synapse
To investigate the role of PD associated genes in synapse biology, a set of synaptic PD
associated genes was identified. Out of 418 PD associated genes (Chapter 3) 205 were
found in the synaptic proteome. Figure 5.11 shows how PD associated genes overlap
with genes in the regional synaptic proteome datasets. The total of 205 genes is the
sum of overlaps between the different combinations of individual synaptic proteomes.
71 genes can be found in all three regional proteomes, while the rest is only found
in one or two of the synaptic proteome subsets. This might suggest that some PD
associated genes affect specific synaptic regions and will be addressed towards the end
of this section. For a more in-depth overview Figure 5.12 shows the proteome overlap
with PD associated genes, when applying protein-coverage filters. This shows that
overall numbers decrease, but the synaptic proteins with detection coverage 2 and 3
still contain 172 and 125 PD associated genes (the total proteome sizes decreases from




















Figure 5.11: Overlap of the three regional synaptic proteomes with PD associated
genes (minimum coverage = 1).
To test for region specific disease enrichment, Table 5.8 shows an overview of the
significance of overlap between the PD associated genes and regional synaptic datasets.
To compute the significance using hypergeometric testing background datasets were
needed. These included either i) all human protein coding genes (estimated at around
20,000 proteins and referred to as “genome background” (Ezkurdia et al., 2014)) or
ii) the synaptic proteome (with a total of 6,706 proteins). The total number of PD








































(b) Minimum coverage = 3
Figure 5.12: Overlap of the three regional synaptic proteomes with PD associated
genes (adjusted coverage of synaptic proteins in all regional datasets).
associated genes was 418 when testing for enrichment given all human protein coding
genes as the reference background and 205 when considering the synaptic proteome
as a background datasets. The significance threshold was set to a p-value of: 0.05.
It can be seen that the synaptic proteome is significantly enriched for PD associated
genes, meaning that the number of PD associated genes found amongst the synaptic
proteome genes is higher than expected, if all the PD genes were distributed equally
over the genome. The corrected p-value is 2.66x10−11 (Table 5.8 column “synapse”,
row “unique hypergeometric enrichment (genome background)”). To test if each of
the synaptic regions is specifically enriched, the overlap of PD associated genes with
regional proteomes was analysed individually. PD genes uniquely found in region
specific gene sets were analysed for enrichment in the respective datasets. The number
of proteins specifically expressed in the region of interest were considered as the gene
set of interest.
Genes unique to the postsynaptic and synaptosome proteome are significantly en-
riched for PD associated genes, compared to the “genome background”. P-values for
the presynapse and compared to the synaptic background are very close to the 0.05
significance threshold (see Table 5.8).
The intersection of the three regional synaptic proteomes is enriched for PD associ-
ated genes relative to both genetic background datasets. This points towards an overall
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general significant enrichment of the disease associated genes in the synapse, rather
than specifically for any of the regional set.
Table 5.8: Overlap of PD associated genes with regional synaptic proteomes. “unique”
refers to disease genes only overlapping with the indicated regional dataset and “total”
refers to all the PD associated genes found in the respective proteome. Hypergeometric
testing was carried out considering the full genome as a background (all human protein
coding genes, referred to as “genome background”) as well as the synaptic proteome.
Grey numbers indicate that the significance threshold of 0.05 was not reached.
presynapse postsynapse synaptosome all three synapse
number of unique proteins 240 571 1,296 1,478 6,706
unique PD count 5 13 34 71 205
unique hypergeometric enrichment (genome background) 5.65x10−01 4.16x10−01 1.01x10−01 3.05x10−11 2.66x10−11
unique hypergeometric enrichment (synapse background) 8.64x10−01 9.00x10−01 8.65x10−01 1.85x10−05
total number of proteins 1,867 5,053 5,862 - -
total PD count 81 162 186 - -
total hypergeometric enrichment (genome background) 1.53x10−10 5.87x10−10 2.14x10−11 - -
total hypergeometric enrichment (synapse background) 1.61x10−04 1.22x10−01 8.50x10−02 - -
To confirm this hypothesis a second calculation included all PD associated genes
found in the regional subsets. The entire regional presynaptic, postsynaptic and synap-
tosome proteomes were tested for enrichment of PD associated genes. In this scenario,
compared to the synaptic proteome as the background, all regional proteomes show
PD enrichment with a p-value of 0.01 or lower. Enrichment compared to the genome
background is significant with p-value < 1.5x10−10.
Combining all these insights the analysis confirms that the synapse is highly en-
riched for PD associated genes. The full synapse as well as the regional sets show
significant disease enrichment. Nevertheless this analysis does not supply evidence
for the disease affecting a specific synaptic region. Therefore it is very likely that PD
associated genes found in the synapse affect a number of shared functions. Chapter
6 focuses on identifying potential commonalities in the function of disease associated
proteins in the different regions of the synapse.
Apart from the synaptic PD associated genes, 213 of the original list were not
found in any of the synaptic proteomes. Identifying common functionalities or regional
expression patterns of these was of further interest and is addressed in the next section.
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5.3.6 PD Affected Functions
After having identified a set of PD associated genes specific to the synapse and a second
set of non-synaptic PD associated genes, functional roles of the proteins were investi-
gated. The synaptic and non-synaptic PD associated gene sets were analysed separately
regarding their functionality. GO enrichment for the two sets was carried out consider-
ing Biological Process, Molecular Function and Cellular Component terms. Different
background lists were used for each set. For both lists the full set of human protein
coding genes was one of them. The second background list was the synaptic proteome
for the synaptic PD associated gene set and the “rest of the genome” (all human pro-
tein coding genes apart from the ones part of the synaptic proteome) for non-synaptic
PD associated genes. Overall results are very similar, but seem slightly more targeted
towards synaptic or non-synaptic functions when using the more specific background
sets.
Results for the synaptic PD associated genes are based on the synaptic background
dataset and are presented in Table 5.9 (column 1, “Synapse”). Enrichment was calcu-
lated using the Fisher exact test, elim algorithm and Benjamini and Yekutieli multiple
testing correction. Top enriched Biological Process terms include “dopamine biosyn-
thetic process” (GO:0042416) as well as “response to drug” (GO:0042493). Before
applying multiple testing correction “clathrin coat disassembly” (GO:0072318) is also
enriched for this gene set (p-value: 3.5x10−5 before and 0.39 after correction), this will
be addressed again in Section 7.6.1. Finding enrichment of dopaminergic biosynthetic
processes associated to genes in the set is likely related to the predominant effects of
PD in dopaminergic neurons.
“Receptor binding” (GO:0005102) is the one enriched Molecular Function in-
dicating PD effects on information transmission between neurons. Enriched Cel-
lular Component terms are “neuronal cell body” (GO:0043025), “terminal bouton”
(GO:0043195), and “axon” (GO:0030424). All these terms confirm known PD af-
fected cellular functions and hint towards more general neuronal functions to be af-
fected as well. Other enriched terms are “blood microparticle” (GO:0072562) and
“platelet alpha granule lumen” (GO:0031093). These terms hint towards neuroin-
flammatory processes linked to PD (Hirsch et al., 2012) which allows and is reflected
through enhanced access of immune response related particles into the brain.
Enriched functions of non-synaptic PD associated genes reveal different functional
terms as the ones found enriched in PD associated genes expressed in the synapse. The
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results consider enrichment compared to a background dataset including all human
protein coding genes but the ones part of the synaptic proteome (Table 5.9, column
“elsewhere”).
“Negative regulation of neuron apoptotic process” (GO:0043524) shows up as an
enriched Biological Process term. This points towards a possible failure in the reg-
ulation of apoptotic processes as an aetiological factor. It could indicates a mech-
anism that fights against neuron loss, induced through apoptosis, specifically under
disease conditions. Enriched Molecular Function terms are “peptidoglycan binding”
(GO:0042834), “transcription factor binding” (GO:0008134), “protein heterodimer-
ization activity” (GO:0046982) and “enzyme binding” (GO:0019899) amongst others.
Finding those less brain specific terms amongst the enriched ones points towards non-
synaptic PD affected regions and processes. Four mammalian peptidoglycan recogni-
tion proteins have been identified that actively recognise components, usually external
to the human body, such as bacteria (Dziarski, 2004). Several studies uncovered their
versatile activity against distinct bacterial strains (Bobrovsky et al., 2016) and showed a
link to the chlamydial two-component stress response system. Identifying such a term
amongst the ones enriched in non-synaptic PD associated genes hints towards elevated
expression of related genes due to enhanced cellular defence mechanism activity. The
other three terms are all related to “activating” processes. Gene transcription initiation
could be enhanced to produce defensive or replacement proteins due to the dysfunction
of others. Heterodimerization as well as enzyme binding can both be reactions to ac-
tivate specific processes. The combination of these may indicate that non-synaptic PD
associated genes are involved in generative processes influencing the cellular protein
composition and contributing to the PD phenotype.
Two of the enriched Cellular Component terms amongst non-synaptic PD asso-
ciated genes are “neuron projection” (GO:0043005) and “cell body” (GO:0044297).
Based on the GO definitions neuron projection refers to the prolongation of a pro-
cess extending from a nerve cell. This could be axons or dendrites. Cell body on
the contrary describes the portion of a cell bearing surface projections from axons
and dendrites, but excluding all cell projections. This combination of terms provides
evidence for the role of PD associated genes linked to information and signal transmis-
sion and reception. This is a crucial synaptic function and its dysregulation can lead
to neuron loss. “Lewy body” (GO:0097413) is another enriched term confirming the
specificity of the dataset containing PD associated genes and highlighting their pres-
ence outside the synapse, but still in the brain. Even though Lewy Bodies are part of
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other pathologies as well their combination with other enriched terms fits well into the
PD pathology.
Table 5.9: Functional GO enrichment of PD associated genes expressed in the synapse
and elsewhere. The gene sets of interest were enriched compared to all synaptic genes
(“synapse”) as well as all human protein coding genes, apart from the ones expressed
in the synapse (“elsewhere”). Results were obtained using the Fisher exact test, elim
algorithm and Benjamini and Yekutieli multiple testing correction; significance p-value
threshold was set to 0.05 (representation in alphabetical order).





negative regulation of neuron apoptotic process
(4.49x10−03)
response to drug (1.85x10−02)
receptor binding (1.15x10−02) BH3 domain binding (1.80x10−02)
copper ion binding (8.68x10−03)
enzyme binding (8.68x10−03)
growth factor activity (1.69x10−02)
Molecular Function identical protein binding (8.68x10−03)
(p-value) peptidoglycan binding (8.68x10−03)
protein homodimerization activity
(1.69x10−02)
transcription factor binding (1.80x10−02)
ubiquitin protein ligase binding (8.68x10−02)






neuronal cell body (1.8010−03) integral component of plasma membrane
(4.76x10−02)
perinuclear region of cytoplasm
(8.65x10−03)
Lewy Body (1.56x10−02)
platelet alpha granule lumen
(6.31x10−03)
membrane raft (1.94x10−02)
terminal bouton (5.10x10−04) neuron projection (6,74x10−06)
Overall this points towards non-synaptic effects of PD to be influencing neuron
projection which could explain a part of the disease phenotype, affecting patients motor
and movement difficulties as well as non-motor symptoms of the disease.
In summary and based on enrichment analysis results, on the one hand synapse
specific PD associated genes have been proven to affect the dopaminergic system as
well as receptor binding, specifically in terminal boutons. On the other hand non-
synaptic PD associated genes are associated with apoptotic processes and affect neuron
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projection. This could indicates that PD causal dysfunctions appear predominantly in
the synapse. These would then project their effects, creating the PD pathology outside
the synapse and brain to more distal body parts.
5.4 Discussion
The growing number of synaptic proteome studies allowed the generation of joint
datasets describing the presynapse, postsynapse, synaptosome and the full synapse.
Publicly accessible data are a great source for high data quality.
Nevertheless the data-joining process was not always straight forward and a num-
ber of challenges were faced. General issues encountered during data extraction and
mapping were based on how information is presented by authors. In some cases sup-
plementary information was in non-machine readable formats (e.g. .pdf-format), re-
quiring manual annotation which is very time consuming and can be error prone.
Once all data were transformed to be machine readable, original identifiers needed
to be mapped to one identifier of choice. In this work the human Entrez ID was cho-
sen. Due to proteomics data obtained from non-human species protein IDs needed to
be mapped between species and from protein to gene identifiers. Therefore mapping
information was used, but at times manual fine-tuning steps were required. The en-
countered challenges highlight common problems of bioinformatics researchers work-
ing with information obtained in different species and from different sources. All these
points might explain why many researchers stick to the use of individual sources avoid-
ing data mapping and comparison. By doing so one full published synaptic proteome
is used and necessary mapping steps are avoided. Nevertheless this approach carries a
high risk of losing valuable additional information contained in distinct studies.
The presented regional proteome sets are hence the currently most complete synap-
tic proteomic datasets. The use of these “complete” proteomes is encouraged and
should guarantee best possible data quality.
The human Entrez ID was chosen since the main application area of the datasets
focus on a human perspective and the ID is considered a very stable source. In the con-
text of this work, the role of PD associated genes was investigated. Furthermore a far
larger amount of human Protein-Protein Interaction (PPI) data are available which will
be combined with the synaptic proteome data described in Section 5.3.1. Therefore
gene identifiers of the proteomes were mapped to Entrez IDs.
Striking size variation appears between the different published proteomic datasets.
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Presynaptic studies for example identified between 49 (Gorini et al., 2010) and 1,158
proteins (Wilhelm et al., 2014). Regarding postsynaptic studies between 34 (Schwenk
et al., 2012) and 3,545 proteins (Distler et al., 2014) were detected. The number of
proteins identified in studies addressing the synaptosome ranges from 157 (Biesemann
et al., 2014) to 4,475 (Distler et al., 2014). These differences are partly due to the
analysed tissue portion. In some cases only a specific receptor complex, membrane
channel or other structural parts were analysed, compared to e.g. the entire presynapse.
Detection potential and sample size also increased in recent years. More advanced
experimental techniques, material, and machines allowed large-scale screens leading
to larger datasets.
The increase in data availability allowed to study multiple detection of synaptic
genes in different studies. Considering the year of first detection of a protein allowed
for a more detailed picture regarding the interpretation of protein detection coverage.
This is specifically the case for more recently detected proteins which might have only
be identified due to more advanced experimental techniques. Keeping this in mind can
help to classify single coverage proteins differently, e.g. assigning lower credibility
to a protein first detected in the early 2000’s and never again, compared to a firstly
discovered protein in 2015 thanks to more advanced experimental approaches.
Given all these insights the total number of synaptic proteins seems extremely
large. It was initially intended to identify a key synaptic proteome. Nevertheless more
data is required to estimate the size of the different synaptic proteomes and identify the
exact set of genes part of these.
With regard to the protein abundance it needs to be remembered that numbers of
proteins used in this Chapter refer to individual protein entities, not considering the
copies of these, present in a cellular region. Additionally the data presented contains
proteins expressed in the synapse at any given time. This does not mean that all of
these are present in the synapse simultaneously, with variations depending on devel-
opmental stages amongst others. Hence numbers presented should not be considered
as a total count of proteins in the synaptic regions, but rather present the diversity of
proteins in the synapse. To estimate such a total count of proteins in the synapse, spa-
tial constraints could possibly be considered. Nevertheless differences in protein size
complicate such an endeavour.
The synaptosome by definition comprises the whole synapse including presynapse
and postsynapse as well as other cell organelles such as synaptic vesicles and mito-
chondria. This explains why a portion of the synaptosome proteome does not overlap
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with neither the pre- nor postsynaptic proteome. The (small) portions of presynaptic
and postsynaptic proteins which do not appear in the synaptosome proteome might be
due to low expression levels, hindering their detection in a larger dataset. Alternatively
they might be detected in future studies. Nevertheless given the pre- and postsynapse
specific genes those could be used to identify region specific functionalities.
Key biological functions of proteins in the presynapse and postsynapse vary largely,
so does the current proteome size (1,867 proteins versus 5,053 proteins respectively).
Nevertheless a large part of the presynaptic proteome (~80%) overlaps with the post-
synaptic one, with only ~20% specific to the presynapse. Due to the larger size of the
postsynapse, only ~30% of postsynaptic genes overlap with the presynapse and ~70%
are specific to the postsynapse.
Based on the available data it is possible that a larger number of presynapse spe-
cific proteins still remain to be identified. If it turns out that the current information
is correct, showing very low numbers of region specific proteins, this confirms that
functional specificity of a cellular region can emerge and be explained by a relatively
small amount of proteins.
To gain insights into similarities and differences in regional synaptic datasets the
top coverage genes were considered. In this way genes with the highest detection
coverage are shown to have well characterised synaptic (region specific) functions.
Presynapse, postsynapse, and synaptosome genes with maximum coverage hint to-
wards different functionalities. Caution needs to be taken since these results might be
biased, based on specific detection methods targeting those proteins, as being highly,
and specifically expressed in the synapse.
Enrichment studies supported the distinct functional focus of genes unique to the
different regional proteomes. Even though region specific sets are relatively small, the
analysis was able to confirm the main known roles of proteins specific to the different
synaptic regions.
Considering the presence of PD associated genes in the synapse revealed that only
~50% of these are expressed in any of the synaptic regions. Nevertheless the overlap
between disease associated genes and the synaptic proteome is significant (based on
hypergeometric testing). More detailed analysis could not identify any of the region
specific sets as overly enriched. Hence the synapse itself was proven to be highly and
ubiquitously affected by PD.
The division of PD associated genes into a synaptic and non-synaptic group gener-
ated two datasets possibly representing different aspects of the disease. The synapse is
112 Chapter 5. The Synaptic Proteome and Parkinson’s Disease
still believed to be a key cellular region where PD manifests itself and shows molec-
ular alterations. To better understand the role of PD associated genes in the synapse
functional enrichment was carried out. This confirmed known details linking PD to
synaptic functions, such as receptor binding. Very likely all these could be considered
disease triggering dysfunctions.
Functional enrichment of PD associated genes not found in the synapse revealed
more generic and pathology related pathways, known to be affected in PD patients and
representing consequences of synaptic PD associated dysfunctions. Finding enriched
functional terms associated to signal releasing as well as signal receiving cellular com-
ponents might have been suspected but has not yet been shown on a large scale. Even
though this might not facilitate the search for drug targets it could point towards dis-
tinct affected cellular regions given different tissues or similar.
Overall, the analysis presented confirms known PD effects on the synapse and other
cellular pathways. It is a first proof that using large-scale analytical approaches, such as
functional enrichment analysis can help to shed light over complex research questions.
Yet the aim is to obtain more specific results and uncover potentially still unknown
disease links and causes. Therefore and to further investigate the influence of PD on
the synapse more in-depth network analytical approaches are used. The following
chapter presents Protein-Protein-Interaction Networks and clustering algorithms used
to divide datasets into subgroups. Together with functional enrichment analysis this
helps to gain better and deeper insight into specifically affected intracellular synaptic
regions and pathways associated to PD.
Chapter 6
Synaptic Protein-Protein-Interaction
Network Analysis and PD
6.1 Hypothesis and Objective
The complexity of Parkinson’s Disease (PD) is reflected at various intracellular levels
and affects a number of different functions. Therefore, it can be hypothesized that
different sets of PD associated genes affect specific pathways. Most of the key, causal
dysfunctions are suspected to be found in synapses. In this way it is suspected that
several cellular functions are affected but via different molecular mechanisms.
To test this hypothesis it is intended to identify molecular pathways embedded
within the synapse and enriched with PD associated gene. Figure 6.1 illustrates the
overall workflow.
Curated synaptic proteomic datasets are used (Chapter 5) and combined with Protein-
Protein Interaction (PPI) information (Chapter 4) to generate Protein-Protein-Interaction
Networks (PPINs). An ongoing challenge in regard to PPINs is to identify patterns and
substructures in analysed datasets. Based on different mathematical approaches clus-
tering algorithms are able to identify highly connected network groups, referred to as
communities.
In this chapter five different clustering algorithms were used to identify sets of
synaptic genes showing an over-representation of PD associated genes. Functional
enrichment analysis is applied to characterise the genes functions.
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Figure 6.1: Overview of data, processes, and outcomes of Chapter 6. Dark blue boxes
refer to published data, light blue boxes are generated datasets, green boxes describe
processes and magenta boxes show outcomes.
6.2 Material and Methods
To gain understanding of a complex disease such as PD, large-scale analytical tech-
niques, as well as high quality datasets, are highly helpful. Previous chapters set
the baseline for the analysis presented in this chapter by obtaining clean and reliable
datasets.
Section 1.4 introduces the principles of network analysis and specifically focuses
on PPINs. The concepts of network generation, clustering algorithms and analytical
methods are explained in Section 2.4.1.
Principles of (functional) enrichment studies can be found in Section 2.3. Con-
sidering functional enrichment with respect to networks, the main gene sets in the
network are: i) all genes in the network, representing the background dataset and ii)
genes in any of the network communities being the subgroup of genes to be tested for
enrichment of a trait of interest.
All the analysis presented in this chapter can be run via a number of scripts. A mas-
ter script allows the full analysis to be performed in one go. Information required are
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the list of genes of interest as well as a PPI list. If the latter is not given, human, direct
PPIs will be used. Should one want to test for gene-disease enrichment, gene-disease
association data needs to be supplied. A number of parameters require command line
input to adjust the analysis. All necessary scripts can be found here1. A README file
is supplied for more information.
6.3 Results
6.3.1 Synaptic Protein-Protein-Interaction Networks
Proteins mediate biological function, and in the majority of the cases they do so by
interacting with each other. Hence using PPINs enhances understanding of interactions
and emerging sub-structures amongst synaptic proteins. To characterise networks and
identify similarities and differences statistical methods are applied.
Static, undirected PPINs of the regional and joint synaptic proteome datasets (Sec-
tion 5.3.1) were built. Therefore human, internal, direct PPIs were used (Section 4.3.2).
Table 6.1 shows some of the parameters obtained after initial analysis and describes the
four networks.
Table 6.1: Overview statistics of the PPINs of the presynaptic, postsynaptic, synapto-
some and joint synaptic proteome. Number of genes refers to the number of proteins
in the proteome (mapped to human Entrez IDs). Nodes are proteins and edges PPIs.
“bcc” stands for biggest connected component. “Clustering Coefficient” refers to the
global measure. “Density”, “Diameter” and “Power-law Alpha” values are overall net-





















presynapse 1,867 1,582 9,092 1,551 9,063 281 0.0892 0.0075 8 2.5714
postsynapse 5,053 4,583 47,152 4,562 47,132 690 0.0655 0.0045 8 2.5326
synaptosome 5,862 5,380 58,974 5,356 58,951 796 0.0643 0.0041 7 2.5135
joint
synapse
6,706 6,094 69,545 6,068 69,520 893 0.0608 0.0037 7 2.5283
Differences between the number of genes and number of total nodes in the network
might indicate that not all expressed proteins undergo interactions with other proteins
in the dataset. Alternatively this can point out weaknesses of the PPI set, meaning
1https://github.com/KFHeil/thesis
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that it is incomplete. This point also touches upon the possibility that the PPI set con-
tains false positive connections emerging through experimental sample contamination
amongst others. Similarly the number of nodes and edges in the biggest connected
component (Table 6.1, “bcc” columns) is smaller than the total numbers. This can be
explained by small numbers of proteins interacting amongst each other, but not with
the majority of other proteins in the dataset, the biggest connected component. These
non-connected subgroups are of minimal size and were not further considered in this
study.
The global clustering coefficient, also referred to as transitivity, ranges between
0.06 - 0.09. This measure describes the modular network topology, ranging between
0 - 1. High(er) values indicate “full connectedness” amongst network nodes, whereas
lower values stand for sparsely connected networks. The observed values indicate that
all synaptic networks are sparsely connected (Hwang et al., 2006).
To further analyse the connection pattern between the proteins, the degree of net-
work nodes was analysed. The degree of a node is the number of edges linked to it and
is often related to its centrality (Section 2.4). Maximum degree in the four presented
networks ranges between 281 up to 893 interactions for single nodes. Top ranking
records are listed in Table 6.2. Apart from the maximum degree, the degree distri-
bution was analysed and fit to a power law distribution. The alpha value (Table 6.1)
describes the fit of the data and ranges around 2.5. This indicates a heavy-tailed degree
distribution of nodes in the networks, meaning that they are scale free (Section 2.4).
From a biological point of view, this means that some very highly connected hubs, high
degree nodes, appear alongside an exponentially increasing number of nodes with very
low node degree.
Other measures listed in the table include network density which is very low in
all four cases. It defines the percentage of edges appearing in the network, compared
to all possible edges, not consider the PPI data, but assuming, that an interaction can
occur between any two nodes in the network. An additional measure is the diameter,
the longest geodesic in the graph. It describes the longest shortest path between two
random nodes in the network. In the networks presented it is either seven or eight.
In summary, sparse network connectivity and scale-free degree distribution indicate
that all four networks represent biological interaction patterns and reflect a known
structure for large biological datasets (Ravasz et al., 2002; Barabási and Albert, 1999).
To gain a more detailed insight into key proteins in the network, node specific val-
ues were analysed. Together with the previously introduced node degree, betweenness
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scores were calculated. Betweenness is another approach to gain detailed information
about the role of nodes in the network and their relationship amongst each other. Table
6.2 shows the top 10 nodes with highest node degree and betweenness score.
Table 6.2: Top 10 nodes with maximum degree and highest betweenness score in the
four different networks. “deg” refers to degree and “btw” to betweenness. Numbers in
parenthesis refer to the rank. Grey scaled numbers are outside the top 10; “-” indicates
















351 APP amyloid beta precursor pro-
tein
281 (1) 241364 (1) 690 (1) 1066084 (1) 796 (1) 1457415 (1) 893 (1) 1853558 (1) YES
7316 UBC ubiquitin C 188 (2) 91665 (2) 446 (9) 347519 (7) 498 (8) 429978 (7) 543 (8) 548387 (7) NO
8452 CUL3 cullin 3 - - 688 (2) 554111 (3) 796 (2) 747686 (3) 840 (2) 841525 (3) NO
2885 GRB2 growth factor receptor bound
protein 2
165 (4) 82041 (3) 370 (13) 327951 (8) 396 (14) 373534 (9) 432 (16) 453681 (9) NO
1994 ELAVL1 ELAV like RNA binding pro-
tein 1
- - 548 (3) 869141 (2) 747 (3) 1284024 (2) 821 (3) 1563969 (2) NO
1956 EGFR epidermal growth factor re-
ceptor
- - 548 (4) 530706 (4) 607 (4) 669252 (4) 645 (4) 773317 (4) NO
2335 FN1 fibronectin 1 - - 540 (5) 318622 (9) 580 (5) 368808 (10) 615 (7) 443895 (10) NO
7514 XPO1 exportin 1 - - 501 (6) 446903 (6) 557 (6) 575025 (5) 622 (5) 729977 (5) NO
9820 CUL7 cullin 7 - - 455 (8) 193952 (12) 509 (7) 249195 (11) 535 (10) 261247 (16) NO
10482 NXF1 nuclear RNA export factor 1 - - 480(7) 454101 (5) - - 616 (6) 619534 (6) NO
4343 MOV10 Mov10 RISC complex RNA
helicase
- - - - 495 (9) 545787(6) 538 (9) 492472 (8) NO
10987 COPS5 COP9 signalosome subunit 5 - - 424 (10) 168899 (16) 469 (10) 202796 (17) 508 (12) 254144 (17) NO
26270 FBXO6 F-box protein 6 - - 403 (11) 249059 (10) 462 (11) 377352 (8) 479 (13) 425790 (11) NO
51547 SIRT7 sirtuin 7 169 (3) 69948 (4) - - - - 518 (11) 322055 (12) NO




152 (5) 53014 (5) 360 (16) 204559 (11) 382 (16) 238447 (13) 413 (17) 288584 (14) YES
55832 CAND1 cullin associated and neddyla-
tion dissociated 1
150 (6) 35132 (8) 374 (12) 94333 (31) 426 (12) 123213 (29) 452 (14) 142042 (32) NO
8266 UBL4A ubiquitin like 4A 142 (7) 46881 (7) 223 (30) 170233 (14) 229 (36) 66085 (63) 244 (40) 84657 (54) NO
7415 VCP valosin containing protein 138 (8) 48896 (6) 267 (20) 68334 (39) 337 (21) 217333 (14) 354 (22) 247929 (18) NO
3320 HSP90AA1 heat shock protein 90 alpha
family class A member 1
129 (9) 34686 (9) 330 (17) 190131 (13) 360 (18) 211259 (15) 403 (18) 280273 (15) NO
988 CDC5L cell division cycle 5 like 120 (10) 34566 (10) - - 361 (17) 203703 (16) 385 (20) 2.03939 (22) NO
The top 10 degree and top 10 betweenness proteins were identified. Most of the
high degree nodes are also the top betweenness nodes. This might indicate that the
central nodes are not just highly connected (hubs), but also transmit crucial information
between different synaptic processes (high betweenness).
Postsynapse, synaptosome and joint synapse top ranking nodes overlap largely,
whereas the presynaptic top nodes vary. Most of the nodes show a high degree in the
other networks, but are not amongst the the top 10 since other nodes in these networks
take over the top 10 positions. These differences indicate region specific functionali-
ties.
Two of the top degree nodes are present in all four datasets. These are the amy-
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loid beta precursor protein (APP) as well as ubiquitin C (UBC). APP is the gene with
highest node degree and highest betweenness score, also showing a link to PD based
on a Gene Reference into Function (GeneRIF) annotation (Compta et al., 2011; Aasly
et al., 2012; Irwin et al., 2013). APP encodes a cell surface receptor and transmem-
brane precursor protein. Its primary function seems to be unknown, but it has been
associated with iron export (specifically in Alzheimer’s Disease) (Duce et al., 2010),
synapse formation regulation (Priller et al., 2006) and neural plasticity (Turner et al.,
2003). Nevertheless APP is mostly known as a the precursor protein of beta amyloid.
As such, it is cleaved and can form the basis of the amyloid plaques found in the brains
of Alzheimer’s Disease patients.
UBC encodes the polyubiquitin precursor protein. Conjugated ubiquitin monomers
or polymers can have various roles within a cell. Depending on the composition,
ubiquitination processes are linked to protein degeneration, DNA repair, cell cycle
regulation, kinase modification, endocytosis and the regulation of other cell signalling
pathways (Kleiger and Mayor, 2014). Even though it does not activate a heat-shock re-
sponse, its expression is enhanced during stress, providing extra ubiquitin to assist the
ubiquitin system and remove damaged or unfolded proteins (Ryu et al., 2007; Tsirig-
otis et al., 2001). This versatile and protective functionality might explain its central
role in all synaptic regions.
A second protein in the list has been associated with PD. The YWHAZ gene, can be
found amongst the top 20 in all four regional datasets (top 10 in the presynapse). It is
linked to PD based on a GeneRIF annotation (Ostrerova et al., 1999). The tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) gene
encodes a protein which belongs to the 14-3-3 protein family. Also being referred to
as 14-3-3σ (protein name), it binds to phosphorylated serine/threonine motifs of target
proteins and influences these in various ways. It is involved in signal transduction,
apoptosis, cell cycle, cell growth and others (Rüenauver et al., 2014; Aghazadeh and
Papadopoulos, 2016). Apart from a link to insulin level regulation and a predicted link
to cancer, a link with Alzheimer’s Disease was suggested previously (Qureshi et al.,
2013).
The growth factor receptor bound protein 2 (GRB2) is the only gene showing a
top 10 betweenness score in all four datasets with the node degree between rank 10
and 20. This might highlight its important role in cross-pathway communication and
information flow regulation. The protein encoded by GRB2 was originally detected
as a binding partner of the growth factor receptor which then forms complexes with
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proline-rich protein regions (Oda et al., 2005). Proteins containing such regions vary
and are involved in a number of pathways, mostly facilitating signal transduction and
cell communication (Lowenstein et al., 1992). More recent studies showed that it
also forms complexes with protein tyrosine kinases, receptor tyrosine kinases, phos-
phatases, adaptors and intracellular scaffolds and can act as a key control point in the
MAPK signalling (Ahmed et al., 2015). In this context MAPK influences information
transmission from receptors to cell nucleus (McCain, 2013) supporting the hypothesis
proposing its role in information flow and transmission regulation, based on the high
betweenness score.
Similarly the F-box protein 6 (FBXO6) appears amongst the top 10 betweenness
score genes in the postsynapse and synaptosome, and ranks 13 in the joint synapto-
some. Nevertheless it is not present in the presynapse. This points towards a central
role implicated in information transmission mainly in the postsynapse. FBXO6 en-
codes a member of the F-box protein family which constitute the ubiquitin protein
ligase complex (SCF). In addition to its role in the ubiquitin system it also seems to
play a role in endoplasmatic reticulum stress-responses (Chen et al., 2016).
Three genes among the top 10 are specifically expressed in only one of the regional
datasets. The sirtuin 7 gene (SIRT7), specifically expressed in the presynapse, is a
homolog to Sir7 in yeast. Its functions in human is still undetermined, but the yeast
counterpart is involved in epigenetic gene regulation. More recently it was suggested
to interact with the human RNA Polymerase I and II to carry out regulatory functions
in chromatin remodelling (Tsai et al., 2012).
The nuclear RNA export factor 1 (NXF1) is the only postsynaptic specific top
10 node degree gene. NXF1 is known to form complexes with NXT1 and functions
as a carrier between the nucleus and cytoplasm. The complex predominantly binds
symmetric RNA substrates such as the CTE-RNA motif which are part of retroviruses
amongst other (Aibara et al., 2015).
MOV10 is the only synaptosome specific gene amongst the top 10 degree nodes.
The Mov10 RISC complex RNA helicase is part of the the RNA-induced silencing
complex (RISC) and enhances its gene silencing function (Robb and Rana, 2007). As
such it has been associated with the inhibition of retrotransposition (Goodier et al.,
2012).
Another five presynaptic (CAND1, UBL4A, VCP, HSP90AA1, CDC5L) and seven
postsynaptic, synaptosome and joint synaptic genes (CUL3, ELAVL1, EGFR, FN1,
XPO1, CUL7, COPS5) are found amongst the top 10 records.
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In summary all the presented proteins play central roles in the synapse. Hence their
alteration very likely lead to crucial dysfunctions possibly triggering disease or cell
death. The two identified PD associated genes are not amongst the most well known
PD triggers, meaning that if solely affected they might not cause the disease outbreak.
Based on this principle, specifically complex diseases, do not tend to affect the most
central proteins in a cellular region, but a number of highly connected proteins. Their
combined dysfunction can then lead to different diseases.
To gain a better insight into the most central PD associated genes, Table 6.3 shows
the 10 PD associated genes with the highest node degree and their rank amongst all
nodes in the network. For these, the respective betweenness scores including their
rank are also provided. Overall the top 10 PD associated genes are amongst the top
109 node degree and top 150 betweenness score nodes in the networks.
Table 6.3: Synaptic PD associated genes with a top 10 degree value and their be-
tweenness scores (together with the overall rank in the respective network). The table
is sorted by coverage in the different datasets and based on the first available node
degree based on the table columns. “degree” refers to node degree and “btw” to be-
tweenness. Numbers in parenthesis refer to the rank. Grey numbers are outside the
top 10; “-” indicates missing genes in the respective datasets.
Gene Name pre degree pre btw post degree post btw synapt degree synapt btw synapse degree synapse btw
APP 281 (1) 241364 (1) 690 (1) 1066084 (1) 796 (1) 1457415 (1) 893 (1) 1853558 (1)
YWHAZ 152 (5) 53014 (5) 360 (16) 204559 (11) 382 (16) 238447 (13) 413 (17) 288584 (14)
HSPA8 81 (20) 23019 (14) 151 (64) 49376 (56) 174 (62) 67866 (56) 188 (63) 83081 (57)
TARDBP - - 199 (33) 29841 (121) 217 (38) 36381 (140) 228 (44) 40748 (157)
LRRK2 - - 193 (35) 62417 (42) 194 (48) 63978 (66) 213 (50) 82473 (60)
AKT1 - - 172 (46) 73603 (36) 184 (52) 86859 (39) 192 (61) 96846 (43)
PTEN - - 149 (66) 48542 (61) 160 (77) 56553 (83) 172 (82) 65191 (89)
WWOX - - 140 (73) 33321 (103) 160 (75) 34787 (145) 170 (85) 43687 (150)
NEDD4 - - 133 (86) 47641 (62) 149 (95) 67956 (55) 167 (92) 82186 (62)
ABL1 67 (27) 16002 (23) - - 184 (53) 89283 (38) 195 (60) 103213 (40)
GSK3B 46 (59) 11081 (50) 119 (99) 44515 (68) 134 (109) 55065 (87) 141 (119) 60889 (99)
ATF2 - - 140 (76) 43096 (74) - - 156 (108) 53502 (116)
SNCA 64 (30) 14085 (28) 108 (120) 31315 (116) 131 (117) 49294 (100) 133 (137) 52410 (120)
CSNK2B 47 (55) 11922 (43) 109 (116) 37432 (90) 124 (124) 57562 (81) 134 (131) 70544 (78)
RAB7A 47 (56) 10060 (53) 97 (139) 34118 (102) 100 (177) 36551 (139) 106 (192) 40308 (160)
HSPA4 44 (61) 7645 (64) 116 (104) 31763 (113) 131 (115) 38350 (134) 147 (112) 48880 (134)
MAPT 40 (69) 5869 (86) 70 (221) 11467 (295) 76 (262) 13797 (337) 77 (314) 14099 (417)
DLG4 33 (90) 12803 (37) 62 (271) 42157 (77) 62 (345) 44762 (112) 64 (399) 54964 (111)
The top two records have already been detected amongst the overall top 10 node
degree genes in the respective networks and information can be found above. A third
gene is amongst the top 10 records in all four datasets. The heat shock protein fam-
ily A (Hsp70) member 8 (HSPA8) is a constitutively expressed member of the heat
shock protein 70 family. As a chaperone it binds to polypeptides facilitating correct
6.3. Results 121
folding. Additionally it has been shown to function as an ATPase in the disassem-
bly of clathrin-coated vesicles. In this role it is specifically active during transport of
membrane components through the cell (Daugaard et al., 2007).
Apart from these three, the glycogen synthase kinase 3 beta (GSK3B) is among the
top 10 degree nodes in presynapse, postsynapse and synaptosome. It is involved in neu-
ronal cell development and body pattern formation as well as the energy metabolism.
Furthermore it has been shown to influence phosphorylation and accumulation of tau
and alpha-synuclein (Credle et al., 2015).
The ABL proto-oncogene 1, non-receptor tyrosine kinase (ABL1) is ubiquitously
expressed and linked to cell cycle functions. It is the one gene that is specific to the
presynapse, synaptosome and joint synaptic dataset but not expressed in the postsy-
napse. As a tyrosine kinase it is involved in cell division, adhesion, differentiation and
stress response functions (Paul and Mukhopadhyay, 2004). Alterations in these func-
tions can lead to neuronal degeneration which might explain the proto-oncogenic role
of ABL1 (Wang, 2014).
Activating transcription factor 2 (ATF2) is specifically expressed in the postsynapse
(as well as the joint synaptosome) and binds to the DNA as part of the leucin zipper
family. As such it is associated with various different functions including transcription,
histone acetylation and DNA damage response (Desai et al., 2014).
No major evidence for region specific appearance of these two genes could be
found but they might be involved in so far unspecified regional processes.
Two of the most prominent PD associated genes: LRRK2 and SNCA are also
amongst the top 10 degree nodes. This could point towards a very central role which
also allowed their early detection and genetic based disease link.
Apart from these another five genes (TARDBP, AKT1, PTEN, WWOX, NEDD4)
are amongst the postsynaptic, synaptosome and joint synaptic genes and five more
amongst the presynaptic top 10 degree records (CSNK2B, RAB7A, HSPA4, MAPT,
DLG4). These are all also present in the other regional datasets but not amongst the
top PD associated degree nodes.
Another way to interpret node degree and betweenness scores is in a reverse com-
bination. A combination of a high betweenness score and low degree value (or vice
versa) is a prominent support for network modularization. Nodes with a low degree
and high betweenness score for example seem to act as a connector between different
pathways by separating the two from each other, but allowing communication between
them (Koschützki and Schreiber, 2008). One such example is DLG4. Even though it
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shows relatively low ranking node degree values its betweenness scores rank amongst
the top records in the networks. As a scaffolding protein (with top detection coverage
in the postsynapse) it likely plays a key role in a range of functions. The ability to con-
nect other proteins can allow information exchange between pathways that are usually
separated, explaining the high betweenness score.
6.3.2 Network Clustering
To gain a more “high-level” insight into the substructures within the PPINs, cluster-
ing algorithms were used to divide the networks into communities. These represent
densely connected network regions which often contain proteins sharing a biological
function (Brun et al., 2004). For an overview of all analytical steps taken in this section,
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Figure 6.2: Detailed overview including network clustering, enrichment, and key-protein
as well as community detection processes in Section 6.3.2. Dark blue boxes refer to
published data, light blue boxes are generated datasets, yellow boxes refer to analytical
tools, green boxes describe processes and magenta boxes show outcomes.
This section considers presynaptic, postsynaptic, synaptosome and joint synaptic
PPINs. All four PPINs were analysed using five different clustering algorithms. These
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were: fast greedy, infomap, louvain, spectral and spinglass (Section 1.4.2 introduces
details and Section 2.4.1 contains technical information). Hence five different topolo-
gies emerge for each of the four networks, leading to a total of 20 differently clustered
topologies.
Figures 6.3 and 6.4 show results for the presynapse and the joint synaptic pro-
teome. Visualizations of the postsynapse and synaptosome are very similar to the joint
synaptic proteome and can be found in Appendix D (Figures D.1 and D.2). The sub-
figures visualize networks based on distinct clusterings: (a) fast greedy, (b) infomap,
(c) louvain, (d) spectral and (e) spinglass algorithm. PD associated genes were located
in the networks and are highlighted in red. The Figures are included to provide a vi-
sual impression of the networks topologies and emerging community structure. These
schematics highlight the differences in community number and size amongst the dif-
ferent networks and algorithms. In addition, in certain cases, PD associated genes
(highlighted in red) tend to be accumulating in a specific network region, but not in
others. To gain a better overview of the presented networks, Table 6.4 summarises key
statistics of the differently clustered networks.
Given the focus of this study, significantly PD enriched network communities were
identified. Hypergeometric testing was used (Mclean et al., 2016) for this purpose
which finds network communities with a higher number of disease associated genes
than expected by chance (compared to a random allocation, given the network envi-
ronment). The significance threshold for disease enrichment was set to a p-value of
0.05. Table 6.4 also includes the number of PD enriched communities in the different
networks.
As Figures 6.3 and 6.4, as well as Table 6.4 show, clustering algorithms divide
networks differently. Irrespective of the clustering algorithm the presynaptic dataset
differs slightly from the others due to its smaller size. The other three networks are
relatively similar. The following sections highlights general properties of emerging
structural topologies based on the use of different network clustering algorithms (in
alphabetic order).
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(a) fast greedy (b) infomap
(c) louvain (d) spectral
(e) spinglass
Figure 6.3: Presynaptic PPINs. Different clustering algorithm results are highlighted.
Red coloured nodes represent PD associated genes. Grey “background” shows net-
work edges.
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(a) fast greedy (b) infomap
(c) louvain (d) spectral
(e) spinglass
Figure 6.4: Joint synapticPPINs. Different clustering algorithm results are highlighted.
Red coloured nodes represent PD associated genes. Grey “background” shows net-
work edges.
126 Chapter 6. Synaptic Protein-Protein-Interaction Network Analysis and PD
Table 6.4: Results obtained from the clusterings of the networks of the different regional
datasets and using different clustering algorithms. Columns 3, 4, 5, 9 and 10 refer to the
number of respective communities. “smaller 4” and “larger 200” refers to the number of






























presynapse fast greedy 17 9 0 404 2 91 4 3
postsynapse fast greedy 25 5 0 1349 2 182 9 0
synaptosome fast greedy 48 9 1 (1) 1939 2 112 23 3
synapse fast greedy 26 8 0 2061 2 233 8 4
presynapse infomap 108 38 1 250 2 14 14 1
postsynapse infomap 199 47 7 (1) 1645 2 23 28 1
synaptosome infomap 235 57 6 1918 2 23 34 2
synapse infomap 258 62 8 2155 2 24 27 2
presynapse louvain 12 12 2 235 25 129 0 2
postsynapse louvain 12 10 0 780 4 380 0 9
synaptosome louvain 13 12 0 1005 4 412 0 10
synapse louvain 13 12 1 977 4 467 0 9
presynapse spectral 53 26 2 (1) 165 1 29 19 0
postsynapse spectral 67 29 1 400 1 68 33 8
synaptosome spectral 95 35 (3) 427 1 56 53 12
synapse spectral 94 32 4 (1) 472 1 65 56 12
presynapse spinglass 11 10 1 221 13 141 0 2
postsynapse spinglass 15 11 0 767 9 304 0 8
synaptosome spinglass 12 10 0 1002 4 446 0 8
synapse spinglass 14 11 0 1115 6 433 0 7
The fast-greedy algorithm produces some large, with up to ~2,000 genes, and some
very small communities. It appears as though PD associated genes allocate in similar
communities, but only one community in the synaptosome PPIN is actually enriched
for PD.
The infomap algorithm produces few, very large communities. Only two are larger
than 200 nodes, but a maximum of 2,155 genes is found in one community. Addition-
ally a large number of small communities can be found. Nevertheless the clustering
results indicate a relatively large number of communities (between 1-8 per network)
being enriched for PD associated genes, in other words showing an over-representation
of PD associated genes. Only one PD enriched community in the network contains less
than four nodes.
Moving on with the louvain clustering results, no community is smaller than four
genes and a large number of big communities, with more than 200 nodes, exists. This
also confirms the large average community size, ranging between 130 and 467 genes.
The spectral clustering results lead to maximum community sizes between 165 and
472 nodes. The average community size ranges between 29 and 68 genes. A number
of communities with more than 200 genes exist, but none of them are extremely large.
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The clustering also leads to the maximum number of small communities. A number
of PD enriched communities can be found in all four networks, with some being small
and in some sense isolating the disease associated genes from others.
The spinglass algorithm seems to perform very similar to the louvain algorithm.
Very large communities emerge with large average sizes and only one (presynaptic)
PD enriched community.
Overall the analysis shows the differences in the clustering results. It appears that
the increased size of the postsynaptic, synaptosome and joint synaptic proteomes make
it harder to identify biologically meaningful and disease enriched communities, com-
pared to the smaller presynaptic PPIN. Considering the different clustering algorithms
it seems that the spectral and infomap approach show the most useful division of the
data into communities, specifically when considering PD enrichment. As previously
shown the emerging communities are very precise considering functional similarities
(Mclean et al., 2016). Since there is no established and straight forward technique to
best classify clustering results and/or compare them amongst each other all generated
communities were considered in the next step. The coming Section 6.3.3 studies PD
enriched communities further, with the aim to identify a significantly affected synaptic
region.
6.3.3 PD Enriched Communities
Since one of the main objectives of this work was to identify most PD affected synap-
tic subregions, significantly disease enriched communities were extracted (p-value <
0.05). 41 PD enriched communities were identified and can be seen in Table 6.5.
Information regarding community sizes and PD enrichment (corrected p-values) are
included. Seven of the identified communities contain less than four genes and were
not considered further. The remaining 34 were specifically addressed regarding their
similarities and differences.
The enriched communities were analysed regarding the regional synaptic dataset
as well as the clustering algorithm. Only communities with a minimum of four genes
were considered. One PD enriched community emerges after fast greedy and spinglass
clustering in the synaptosome and presynaptic network respectively. The louvain clus-
tering leads to a little more with three enriched communities. Overall the spectral and
infomap clustering results show the highest numbers of enriched communities.
These insights reflect a previous observation that the spectral and infomap algo-
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rithms seem to be most appropriate to divide large PPINs into biologically interpretable
communities containing proteins with common functions (Section 6.3.2) (Mclean et al.,
2016).
Table 6.5: PD enriched communities in the different networks based on one of the
four datasets and one of the five clustering algorithms (p-value < 0.05, after multiple
testing correcition). All enriched communities are listed, irrespective of their size. Rows
are ordered based on dataset and algorithm. “synapse” refers to the joint synaptic











presynapse infomap 90 4 2 1.23x10−02
presynapse louvain 3 25 4 2.69x10−02
presynapse louvain 11 209 25 2.78x10−06
presynapse spectral 10 3 2 6.11x10−03
presynapse spectral 69 17 3 4.02 x10−02
presynapse spectral 72 79 11 6.81x10−04
presynapse spinglass 3 183 20 1.49x10−04
postsynapse infomap 10 72 6 3.35x10−02
postsynapse infomap 22 37 7 1.91x10−04
postsynapse infomap 54 12 2 5.98x10−02
postsynapse infomap 69 10 2 4.26x10−02
postsynapse infomap 81 10 1 4.26x10−02
postsynapse infomap 84 9 2 3.48x10−02
postsynapse infomap 126 7 2 2.12x10−02
postsynapse infomap 177 3 1 3.32x10−03
postsynapse spectral 55 55 6 9.70x10−02
synaptosome fast greedy 12 11 1 4.85x10−02
synaptosome fast greedy 24 3 1 3.15x10−03
synaptosome infomap 9 78 6 4.22x10−02
synaptosome infomap 27 32 6 5.14x10−04
synaptosome infomap 76 12 2 5.70x10−02
synaptosome infomap 88 10 2 4.06x10−02
synaptosome infomap 101 10 1 4.06x10−02
synaptosome infomap 137 8 1 2.63x10−02
synaptosome spectral 48 1 1 3.27x10−02
synaptosome spectral 60 1 1 3.27x10−02
synaptosome spectral 85 1 1 3.27x10−02
synapse infomap 12 68 6 2.09x10−02
synapse infomap 35 25 3 4.41x10−02
synapse infomap 60 15 3 1.10x10−02
synapse infomap 71 14 3 9.00x10−03
synapse infomap 96 10 3 3.20x10−02
synapse infomap 98 12 2 5.43x10−02
synapse infomap 102 11 2 4.62x10−02
synapse infomap 200 6 1 1.40x10−02
synapse louvain 6 75 7 2.51x10−03
synapse spectral 3 148 9 4.58x10−02
synapse spectral 27 150 9 4.92x10−02
synapse spectral 54 55 10 7.11x10−06
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Table 6.5: PD enriched communities in the different networks based on one of the
four datasets and one of the five clustering algorithms (p-value < 0.05, after multiple
testing correcition). All enriched communities are listed, irrespective of their size. Rows
are ordered based on dataset and algorithm. “synapse” refers to the joint synaptic











synapse spectral 97 1 1 3.18x10−02
synapse spectral 100 4 2 5.73x10−03
Considering differences amongst regional datasets, six presynaptic, eight postsy-
naptic, seven synaptosome and 13 full synapse communities are amongst the enriched
ones (with a minimum of four genes). This relatively even distribution can also be ob-
served amongst the communities detected after clustering with the infomap and spec-
tral algorithm.
Taking these findings into account, there was no obvious trend towards one of
the datasets being specifically associated to PD. Therefore all PD enriched com-
munities with at least four genes were compared amongst each other. Figures 6.5
shows the 71 PD associated genes in the 34 significantly enriched communities (x-
axis). The heatmap shows clusters of communities based on the genes shared between
them, following a hierarchical, agglomerative clustering approach (implemented in
the Python seaborn.clustermap package2. The labelling of the y-axis reflects the
dataset (presynaptic, postsynaptic, synaptosome or joint synaptic proteome) as well
as the clustering algorithm (fast greedy, infomap, louvain, spinglas, spectral) and the
number of the enriched community in the respective (network) topology. Apart from
considering PD associated genes only, all 819 genes in the enriched communities were
considered, clustered and visualized. Figure 6.6 shows the results.
The clustering of PD associated genes in PD enriched communities (Figure 6.5)
leads to three prominent “gene blocks”. These are highlighted in a green, blue and red
box and will be referred to as Cluster 1, Cluster 2 and Cluster 3. Clusters represent
PD associated genes appearing together in a number of communities in the differently
clustered networks. Similarly three blocks can be identified considering the similarity
between the full communities (Figure 6.6). Closer examination reveals that indepen-
dently of considering only PD associated genes in enriched communities, or all genes
in enriched communities Cluster 1, 2 and 3 contain similar network communities.
2http://seaborn.pydata.org/generated/seaborn.clustermap.html





Figure 6.5: Clustering highlighting the overlap of PD associated genes in significantly
PD enriched communities. The x-axis shows Entrez IDs and the y-axis indicates the
dataset, algorithm and community number in which the community was found to be
enriched for PD associated genes. “pre”, “post”, “synapt” and “synapse” refer to the
presynaptic, postsynaptic, synaptosome and joint synaptic proteome.
This consistency supports credibility of the community structure. Hence even
though clustering algorithms are based on different principles they all detected highly
similar PD enriched communities containing the same set of PD associated genes.
Genes in these clusters show a high probability of being associated with PD, as well as
influencing its development and manifestation.
A closer look at the communities in the clusters suggests that these were mostly
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found in either postsynaptic of full synaptic PPIN communities. Nevertheless presy-
naptic communities show enrichment as well. Overall enriched communities emerged
in networks based on different regional datasets. This may indicate ubiquitous effects
of PD on the synapse, not targeting a specific synaptic region. As suspected based on
the overall number of enriched communities emerging through the different cluster-





Figure 6.6: Clustering highlighting the overlap of all genes in significantly PD enriched
communities (including all community genes). x- and y-axis labelling are as in Figure
6.5.
To investigate the clustered communities in more detail, Table 6.6 shows a sum-
mary of these. Information overlaps with Table 6.5 but contains further community
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cluster information and the colour code corresponds to the ones in Figures 6.5 and 6.6.
Table 6.6: Three clusters of PD enriched communities. Cluster numbers and colour
code as in Figures 6.5, 6.6 and 6.7. “Community Number” refers to the community in
the original network; “Genes” refers to the number of genes in the community; “Com-
munities in cluster” refers to the colour coded clusters; columns 8-12 refer to community







































1 synapse spectral 27 150 9 4 368 172 92 27 9
1 synapse infomap 12 68 6 4 368 172 92 27 9
1 post infomap 10 72 6 4 368 172 92 27 9
1 synaptosome infomap 9 78 6 4 368 172 92 27 9
2 post infomap 22 37 7 5 217 113 53.25 30 11
2 synapse louvain 6 75 8 5 217 113 53.25 30 11
2 synapse infomap 71 14 3 5 217 113 53.25 30 11
2 post spectral 55 55 6 5 217 113 53.25 30 11
2 synaptosome infomap 27 32 6 5 217 113 53.25 30 11
2 synapse spectral 100 4 2 5 217 113 53.25 30 11
3 pre spectral 69 17 3 5 54 37 13.5 11 4
3 synapse infomap 200 6 2 5 54 37 13.5 11 4
3 synaptosome infomap 101 10 2 5 54 37 13.5 11 4
3 post infomap 81 10 2 5 54 37 13.5 11 4
3 synaptosome fast greedy 12 11 2 5 54 37 13.5 11 4
For an even better understanding and to identify the potential new PD associated
gene sets, coverage of individual genes amongst the different communities in the clus-
ters was analysed. Figures 6.7 a and b show the coverage of PD associated genes, as
well as all genes in the 15 enriched communities belonging to one of the three clusters.
As Table 6.6 and Figure 6.7 show, there is variability in the total number of genes
in the clusters. To confirm the overlap of genes between the communities in each of
the clusters with more detail, their coverage was analysed. Figure 6.7 a shows that
a substantial number of PD associated genes in the different clusters, illustrated with
different colour bars, appear in more than only one community of the cluster, meaning
that the coverage is higher 1. Similarly Figure 6.7 a) highlights that a substantial
proportion of genes appears in more than one community in the respective cluster.
More precisely, Cluster 1 is the largest one with a total of 172 unique genes out
of which less than half (82) appear in only one community. Cluster 2 contains 113
unique genes with a slightly higher proportion (slightly less than two thirds) of genes
detected in only one community . With 37 unique genes out of which 31 have only
been detected once, Cluster 3 is the least consistent one.
For best data consistency and to identify a core key target gene set, genes were only
considered further if they appeared in at least two of the four, five or six communities
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(a) PD associated genes






































Figure 6.7: Coverage of different proteins in the PD enriched communities in the three
enriched community clusters. Colours represent clusters. The x-axis indicates the
coverage. Genes are associated to the coverage based on the number of PD enriched
communities in the respective cluster they appear in.
per cluster. Hence Cluster 1 contains 90, Cluster 2, 43 and Cluster 3 six core genes,
including six, six and two PD associated ones amongst them (Figure 6.7). Appendix E
contains the full list of genes in these clusters.
Based on these insights properties of the gene sets as well as individual genes in
the three clusters were further investigated.
6.3.4 Synaptic PD Affected Functions
After having identified most PD affected synaptic regions, these were analysed regard-
ing their predominant overall functions. Gene Ontology (GO) enrichment analysis (for
the three categories Biological Process, Molecular Function and Cellular Component)
was carried out. This was initially done for each individual community in the enriched
clusters. The background dataset was chosen to be the joint synaptic proteome and
the analysis was carried out with topONTO using the Fisher exact test, elim algorithm
and Benjamini and Yekutieli multiple testing correction. This allowed identification
of very specific enriched terms, being found in the lower levels of the ontology trees,
guaranteeing the optimum and most specific insight into the joint and dominating func-
tionality of the genes in the communities.
Enriched terms for individual communities in a cluster were compared and over-
lapped largely. Every term appearing in at least two of the communities in a cluster
was taken forward, and included in the final results. The following paragraphs address
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the three clusters individually.
6.3.4.1 Cluster 1
Cluster 1 consists of four communities and contains 90 genes appearing in two or more
of them. For a better overview, the 90 genes are visualised in Figure 6.8. It can be seen
that all genes undergo interactions with each other. There are 246 internal PPIs in total.
Figure 6.8: Genes in Cluster 1 (minimum coverage of two). Opacity represents the
coverage. Red squares are PD associated genes.
As highlighted in Figure 6.8 six PD associated genes can be found in Cluster 1.
Table 6.7 lists these, as well as three additional ones with a coverage of 1. Two to three
different functional areas are covered by the PD associated genes in this cluster.
DLG1, DGL2, DLG4 encode scaffolding proteins, playing a main role in the struc-
tural organisation of proteins and facilitating their full functionality. DLG1 is required
for “normal development”, playing a major role in signal transduction, cell prolifera-
tion and synaptogenesis. It is also referred to as SAP-97 (Howard et al., 2010). DGL2
and DLG4 encode proteins which heteromultimerize to form the membrane-associated
guanylate kinase (MAGUK) and are also referred to as PSD-93 and SAP-102. As such
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Table 6.7: PD associated genes in Cluster 1. Ordered by coverage and Entrez ID.
Gene ID Gene Name Short Gene Description Coverage
1739 DLG1 DLG1 discs large MAGUK scaffold protein 1 4
1740 DLG2 DLG2 discs large MAGUK scaffold protein 2 4
1742 DLG4 DLG4 discs large MAGUK scaffold protein 4 4
2903 GRIN2A GRIN2A glutamate ionotropic receptor NMDA type subunit 2A 4
2904 GRIN2B GRIN2B glutamate ionotropic receptor NMDA type subunit 2B 4
4842 NOS1 NOS1 nitric oxide synthase 1 4
1609 DGKQ diacylglycerol kinase theta 1
8851 CDK5R1 cyclin dependent kinase 5 regulatory subunit 1 1
23113 CUL9 cullin 9 1
they interact with the postsynaptic membrane, being recruited into NMDA receptor
and potassium channel clusters. In these regions they form a scaffold for the clustering
of receptors, ion channels and associated signalling proteins (Oliva et al., 2012; Sun
and Turrigiano, 2011).
Furthermore two glutamate ionotropic receptors are amongst the PD associated
genes in Cluster 1. GRIN2A and GRIN2B both encode for proteins of the N-methyl-
D-aspartate (NMDA) receptor family, also referred to as GluN2A and GluN2B. These
receptors are both ligand- and voltage dependant and involved in long-term potenti-
ation and synaptic transmission efficacy, showing links to specific memory types and
learning. These functionalities are regulated based on Ca2+ influx into the postsynapse
(Paoletti et al., 2013). Apart from their joint properties GRIN2B specifically acts as an
agonist binding site for glutamate (Hu et al., 2016).
Additionally NOS1 is amongst the six PD associated genes. Nitric oxide synthase
1 belongs to the family of nitric oxide synthases, synthesizing nitric oxide from L-
arginine (Stuehr, 2004). Nitric oxide has been linked to neurodegenerative disease
since it adopts a neurotransmitter like role inducing neurotoxicity (Dawson and Daw-
son, 1996).
In summary, the PD associated genes are associated with functions generally known
to be linked with PD. In addition, apart from generic terms, some findings point to-
wards much more concrete dysfunctions. A slight focus towards postsynaptic dysfunc-
tions can be detected based on information in Cluster 1.
To understand the overall function of all genes in Community 1 common enriched
functions were identified. Table 6.8 shows GO terms enriched amongst all genes in
the PD associated communities from the Biological Process, Molecular Function and
Cellular Component ontologies. Appendix Table F.1 shows the GO terms, IDs as well
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as short definitions of the terms. These were retrieved from QuickGO3 via GONUTS4.
Table 6.8: GO terms enriched in at least two communities of Cluster 1 (alphabetical
order); significance p-value threshold was set to 0.05. The gene sets of interest were
enriched compared to all genes expressed in the synapse. Results were obtained
using the Fisher exact test, elim algorithm and Benjamini and Yekutieli multiple testing
correction. Exact p-values not supplied since different in distinct enriched clusters).
Biological Process Molecular Function Cellular Component
GDP metabolic process cell adhesion molecule binding basolateral plasma membrane





GMP metabolic process guanylate kinase activity cell junction
ionotropic glutamate receptor sig-
naling pathway
ionotropic glutamate receptor bind-
ing
dendritic spine
maintenance of epithelial cell api-
cal/basal polarity
L27 domain binding dystrophin-associated glycoprotein
complex
negative regulation of peptidyl-
cystein S-nitrosylation
neurexin family protein binding exocyst
neurotransmitter secretion neuroligin family protein binding juxtaparanode region of axon
positive regulation of excitatory
postsynaptic potential
NMDA glutamate receptor activity MPP7-DLG1-LIN7 complex
positive regulation of synapse as-
sembly
PDZ domain binding myelin sheath abaxonal region
positive regulation of synaptic vesi-
cle clustering
scaffold protein binding neuron projection
postsynaptic density protein 95 clus-
tering
NMDA selective glutamate receptor
complex
protein localization to basolateral
plasma membrane
postsynaptic density of dendrite
receptor localization to synapse postsynaptic membrane
regulation of grooming behaviour presynaptic membrane









The following paragraphs highlight some of the enriched functions that stand out




As previously highlighted by the functions of individual PD associated genes,
“positive regulation of synapse assembly” and “receptor localization to synapse”, ap-
pear amongst the enriched Biological Processes. Finding “scaffold protein binding”
amongst the enriched Molecular Function terms confirms the functional role of pro-
teins in Cluster 1 with respect to scaffolding proteins. These findings support the hy-
pothesis that scaffolding proteins, and more generally the spatial organisation of genes,
is affected in brain cells of PD patients.
Similarly “ionotropic glutamate receptor signalling pathway” as well as “neuro-
transmitter secretion” are amongst the enriched Biological Process terms. This is con-
firmed through the Molecular Function terms “ionotropic glutamate receptor binding”
as well as “NMDA glutamate receptor activity” and the Cellular Component “NMDA
selective glutamate receptor complex”. Hence, it seems quite likely that NMDA re-
ceptors can be highly affected in PD patients. Their role in the disease pathology can
also be confirmed by the use of glutamatergic receptors as therapeutic targets (Johnson
et al., 2009; Hallett and Standaert, 2004).
A number of other overall affected pathways appear. Enriched Cellular Component
terms largely focus around the “synapse”. More specifically they including terms such
as the “presynaptic membrane” as well as “postsynaptic membrane”. Together with
the term “cell junction”, this supports the theory that PD has a substantial influence on
synaptic information transmission.
Further terms based on the Biological Process ontology include terms related to
(intra-) cellular structure. “gephyrin clustering involved in postsynaptic density as-
sembly”, “positive regulation of synaptic vesicle clustering” as well as “protein local-
ization to basolateral plasma membrane” confirm the possible alteration of structure
related processes in the brain cells of PD patients.
Overall, enriched terms partly overlap with the known PD associated genes. The
generation of an extended set of so far non-PD associated genes indicates their role in
disease affected processes and makes these genes potential next targets to investigate
regarding their link to PD and their potential use as a drug targets or biomarkers.
Apart from the presented PD associated genes, eight genes in Cluster 1 could be
found in at least one of the analysed PD expression data studies presented in Sec-
tion 3.3.2. These are: FBG12 (2257), DTNA (1837), NRXN2 (9379), GUCY1B3
(2983),APBA1 (320), ATP2B2 (491), ERBIN (55914), PKP4 (8502). This overlap
is an indication of having identified a highly PD affected synaptic gene set.
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6.3.4.2 Cluster 2
Cluster 2 consists of six communities which contain 43 genes with a minimum cov-
erage of two. The 43 genes undergo 74 internal interactions and Figure 6.9 visualises
these. Six PD associated genes with a minimum coverage of two can be found in the
set as well as another five appearing in only one of the communities. Table 6.9 lists
these.
Figure 6.9: Genes in Cluster 2 (minimum coverage of two). Opacity represents the
coverage. Red squares are PD associated genes.
It seems that PD associated genes in Cluster 2 are linked to four different function-
alities which are presented in the next paragraphs.
FGB and FGG are the beta and alpha chain of fibrinogen, a blood-borne glyco-
protein comprised of three pairs of non-identical polypeptide chains. Fibrinogen is
a protein which is highly involved in the formation of blood clots. It is cleaved by
thrombin and its cleavage products have been associated with cell adhesion and cell
spreading. Furthermore they showed vasoconstrictor and chemotactic activities. Since
these functions do not seem specific to the synapse the expression pattern of FGB and
FGG was investigated. Both of the protein products are highly expressed in the liver,
but expression for FGG was confirmed in the presynapse, postsynapse and synapto-
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Table 6.9: PD associated genes in Cluster 2. Ordered by coverage and Entrez ID.
Gene ID Gene Name Short Gene Description Coverage
2244 FGB fibrinogen beta chain 6
2266 FGG fibrinogen gamma chain 6
216 ALDH1A1 ALDH1A1 aldehyde dehydrogenase 1 family member A1 5
335 APOA1 APOA1 apolipoprotein A1 4
1356 CP CP ceruloplasmin 4
7018 TF transferrin 2
718 C3 complement C3 1
1191 CLU clusterin 1
3075 CFH complement factor H 1
3240 HP haptoglobin 1
5265 SERPINA1 serpin family A member 1 1
some proteome, while FGB is expressed in the postsynapse and synaptosome with a
coverage of five or higher.
ALDH1A1 is a gene involved in the alcohol metabolism and APOA1 is the major
component of the high density lipoprotein HDL in the plasma. Its transcript is involved
in promoting cholesterol efflux from tissues to the liver. Both of these genes are also
highly expressed and transcribed in the liver.
The remaining two genes ceruloplasmin (CP) and transferrin (TF) are also promi-
nent in the liver. Ceruloplasmin binds most of the copper in the plasma and is involved
in peroxidation of Fe(II)transferrin to Fe(III)transferrin. Its dysfunction leads to iron
accumulation inducing tissue damage and neurologic abnormalities. Transferrin itself
acts as an iron transporter from the intestine and reticuloendothelial system as well
as the liver parenchymal cells, to all proliferating cells in the body. Transferrin has
also been associated with PD in at least one of the PD expression studies (Section
3.3.2). Additionally APP the gene with highest node degree and betweenness score in
all networks is linked to iron export (Section 6.3.1).
It seems as though a number of PD associated genes are highly related to liver
functions. This might be surprising since all of these genes are also expressed in the
synapse. To confirm these findings Table 6.10 shows Biological Process, Molecu-
lar Function and Cellular Component terms enriched in at least two communities in
Cluster 2. Appendix Table F.2 shows the respective GO terms, IDs, as well as short
definitions of the terms (retrieved from QuickGO via GONUTS).
Compared to the first cluster, far less functional terms are enriched for genes in
Cluster 2. This might be due to the smaller size or more diverse functionality of genes
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Table 6.10: GO terms enriched in at least two communities of Cluster 2 (alphabetical
order); significance p-value threshold was set to 0.05. The gene sets of interest were
enriched compared to all genes expressed in the synapse. Results were obtained
using the Fisher exact test, elim algorithm and Benjamini and Yekutieli multiple testing
correction. Exact p-values not supplied since different in distinct enriched clusters).
Biological Process Molecular Function Cellular Component
complement activation,
classical pathway
immunoglobulin receptor binding blood microparticle
serine-type endopeptidase activity external side of plasma membrane
fibrinogen complex
immunoglobulin complex, circulating
platelet alpha granule lumen
leaving less terms enriched. Nevertheless, the results partly confirm functionalities
detected based on PD associated genes in this cluster.
“Complement activation, classical pathway” is the enriched Biological Process
term. It is a component of the innate immune system (Schlachetzki and Winkler, 2015)
and has previously been linked to PD. This could point towards an autoimmune reac-
tion leading to the cell death of neurons (specifically in PD patients). Immune system
related terms can be found amongst the enriched Molecular Functions as well. “Serine-
type endopeptidase activity” as well as “immunoglobulin receptor binding” have been
identified. Quite often immune responses are triggered from the liver which hosts a
large number of natural killer and natural killer T cells (Racanelli and Rehermann,
2006). Hence, this finding overlaps with the regional specificity highlighted, based on
the functionality of PD associated genes.
Considering the enriched Cellular Components “immunoglobulin complex, circu-
lating” confirms identified Biological Process and Molecular Function terms. Further-
more the functionality of PD associated genes is reflected by “blood microparticle”,
“platelet alpha granule lumen” and “fibrinogen complex”. All these terms associate
with the neuroinflammatory pathway which leads to an increase in brain barrier per-
meability. This can lead to the detection of these terms in association to PD (Section
1.1.1.1).
These terms highlight a possible different explanation to the manifestation and/or
the underlying causes of PD. A direct link between fibrinogen levels in elderly Japanese-
American men and PD prevalence could be shown (Wong et al., 2010) and well as
overall elevated fibrinogen levels in PD patients (Lu et al., 2014). Furthermore, a link
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between the immune system and PD has been discussed, and this analysis supplies a
more concrete set of 6 PD associated genes in addition to another 37 genes, with a
potential high impact and link to the disease.
6.3.4.3 Cluster 3
Cluster 3 consists of five communities and has the smallest number of genes. Out of 37
only six genes show a coverage of two or higher. These are connected via six internal
PPIs. Figure 6.10 gives an overview and Table 6.11 lists all PD associated genes in
Cluster 3. Two of these are found in more than two communities and two others only
in one.
Figure 6.10: Genes in Cluster 3 (minimum coverage of two). Opacity represents the
coverage. Red squares are PD associated genes.
Table 6.11: PD associated genes in Cluster 3. Ordered by coverage and Entrez ID.
Gene ID Gene Name Short Gene Description Coverage
775 CACNA1C CACNA1C calcium voltage-gated channel subunit alpha1 C 5
57019 CIAPIN1 CIAPIN1 cytokine induced apoptosis inhibitor 1 4
2915 GRM5 glutamate metabotropic receptor 5 1
4900 NRGN neurogranin 1
One of the PD associated genes in Cluster 3 is CACNA1C which encodes an alpha-
1 subunit of a voltage-dependent calcium channel. As such it is involved in membrane
depolarization and Ca2+ influx into neurons. As a member of the receptor subfamily
1 its main roles are integration of synaptic input in neurons and synaptic transmis-
sion (Catterall, 2011). More generally Ca2+ levels are also crucial to maintain energy
homeostasis which is highly important to maintain a healthy cell state and alterations
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have been linked to PD previously (Hurley and Dexter, 2012). Additionally the gene
CACNB3 (784) is one of the other genes in the community and found in at least one
of the analysed expression studies identifying PD associated genes (Section 3.3.2). It
is involved in the regulation of voltage-dependent calcium channels confirming the
importance of a link between Ca2+ and PD.
Furthermore CACNA1C has been linked to a large number of other neurodegenera-
tive diseases (Lee et al., 2016) such as schizophrenia, bipolar disorder and others. First
studies have proposed to use it as a drug target, as a key member of calcium channels
(Imbrici et al., 2013).
The second PD associated gene is the cytokine induced apoptosis inhibitor 1, CIA-
PIN1, which points towards another PD affected pathway: apoptosis. Apoptotic pro-
cesses are also regulated based on Ca2+ levels (Pinton et al., 2008), which might ex-
plain the link between the two genes appearing in the same communities across the
analysed networks.
Based on these brief insights relying on the PD associated genes overall gene func-
tions in Cluster 3 were studied. Given the small cluster size it was uncertain if signif-
icant results could be obtained. Table 6.12 shows GO Biological Process, Molecular
Function, Cellular Component GO terms found in at least two communities in the clus-
ter. For further details Appendix Table F.3 shows the respective GO terms with their
IDs as well as short definitions of the term. These were retrieved from QuickGO via
GONUTS.
Table 6.12: GO terms enriched in at least two communities of Cluster 3; significance
p-value threshold was set to 0.05. The gene sets of interest were enriched compared to
all genes expressed in the synapse. Results were obtained using the Fisher exact test,
elim algorithm and Benjamini and Yekutieli multiple testing correction. Exact p-values
not supplied since different in distinct enriched clusters).
Biological Process Molecular Function Cellular Component
neuromuscular junction develop-
ment
high voltage-gated calcium channel
activity
L-type voltage-gated calcium chan-
nel complex
The enriched functions are “neuromuscular junction development” (Biological Pro-
cess), “high voltage-gated calcium channel activity” (Molecular Function) as well as
“L-type voltage-gated calcium channel complex” (Cellular Component). Two of the
terms relate to calcium channels, and the third the neuromuscular junction. Since the
neuromuscular junction relies on Ca2+ input a clear link between the three terms is
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proposed. Additionally Ca2+ levels are linked to apoptosis and intracellular energy
regulation. Therefore full functionality of related processes is crucial to maintain cells
in a healthy state.
The case presented is an example how PD associated genes can help to identify
specific disease affected pathways. Even though individual PD associated genes are
not specific to a function, knowing their close interactors, found in the network com-
munities, can point towards the affected pathways.
Furthermore and similar to Cluster 2, even though these terms were found based
on (brain) synaptic gene communities, they might reflect the effects of PD on general
cellular functions. The enrichment of neuromuscular activity can also point towards
peripheral dysfunctions in the body of patients’.
6.3.5 Summary
Thanks to the curated core PD gene set and a combination of PPIN analysis, clustering
algorithms, as well as functional (GO) enrichment this chapter could highlight key
synaptic gene sets and functions affected by PD.
Being able to divide large datasets into connected subgroups is a key contribution to
current research needs and developments. The ability to identify concrete gene groups
as well as a core and extended gene set is a great step forward. This not only confirms
and highlights most affected (synaptic) PD associated functions, but supplies benefi-
cial information to a number of additional research questions. Hence new hypotheses
can be established and further experimental studies can specifically target these newly
proposed genes to gain more in-depth understanding.
Overall this confirms that the use of PPINs is a powerful tool to shed light on
complex biological questions involving large datasets. Furthermore, results supply
details for more efficient, in-depth and highly targeted follow-up research, specifically
in the field of complex diseases.
6.4 Discussion
The use of PPINs is a growing area of research especially in the biological and medical
field. Even though standardised procedures are not yet available this work illustrates
their potential.
The large variety and possible uncertainty regarding data quality at several levels
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decreases the predictive power of the results. Therefore, any additional data curation
steps contribute to the quality. The use of proteomic data together with a curated
list of PPIs allows for a best possible network representation of the data of interest.
Even though this might not guarantee that all predicted interactions happen at the same
time and/or are actually valid, the use of proteomic data highly rises the quality of the
network providing information about proteins experimentally detected in the region
studied.
The use of local network measures gives first insights to the PPIN structure and
some of the most and least central proteins. Nevertheless, especially in large networks,
these values can be influenced by properties of various unnaturally behaving nodes.
Hence, best characterisation is achieved when analysing these statistical measures in a
joint manner.
For more in-depth insight it is recommended to work with node or edge specific
characteristics. These might be hard to analyse individually, but considering nodes and
edges with extreme values can help to identify genes with key roles amongst the data.
Using such a measure can also be misleading or biased since more studies focusing
on a specific gene, e.g. due to its importance in disease, can lead to biased results
and artefacts in the data. Again, the combination of different measures can help to
add certainty to observed results. An alternative approach to analyse node and edge
specific parameters is to consider the correlation between two values. For example,
this can help to identify nodes with extreme values for two parameters giving more
specific insight, which was illustrated in the case of the the connecting role of DGL4,
supporting information flow without being in a top central network position (Section
6.3.1).
Generally it could be seen that the smaller presynaptic network seems to show
slightly different properties compared to the larger postsynaptic, synaptosome and joint
synaptic ones. This highlights the potential impact of size on network measure and a
suggested need to normalise values before comparing them with each other. A similar
phenomena can be observed considering the PPIN topology emerging after network
clustering. Compared to the very node specific approaches outlined above, network
clustering identifies highly connected gene sets. In recent years this has proven to be
a profoundly beneficial tool. Especially addressing complex questions related to large
datasets, such as the case presented, has been facilitated.
Clustering algorithms rely on distinct analytical principles leading to varying com-
munity compositions. Classifying the quality of a clustered network is an ongoing
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challenge which might never be answered. One of the reasons is the subjective defini-
tion of a “good cluster” as well as its mathematical definition and the lack of a ground
truth dataset to be used for comparison. Visualization is an additional challenge which
can be addressed in different ways, either focusing on details or the overall pattern, but
no ideal solution is available. Therefore statistical approaches are even more important.
With regard to identifying the most adequate clustering algorithm additional mea-
sures can be used. Community robustness for example describes the probability of
specific nodes to belong to one or another community. Such information indicates how
stable a network topology is, contributing to its detailed understanding, but hard to
apply to 20 different network topologies. In addition it leads to the same question con-
cerning network cluster cross-comparison. One possible approach to identify the most
representative clustering of a network is the use of the cumulative distribution function
of network consensus matrices. Information regarding the proportion of ambiguously
clustered pairs can also help to identify the best fit. This approach is presented in the
draft in preparation presenting the synaptic proteome (Section 5).
Overall, using a range of different clustering approaches complicates the thorough
analysis of the quality of individual topologies and might not be the most economic
choice. Nevertheless, the results presented showed that the approach was efficient
given the addressed research question. The convergence of results emerging due to
different clusterings, based on different mathematical concepts and different datasets,
describing distinct synaptic regions, is promising. These findings support the credibil-
ity of obtained outcomes.
Therefore, the presented combinatorial approach leading to a set of core commu-
nities, gathering in three clusters could be a recommended choice for use in similar
studies. The combination of different clustering algorithms can be considered as a
varied and multi-angle approach towards interpreting one and the same dataset.
PPINs are static representations of PPIs assigning nodes to only one specific com-
munity. Given a dynamic cellular background this is most likely not the case. Further-
more networks only contain one representation of each protein which ignores the fact
that many proteins are involved in distinct cellular functions. Such details can be in-
cluded in a network model by assigning probabilities to nodes reflecting the likelihood
to belong to a community. Robustness studies, as mentioned previously, can be used
to calculate such values. Integrating these aspects could be a beneficial extension of
the presented results, addressing networks individually.
Using network communities as cellular groups and applying enrichment tests is key
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to identify disease enriched synaptic structures. The use of hypergeometric testing is a
well established approach to do so. Multiple testing correction adds to the credibility
of the obtained significance. Another aspect could be the application of permutation
tests. These would also consider community robustness and increase the certainty of
encountered results even more.
Currently available literature has not yet considered the comparison of commu-
nities emerging from differently clustered networks to investigate disease enrichment
in specific cellular regions. Hence, the identification of three key sets containing a
significant number of PD associated genes is a valuable achievement. Using a cover-
age threshold to identify a core gene set for each cluster is another way to focus on
potential key genes with a strong link to PD. These steps allow to fine-tune future
research questions based on the set of identified genes. Hence, the extended gene set
is a valuable references to verify new research outputs.
It might be asked why none of the most traditional and well known PD associated
genes appear in the disease enriched communities. One possible explanation could be
that these are able to trigger the disease by themselves not leading to enrichment of the
affected community. Such a behaviour might be due to their central role in a synaptic
pathway. Nevertheless most often disease complexity emerges due to a combination
of molecular dysfunctions affecting one pathway inducing functional alterations. This
can lead on to the question why not all PD associated genes grouped and allocated
in disease enriched communities. Technical and phenomenological points might ex-
plain this. Challenges associated to clustering algorithms, not always leading to the
most representative communities, difficulties obtaining a concise set of disease associ-
ated genes and multiple testing approaches can influence the results. In regard to phe-
nomenological reasons some of the disease genes can be rather consequential, meaning
that they show a close link to the disease phenotype. In such cases the effects can be
quite diverse not specifically accumulating in equal pathways and showing enrichment.
The interpretation of the dominating functions amongst genes in a network com-
munity using GO terms is of considerable interest. Available enrichment analysis tools
are used and allow for specific adjustments to obtain best results. In many cases re-
sults confirm, that the joint functionality of genes in the set aligns with the one of
the known PD associated gene. In addition and since individual gene functions are
often very versatile, knowing direct interactors allows to specify concrete affected cel-
lular functions. Results including cases such as rather unexpected disease associated
pathways intuitively happening in other organs, such as the liver, can lead to reconsid-
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eration of long-standing assumptions and lead to new hypotheses. Hence, readjusting
the research focus based on insights obtained through network analysis is just another
benefit of PPIN analysis.
In summary, approaches presented contribute largely to the ongoing development
in the growing field of Systems Biology and integrated medical research. Combin-
ing these endeavours with further experimental and clinical studies can lead to break-




This chapter discusses critical steps, challenges and findings. Relevant ideas for fu-
ture extensions of this work and more in-depth analysis are addressed. Finally key
contributions to the research field are highlighted.
During the execution of the presented research a number of challenges were faced.
Most of them could be solved through alternative methodologies or re-consideration
of the underlying research question. Some of these steps contributed insights that are
worth sharing for consideration in future studies.
7.1 Data Consistency
Describing a disease including as much detail as possible is a crucial step to understand
its diverse, genetic origin and effect on individuals. Recent experimental and techno-
logical advances have allowed a wide range of gene-disease associations to become
publicly available. A good example therefore is the Gene Expression Omnibus (GEO)
database (Edgar et al., 2002) which gives access to a vast quantity of raw and published
high-throughput data, covering gene expression microarray experiments from almost
20 000 published manuscripts (Barrett et al., 2012). Even though such a data reposi-
tory sounds like a great source, in practise it can be notoriously difficult to access and
re-analyse the stored data. Lack of standards covering the use of analytical programs,
significance thresholds, data formats, and other complications mean that meta-analysis
down-stream of the available data can be a challenge, proving very difficult at times.
This phenomena leads to concerns about data-quality. This is specifically acute where
if published results have not been reproduced.
Genome Wide Association Study (GWAS) studies have similar issues. However, in
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this research area standards are more commonly accepted and followed, meaning that
raw experimental data is more easily accessible. This makes data more comparable
across publications and platforms, enhancing their credibility and allowing for down-
stream analysis.
When raw experimental data of interest is obtained, one of the fundamental re-
quirements to identify similarities and differences between the datasets is a common,
unique identifier. This is when annotations become very important and the role of
“data mapping” becomes crucial. Genes and proteins have different, non interchange-
able identifiers. Generally every protein is encoded by a single gene, meaning that
the up-stream dependency of a protein to a gene can be clearly identified; often sev-
eral proteins can be transcribed from a single gene, since splicing and a number of
post-transcriptional modifications may induce additional variety. Depending on the
experimental techniques used, post-transcriptional modifications may be missed, es-
pecially when working with large-scale approaches. It is therefore often adequate to
consider gene identifiers as the unique reference identifier ID for all genes and proteins
to avoid any potential bias. Such steps might limit detailed analysis, but guarantee con-
sistency, reducing the number of false positive records, and allowing data consistency
and usability in the future.
Using single identifiers facilitates further down-stream data analysis, as well as
providing a single reference point. National Center for Biotechnology Information
(NCBI) Entrez IDs were chosen for this purpose. These guarantee stable gene ref-
erences which are widely used amongst the community (Maglott et al., 2010). Con-
sidering that not all data used in this study was retrieved from human samples, cross-
species mapping was required as well. Publicly available homology information was
used for this endeavour, which facilitated the use of all available data (without restric-
tions) from the original species (mouse, rat or human). This was particularly necessary
when building the synaptic proteome datasets. Moreover the available human specific
Protein-Protein Interaction (PPI) set was larger than that for mouse and rat. Since ev-
ery mapping step shows a slight risk of inaccuracy, minimizing the required mappings
was important.
In summary, these challenges in data consistency are currently addressed in ongo-
ing efforts involving a wide range of researchers and research fields. The scientific
community is working towards adapting many standardised formats for data and asso-
ciated meta data in a guided way. This will help facilitate interoperability of datasets,
reusability of data as well as its findability and accessibility. With a comprehensive im-
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plementation of such standards, as proposed by the FAIR initiative (Wilkinson et al.,
2016), many research questions could be answered more efficiently.
7.2 Proteomic Datasets
Proteomic data can provide detailed insight into the molecular constitution of a tissue
region under investigation. As pointed out in Section 7.1 data quality is important to
obtain best possible, most reliable, and consistent research results. While building the
synaptic proteome datasets, Entrez IDs were used as unique identifiers for individual
genes and proteins. This guarantees consistency and uniformity across datasets and
best possible use of all available information, for example across studies, sources and
species. In addition it facilitates data comparison with the set of Parkinson’s Disease
(PD) associated genes (Section 3.3.5).
Most difficulties related to the generation of proteomic datasets reside around ex-
perimental setups. Some of these are common challenges in the field of proteomics and
include tissue extraction, homogenization and mass-spectrometry analysis. Therefore
the joining together and comparing of various studies can help lead to increase in data
quality and credibility. Analysis of the joint dataset can also highlight differences be-
tween available data, and point towards possible false positive records. Specifically due
to the very large total number of proteins identified in the synaptic proteomes defining
a core set was considered. However, using coverage as an approach to cut-off and iden-
tify a core proteomic dataset as described in Section 5.3.2, can lead to problems. For
example genes detected with newer, more fine-grained technologies can be penalised
or unwillingly excluded. Considering the first detection approach for filtering could
help to prevent this.
However, a more generic approach can assist in the endeavour of filtering the full
gene list reflecting detection consistency, and hence protein presence in the respective
tissue region. The postsynaptic proteome which has been analysed in 23 published
studies (Chapter 5) could be “cleaned” with such an approach. For the presynaptic
proteome, further datasets are needed before being able to define a representative cut-
off considering the year of first detection of a protein. The idea of a relative cut-off,
depending on e.g. the year of first publication as proposed here has not been addressed
in published literature so far, but could lead to more consistent results and a smaller,
more representative synaptic proteome.
Although no additional filtering steps were applied to the generated proteomic
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datasets for the purpose of this study, the large total numbers of proteins in the synap-
tic proteomes suggest that the total number of identified proteins exceeds the real one.
The high number of proteins detected in only one of the synaptic studies proposes that
these proteins might not actually be found in any of the synaptic regions. Therefore
a combination of protein coverage and detection year together with other parameters
should be considered to contributing towards identifying a core synaptosome providing
even higher data quality.
Working with the large number of proteins in the proteomic datasets, ranging be-
tween 1,867 and 6,706 proteins in the presynaptic and joint synaptic proteome, re-
quired large-scale analytical techniques. The use of such is one way to gain insight
into the data structure and role of PD in this region. Therefore Section 7.3 discusses
the application of large-scale analytical techniques, in the context of Protein-Protein-
Interaction Networks (PPINs).
7.3 Protein-Protein-Interaction Networks and PD
Datasets associated with a complex diseases, such as PD, tend to contain relatively
large numbers of genes which are not obviously interacting or affecting similar biolog-
ical pathways. These properties represent a challenging territory for in-depth analysis.
Under such conditions the use of data-driven models and representations, machine
learning techniques and tools, and statistical analysis and interpretation is of great
value to gain new biological insights. This research focused on the use of PPINs as a
promising tool to represent and analyse complex data encapsulating disease informa-
tion, for example related to PD. Data-driven models, such as the PPINs proposed, can
also assist in testing hypotheses emerging from experimental studies, usually focusing
on single, specific disease mechanisms.
To ensure data-quality, PPIs used to generate the PPINs, were mined and internally
assessed (Section 4.3.1). This lead to the best possible set of human, direct PPIs for
the purpose of this work. Adding this extra effort to the workflow helped to reveal
differences between the main PPI databases and how they obtain their interaction in-
formation. The steps taken whilst generating the PPI list (Section 4.3.2) helped to
identify the final filter settings. For example the exclusion of non-direct interactions
helped to ultimately obtain a high quality dataset.
In light of using PPI data in a human focused analysis, filtering only direct and hu-
man specific PPIs to build networks is highly recommended. The number of available
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human PPIs seems relatively “complete” which might not the case for other species.
For example the mouse PPI set currently only contains ~15,500 specific PPIs, com-
pared to ~200,000 human PPIs. When working with purely mouse specific data it is
hence recommendable to make use of data obtained in other species, for a more com-
prehensive dataset. Nevertheless, not having to fall back on cross-species mapping, as
when working with human-only data, increases quality of the network structure and
allows for better predictions.
The use of species specific information can generally help to avoid bias in the
PPINs. Additionally using proteomic datasets to build the networks imposes further
quality standards, for example, by only considering those proteins found in datasets
expressed in the tissue region of interest. By doing so however, a number of verified
PPIs are excluded from the network, due to not having detected one or both of the
interactors in the analysed proteome. The PPIN can therefore only represent a limited
spatial and temporal overview. More advanced and fine-tuned experimental techniques
are required to capture spatial and temporal changes in the proteome to obtain more
fine-grained insights and construct specific networks.
The current procedure proposed during this research, using proteomic data and
applying filtering criteria to the mined PPIs, shows the best quality control for network
building and insightful analysis currently available. This procedure has lead to identify
key proteins in the networks, and in the context of PD has helped to confirm the most
central disease genes.
Apart from that there was further interest uncovering the underlying complex struc-
ture of PD related genes in the synaptic PPINs. Such knowledge can help to identify
disease subtypes, disease manifestation mechanisms, and help to make predictions
regarding potential biomarkers. The use of machine learning techniques, such as com-
munity detection algorithms, was crucial in this aim. Choosing an appropriate clus-
tering algorithm for a specific PPIN was no trivial task. This is specifically true when
working with large datasets as addressed in this work (Section 6.3.2).
Another additional challenge is how to compare clustering results between algo-
rithms, when no ground truth data exists for the PPINs. Clustering algorithms employ
different machine learning techniques, metrics, parameters and values, when dealing
with how to divide a network into communities. This diversity leads to largely varying
community sizes amongst other network parameters. Hence trying to identify what
constitutes the “best” clustering for a specific network plays an important role. Differ-
ent research questions might require more coarse- or fine-grained groupings (commu-
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nities) to advance understanding of the data, and potentially answer open questions.
The choice of which clustering algorithm to use needed to be taken. Due to the
network size of up to 6,068 nodes and 69,520 edges, which is considered large for
a biological system, the chosen algorithm had to be able to break down the structure
into communities, in a reasonable computing time. Since there was no obvious best
choice, a set of clustering algorithms also seemed a good way to address the question
of “best” clustering. Based on results obtained none of them seemed to outperform the
others. Hence, all algorithms and communities were considered with equal probability
and taken forward for PD and functional enrichment analysis.
In summary, this part of the research showed the use of PPINs as being crucial for
analysis of large proteomic datasets and disease. The difficulty of finding the most
adequate algorithm was bypassed through the combination of several what specifically
addressed the research question. It turns out that such an approach lead to results,
regarding the question of interest, which were both highly consistent and promising.
Hence this supports the idea that synaptic gene communities are associated to PD in-
dependently of the applied clustering strategy. In general, this result should be trans-
ferable to detecting communities specific to other diseases as well.
7.4 Systems Biology and PD Research
Studying complex diseases is a non-trivial task, especially given continuous growth
of experimental data, such as GWAS and microarray expression results, and genetic
information associated with the disease. Such complexity requires a systems approach,
the use of PPINs for example, to gain an understanding of (i) biological processes
active in the synapse and (ii) relationship between datasets.
Since complex diseases are caused by a combination of genes and their dysfunc-
tions, these genes are often affecting similar pathways or cellular regions. Hence un-
derstanding which disease associated genes act together and identify their closest in-
teractors is a promising approach to deepen knowledge about the diseases and guide
future research endeavours.
Clustering PPINs to communities is one way to identify such gene communities.
Based on the known PD associated genes in the communities, it is possible to identify
gene sets showing a significant over-representation of PD, and hence reveal possibly
new links between known and unknown PD associated genes.
Since communities shed light on the nearest neighbours of known PD associated
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genes in disease affected synaptic regions, they can also help minimise the number of
potential key PD associated genes required to alter and/or are involved in the alterations
of disease related functions. Hence identifying subsets of genes associated to a specific
disease, tissue, or function is of great benefit to understand the disease.
Furthermore the overall function of all genes in the enriched community can be
studied. The use of Gene Ontology (GO) enrichment is a powerful approach here,
even though the vast ontology structure makes it difficult to use. Using annotated gene-
function information, as deposited in the GO database, can assist the identification of
non-random functional similarities between genes in a set. Various techniques are
available, and the focus on more specific functional terms, found in lower levels of the
ontology tree, seems to be the most beneficial approach. Therefore the elim algorithm
was chosen (Alexa et al., 2006).
The enrichment of highly specific GO terms could be found, confirming function-
alities based on known PD associated genes. Additionally, functional enrichment re-
sults were able to specify further PD associated pathways, which have not yet been
addressed in detail as being associated to PD.
As a further development to functional enrichment studies and to fine-tune func-
tional enrichment results other concepts are being developed. One of them is the pos-
sible clipping of the GO tree to obtain a more targeted, for example neurology specific
test environment (Geifman et al., 2010). Such advances can contribute interesting,
mostly similar, results.
In summary, the potential of using PPINs to answer complex biological questions
is promising, but its benefits are only just being discovered. Unravelling densely con-
nected gene groups allows for further analytical steps such as gene-set specific enrich-
ment studies. This combination of large-scale analytical approaches such as clustering,
disease, and functional enrichment was then applied to study the set of PD associated
genes (Section 3.3.5).
7.5 Synaptic Dysfunctions and PD
Apart from affecting multiple molecular functions, complex diseases affect cells at
different levels. Joining available data was crucial to make better predictions, but was
also a very challenging task. Varying quality controls and standards was the main issue
in generating a final PD associated gene set.
This often meant excluding possibly useful information, which did not reach a
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certain quality threshold. Nevertheless, a valuable core and extended gene disease
association dataset could be generated, which showed that some of the later identified
genes had been linked to PD previously. This could be confirmed by the detection
of some genes associated to PD, found in experimental expression data, and amongst
gene sets enriched for PD in network clusters. This also underlines the hypothesis
that (i) distinct experimental approaches capture different facets of the disease and
(ii) distinct cellular levels are affected in specific ways by the disease manifestation.
This combination and flexibility reflects different cellular dysfunctions making up the
disease genotype or forming part of its phenotype.
The final PD associated gene set was concise and robust enough to work with, al-
lowing further knowledge to be gained. Therefore results provide a proof-of-concept,
confirming known disease-gene links and finding new candidates. This is specifically
true since this work put a large effort into identifying PD associated genes from differ-
ent sources, and combining these in a comprehensive way.
One might think this replicates the work presented in the PD-map (Fujita et al.,
2014). This in-depth analysis provides a great tool to visualize PD affected molecular
functions and synaptic regions, but does not allow key sets of disease associated genes
to be directly and computationally accessed. Information regarding direct or indirect
links or associations are not available, making it almost impossible to directly use the
supplied data in the context of this work. Therefore the manually curated core gene set
was used.
The exercise of combining publicly available knowledge, describing PD gene asso-
ciations, allowed to show significant overlap of data from distinct sources, confirming
their PD specificity by highlighting their disease focus.
Once the core PD gene set was defined, further analysis using a systems biological
approaches could be considered. Network analytical techniques were able to pin-point
main affected PD associated pathways (Section 6.3.4). Even though initial clustering
results varied based on the chosen clustering algorithm, comparative analysis and re-
sults were consistent and reassuring. This suggests the presented strategy could be
used for other studies as well.
With respect to PD three main gene sets were highlighted as being highly influ-
enced. A number of postsynaptic functionalities include receptor localization, recep-
tor signalling pathways and neurotransmitter secretion (Sections 1.1.1.1 and 6.3.4.1).
Furthermore, liver associated pathways were found associated to PD associated genes
in the enriched Cluster 2 (Section 6.3.4.2). Such abnormalities in liver enzymes have
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been linked to PD as early as 1991 (Tanner, 1991). More specifically fibrinogen was
studied and findings confirmed a link between elevated fibrinogen levels and PD in
men, older than 75 years of age. These pathways point towards an inflammatory re-
action linked to the disease and could also be classified as an autoimmune response.
Recent research has also proposed the liver drug UDCA to treat PD patients showing
first protective effects on nerve cells in a genetic mouse model (Mortiboys et al., 2015).
Having verified not just the affected processes, but also a concrete set of genes
linked to known PD associated ones, allows further gene targets to be researched. The
identification of known disease associated functions is a proof-of-principle for the pre-
sented idea. Nevertheless the real advance lies in the generation of concrete, relatively
concise gene sets. Proposed disease target genes, highly linked to known PD associated
ones are a substantial source for future advances. Follow-up studies can now analyse
the role of these genes from various perspectives advancing knowledge in their detailed
functionality and impact on molecular dysfunctions linked to PD. These can consider
the genes to be (i) so far unsuspected disease triggers, (ii) potential drug targets, due to
their close link and influence on disease associated genes or (iii) biomarkers, allowing
better diagnosis.
7.6 Future Research Perspectives
Every study is limited by time and resources and often interesting follow-up questions
arise at more advanced stages of a project. In the study presented, the developed con-
cept could be used to answer other similar research questions.
This thesis covers a range of aspects which come together to shed light over com-
plex diseases given an affected tissue. This “pipeline” allowed me to identify core
disease associated gene sets as well as their dysfunctions, helping to uncover unknown
or unsuspected links between diseases and pathways as well as cross-pathway inter-
action. The use of a range of network parameters combined with curated datasets
guaranteed best possible quality of analysis and results.
Given the flexibility of the pipeline one might wonder why the analysis was not
carried out for a second reference tissue and/or another neurodegenerative disease.
Results for either of the scenarios could confirm the specificity of the results to PD and
highlight more general neurological effects. The biggest challenge was the remarkable
importance of data quality, considering the set of disease associated genes as well as
the proteome of interest. No equally high standard datasets could be easily obtained,
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but future studies should take these proposals into account.
Apart from questions related to complex diseases the approach is able to cover
other aspects. For example, protein datasets, containing proteomic data from different
tissues could be used to associate e.g. disease to a specific organ. More phenomeno-
logical trait information, such as obesity markers, retrieved from the Human Pheno-
type Ontology (Köhler et al., 2017), amongst others, can give insights into underlying
molecular mechanisms.
Due to current data availability, presented results describe “an average synapse”,
not considering subtypes or alike. PD mostly affects dopaminergic neurons in the
substantia nigra pars compacta. Building a PPIN of proteins expressed in specifically
these neurons can enhance insights and results would be more specific. For example
the Allen Brain Atlas (Hawrylycz et al., 2012, 2014)1 supplies detailed insights for
human brain tissues. Nevertheless the data are based on a very small sample size
of only three individuals (at time of study). The Human Protein Atlas (Uhlén et al.,
2015)2 might be another data source. Brain region specific tissues are not yet available
in this repository but cell type specific data is increasing. A major drawback in both
cases is the supplied data type. Information is based on gene-expression data, which
based on the central dogma of molecular biology (Figure 1.1), does not allow concrete
prediction of the proteome since it disregards the transcription step. Hence available
data does not reflect standards of a proteomic dataset and can influences the network
topology and ultimately obtained results. Upcoming technologies are addressing these
challenges which might be overcome in the next decade. Therefore, data from the
before mentioned sources supply good starting points to explore the benefits gained
through more specific datasets.
Two additional aspects need consideration. Variation in the proteome based on de-
velopmental stages (temporal aspect) and spatial restrictions. The proteome changes
over the course of cell and tissue development and possibly under disease conditions.
Furthermore spatial intracellular division likely prevents a number of PPIs from oc-
curring. This can be explained by cellular compartments such as the nuclear or endo-
plasmatic reticulum membrane acting as physical barriers. Apart from gaining more
specific insight based on more precise data the simulation and comparison of several
proteomes can illustrate the development of for example disease effects on a system
such as the synapse. The field of multi-scale modelling (Hirakis et al., 2015) is cur-
1http://www.brain-map.org/
2http://www.proteinatlas.org/
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rently exploring advances in this field and has shown first promising results.
Furthermore PPINs are static representations of protein interactions. Protein abun-
dance, interaction probabilities and the fact that some proteins are more likely to be-
long to two communities than to one can not be reflected. Nevertheless the possibility
to divide networks and identify specifically disease enriched gene sets is of substan-
tial value. This makes PPINs a very powerful, currently available, tool in the area of
systems biology allowing to formulate new, more specific research hypotheses.
To address some remaining challenges two side projects were carried out along-
side this PhD research and illustrate additional areas of advancement. PPINs allowed
to identify a potential new key set of disease associated genes and functional associa-
tions to consider more closely in future studies (Section 6.3.4 and Appendix E). Hence
apart from focusing on a regional, proteome level, the impact of PD on the synapse
was addressed from a more low-level perspective. To consider the implications of the
disease on a whole system more perspective needed to be gained. The impact of PD on
neuronal information transmission requires such a higher level systems understanding,
modelling the behaviour of the entire synapse or neuron. Such a model also allows
better analysis of drug effects and might allow the detection for disease biomarkers
since it considers an entire system.
Both, the lower and higher level angle were addressed in shared side projects, and
are introduced in the next sections.
7.6.1 Clathrin Mediated Endocytosis - a Dynamic Model
As Section 5.3.6 shows, one of the PD associated subsystems is the “clathrin coat as-
sembly” cycle. It relates to the larger system of Clathrin Mediated Endocytosis (CME),
which involves around 30 proteins undergoing about 60 internal PPIs (McMahon and
Boucrot, 2011). Eight of the 30 proteins have been previously linked to PD. These
are the proteins and genes actin, auxilin, cortactin, endophilin, EPS15-EPS15R, GAK,
HIP1R, and HSC70 which are part of the pathway, as well as NSF and LRRK2 showing
a link to the clathrin light chain as well as cytoskeletal signal transmission respectively.
To better understand the system and analyse implications of individual disease as-
sociated genes, a dynamic CME model was generated. This work was carried out
together with Oksana Sorokina, Anatoly Sorokin and Douglas Armstrong. One of the
elaborated models (which was implemented by myself; “model 2”) contains individual
clathrin molecules and describes their interaction leading to the formation of clathrin
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coated vesicles in a detailed way. A rule-based modelling approach, specifically kappa
modelling (Danos et al., 2008)3 was used to simulate the system in detail.
Even though a large amount of research has previously focused on the CME system
from an experimental as well as computational point of view, the rule-based model
allows for relatively easy extension. Hence, a more detailed view of a PD affected
process was generated. This is a first step towards simulating the effect of dysfunctions
on the system which can for example predict the impact of PD on CME or vice versa.
Some of the aforementioned genes have already been added to preliminary models and
need to be further explored.
A joint draft is currently in preparation, proving the concept of using a rule-based
modelling approach to simulate the dynamic CME system. The current version can be
found in Appendix G.
For a broad understanding of disease mechanisms, not only more in-depth insights
are required. Broader system understanding is necessary to grasp the effect of changes
in individual proteins on a whole system such as a whole neuron and its role in infor-
mation transmission.
7.6.2 Disease in Computational Models of Neurons
A large number of computational models of neurons are available. Most of these focus
on slightly different research questions which contain topics around information trans-
mission between neurons. Due to the lack of standardised modelling languages and
common nomenclature it is very challenging to systematically analyse and compare
models and identify their key components.
In a joint effort, together with Emilia Wysocka and David C. Sterratt, both Uni-
versity of Edinburgh, a number of synaptic models were analysed and a key set of
modelled synaptic genes could be identified. A publication is in preparation and the
current version can be found in Appendix H.
The annotation of synaptic models and extraction of entities appearing in these
models was a non-trivial task. Once a set of modelled genes was identified it was
compared to a list of genes commonly found in seven neurodegenerative diseases. The
study showed that a large number of disease associated genes are not modelled in the
analysed computational models of neurons. The availability of the list of modelled
genes together with a set of disease associated genes can now help to identify most
3http://dev.executableknowledge.org/
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suitable available models to extend and gain more disease related insights.
Thus this study showed that considering higher system-level models, by first iden-
tifying their general focus and modelled elements, can help to find the best fit pre-
existing model to be extended to answer specific disease related questions. Studying
the effect of drugs and identifying disease biomarkers is highly facilitated by such a
system and should be considered for future analysis.
7.7 Conclusion
To gain better understanding of a complex disease, which shows its main effect at the
synapse, a highly regulated brain region, proved challenging. Nevertheless the curation
of high quality datasets, systems biological approaches and in-depth statistical and
functional analysis allowed me to obtain new insights into the disease.
The use of PPINs as a mathematical representation of complex diseases helped me
to identify PD associated gene sets, and their closely connected interactors, showing
a novelty which has not yet been addressed in PD research. The use of PPINs added
detailed, functional insight and moved from the analysis of single disease genes to
gene sets. This helps to show the joint impact of several genes on disease development
and manifestation.
Network analysis cannot hope to solve all research problems in their entirety, but
can contribute to speeding up the process of finding answers to complex questions;
specifically by advancing and better defining future research questions and directions.
Hence this study is a proof-of-concept, highlighting the need of large-scale techniques,
to address detailed research questions related to complex disease.
The static nature of interaction networks did not prove a major obstacle, supported
by the fact that numerous slightly different datasets as well as clustering algorithms
lead to very similar results. It might be argued that the combination of datasets and
clustering algorithms was needless since similar results were obtained (Section 6.3.3).
Nevertheless it is the combination and mutual confirmation of results which strength-
ens the outcomes and make them more trustworthy.
Considering PD specifically three new functionally defined gene sets were identi-
fied (Section 6.3.3). These contain know PD associated genes and a number of reliably
linked others. The core datasets are available to be considered in future research into
underlying disease causes, disease subtypes, biomarkers, and drug targets. Identifying
known functional GO terms related to spatial organisation, involving scaffolding pro-
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teins and vesicle cycling confirms the potential of the enrichment approach (Section
6.3.4.1). New hints towards immune response related functions should drive research
to emphasize on these fields in upcoming PD related studies (Section 6.3.4.2).
Overall, this work presents a combination of systems biological approaches, in-
cluding the use of PPINs and functional enrichment studies. It was possible to identify
new potential gene sets and their overall function, playing key roles in PD. Such find-
ings are very beneficial in the light of further understanding the disease complexity.
In summary, existing techniques were used to to confirm known and unravel un-
known details regarding PD. Results obtained are very promising and further devel-
opment of presented ideas and findings can lead to major contributions in theoretical,
experimental and clinical PD research. Available knowledge was enriched and ex-
tended and future analysis of many other open challenges, not only related to PD, but
other complex diseases can be made more targeted and efficient.
Appendix A
Literature based Parkinson’s Disease
associated genes
Table A.1: Genes manually identified to be linked to PD in reviewed papers (ordered
alphabetically by Gene Name short). PMCID shows the reference where the gene-
disease association was identified.
Entrez ID Gene Name short PMCID
130013 ACMSD 22438815, 21812969
135 ADORA2A 24032478
351 APP 22438815
23400 ATP13A2 23380027, 2650009











2580 GAK 22438815, 21812969, 22786590
2629 GBA 23380027, 20495568, 22438815, 21812969
26058 GIGYF2 20495568
2861 GPR37 23251443
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3920 LAMP2 23380027
27074 LAMP3 22438815, 21812969, 22786590
120892 LRRK2 3035023, 23380027, 20495568, 22438815, 21812969, 22786590
4137 MAPT 22438815, 22806825
4163 MCC 22438815





5071 PARK2 3035023, 23380027, 20495568, 22581678, 21812969
11315 PARK7 3035023, 23418303, 23380027, 20495568, 22581678, 21812969
677662 PARK12 17068789
100359403 PARK16 22438815, 21812969





6622 SNCA 3035023, 23380027, 20495568, 22438815, 21812969, 22786590, 21412835
9627 SNCAIP 23127794
27347 STK39 22438815, 21812969, 22786590








Table B.1: MI IDs specifying all direct interaction types, used to filter PPIs (orderd al-
phabetically based on the description).
Interaction MI-ID Description
0192 acetylation reaction
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0212 lipid cleavage reaction
0213 methylation reaction




0910 nucleic acid cleavage
0986 nucleic acid strand elongation reaction
0881 nucleoside triphosphatase reaction







1237 proline isomerization reaction
0570 protein cleavage
1127 putative self interaction
0902 rna cleavage







0218 obsolete: physical interaction
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Extended Overview of Synaptic
Proteomic Studies
Table C.1: Presynaptic proteome publications and respective datasets. “Count” shows
the number of proteins, mapped to human Entrez IDs found in the study.
Study Year Reference Short Description Species Method Description Count
MORCIANO 2005 Morciano et al.
(2005)
synaptic vesicle rat Co-IP with SV2, MALDI-
TOF-MS and 2D BAC/SDS-
PAG
Synaptic vesicle proteins from
nerve terminal proteome
85
BURRE 2006 Burré et al.
(2006)
synaptic vesicle rat 1-D SDS-PAGE & nano-LC
ESI-MS/MS, or 2-D SDS-
PAGE & (BAC)/SDS-PAGE,
or SDS (dSDS)-PAGE &
MALDI-TOF-MS
Synaptic vesicle proteins 157
MORCIANO 2009 Morciano et al.
(2009)
synaptic vesicle rat IP, MALDI-TOF-MS,
nanoLC ESI MS/MS and
2D BAC/SDS-PAGE
Using a monoclonal antibody
against synaptic vesicle pro-
tein 2 we immunopurified a
presynaptic compartment con-
taining the active zone with
synaptic vesicles docked to
the presynaptic plasma mem-
brane as well as elements of
the presynaptic cytomatrix
308
GORINI 2010 Gorini et al.
(2010)
presynaptic mouse CO-IP, MALDI-TOF-MS and
MASCOT
Presynaptic vesicle re-
cycling: We used co-
immunoprecipitation fol-
lowed by mass spectrometry
or western blotting to inves-
tigate the synaptic protein





GRONBORG 2010 Grønborg et al.
(2010)




BOYKEN 2013 Boyken et al.
(2013)
presynaptic rat LS/MS-MS, iTRAQ Synaptic vesicle docking and
endocytosis
414
WILHELM 2014 Wilhelm et al.
(2014)
synaptic vesicle rat quantitative IP and LS/MS-
MS
Synaptic vesicle cycle pro-
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Table C.1: Presynaptic proteome publications and respective datasets. “Count” shows
the number of proteins, mapped to human Entrez IDs found in the study.





presynaptic mouse CoIP with SV2, SDS-PAGE
and LC-MS/MS
Presynaptic active zone 467
Table C.2: Postsynaptic proteome publications and respective datasets. “Count” shows
the number of proteins, mapped to human Entrez IDs found in the study.
Study Year Reference Short Description Species Method Description Count
WALIKONIS 2000 Walikonis et al.
(2000)
postsynaptic rat MALDI-TOF-MS and SDS-
PAGE
Forebrain PSD 29
PENG 2004 Peng et al.
(2004)
postsynaptic rat liquid chromatography and
LC-MS/MS
Forebrain PSD 325
SATOH 2002 Satoh et al.
(2002)
postsynaptic mouse 2D LC/MS/MS Forebrain PSD 45
YOSHIMURA 2004 Yoshimura et al.
(2004)
postsynaptic rat 2D LC/MS/MS Forebrain PSD 435
FARR 2004 Farr et al. (2004) MGLUR5 rat co IP mGluR5 interacting complex
(co IP)
71




nanoflow HPLC and LC-
MS/MS
Brain PSD 390
LI 2004 wan Li et al.
(2003)





TRINIDAD 2005 Trinidad et al.
(2005)
postsynaptic mouse Nano-LC-ESI-QTOF MS/MS Forebrain PSD 234
CHENG 2006 Cheng et al.
(2006)
postsynaptic rat LC-MS/MS PSD identifications found in
both cerebellum and forebrain
288








mouse 1D SDS-PAGE and LC-
MS/MS, immunoprecipita-
tion with antibody against




G2C PSD dataset, immuno
-purification for NR2B,
NR1 or GRIA2 (AMPA),
NRC/MASC complex = total
from NR1 + NR2B above;
Consensus PSD calculated
by Collins et al, more than 2
mentionings in 6 published
proteomic studies and 119
individual papers
717
DOSEMESI 2006 Dosemeci et al.
(2006)
postsynaptic rat 2D LC/MS/MS PSD from hippocampus 113
DOSEMESI 2007 Dosemeci et al.
(2007)
postsynaptic rat LC-MS/MS; LC-MS/MS, IP
with PSD95
Cortex PSD, PSD95 protein
complex
548
TRINIDAD 2008 Trinidad et al.
(2008)
postsynaptic mouse Nano-LC-ESI-QTOF MS/MS PSD relative quantification of
expression and phosphoryla-




SELIMI 2009 Selimi et al.
(2009)




(QqTOF) MS and MALDI










mouse TAP tag, LC-MS/MS TAP-PSD-95 pull-down core
list and full list
292





human LC-MS/MS Human neocortex (hPSD)
biopsy PSD consensus and
full list
1441





mouse LC-MS/MS Cortex PSD consensus 1545
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Table C.2: Postsynaptic proteome publications and respective datasets. “Count” shows
the number of proteins, mapped to human Entrez IDs found in the study.
Study Year Reference Short Description Species Method Description Count
SCHWENK 2012 Schwenk et al.
(2012)






AMPA receptor complex 34
DISTLER
PSD1
2014 Distler et al.
(2014)
postsynaptic I mouse LS/MS-MS with
iTRAQUDMSE, ISOQuant
mouse hyppocampus PSD 3545
DISTLER
PSD2
2014 Distler et al.
(2014)
postsynaptic II mouse LS/MS-MS with
iTRAQUDMSE, ISOQuant
mouse hyppocampus PSD 2092
BAYES 2014 Bayés et al.
(2014)
postsynaptic, MASC human SDS-PAGE and nanoLC-
MS/MS
PSD (post-mortem neocortex
samples and biopsy tissue),
MASC (post mortem neocor-
tex samples and biopsy tissue)
1141




mouse in vivo affinity purification
approach BioID (iBioID) +
streptavidin-based affinity
purification and mass spec-
trometry (MS), DLG4-BirA,
collybistin(Arhgef9)n-BirA
and InSyn1-(BirA) & gephyin
-BirA, InSyn1-coIP, LS-MS
pilot iPSD: BirA, PSD95-
BirA, gephyrin- BirA, ePSD,




FOCKING 2016 Föcking et al.
(2016)
postsynaptic human Label free LC-MS supragenual (BA24) - anterior
cingulate cortex (ACC)
2026
Table C.3: Synaptosome proteome datasets and respective publications. “Count”
shows the number of proteins, mapped to human Entrez IDs found in the study.
Study Year Reference Short Description Species Method Description Count
FILIOU 2010 Filiou et al.
(2010)





DAHLHAUS 2011 Dahlhaus et al.
(2011)
synaptosome mouse MALDI-MS and iTRAQ Synaptic proteome from
mouse visual cortex
638
ZIV synapse 2013 Cohen et al.
(2013)
synaptosome rat Stable Isotope Labeling with
Amino acids in Cell cul-
ture (SILAC), mass spectrom-
etry (MS), Fluorescent Non-





ZIV full 2013 Cohen et al.
(2013)
synaptosome rat Stable Isotope Labeling with
Amino acids in Cell cul-
ture (SILAC), mass spectrom-
etry (MS), Fluorescent Non-





BIESEMANN 2014 Biesemann et al.
(2014)







CHANG 2015 Chang et al.
(2015)
synaptosome human SCX fractionation with
SWATH analysis
Synaptic proteome from hyp-
pocampus and motor cortex in
autopsy brain for Alzheimer’s
disease and control
2076
DISTLER 2014 Distler et al.
(2014)
TOTAL mouse LS/MS-MS with
iTRAQUDMSE, ISOQuant
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(a) fast greedy (b) infomap
(c) louvain (d) spectral
(e) spinglass
Figure D.1: Postsynaptic PPINs. Different clustering algorithm results are highlighted.
Red coloured nodes represent PD associated genes. Grey “background” represents
network edges.
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(a) fast greedy (b) infomap
(c) louvain (d) spectral
(e) spinglass
Figure D.2: Synaptosome PPINs. Different clustering algorithm results are highlighted.




Core PD associated gene sets
Cluster 1 (sorted by Entrez ID)
19 (ABCA1), 88 (ACTN2), 89 (ACTN3), 320 (APBA1), 491 (ATP2B2), 493 (ATP2B4),
575 (ADGRB1), 796 (CALCA), 1501 (CTNND2), 1739 (DLG1), 1740 (DLG2), 1741
(DLG3), 1742 (DLG4), 1756 (DMD), 1837 (DTNA), 2257 (FGF12), 2902 (GRIN1),
2903 (GRIN2A), 2904 (GRIN2B), 2905 (GRIN2C), 2906 (GRIN2D), 2977 (GUCY1A2),
2983 (GUCY1B3), 3736 (KCNA1), 3738 (KCNA3), 3739 (KCNA4), 3761 (KCNJ4),
4130 (MAP1A), 4355 (MPP2), 4842 (NOS1), 5332 (PLCB4), 6323 (SCN1A), 6329
(SCN4A), 6331 (SCN5A), 6640 (SNTA1), 6641 (SNTB1), 6645 (SNTB2), 7402 (UTRN),
8502 (PKP4), 8525 (DGKZ), 8573 (CASK), 8777 (MPDZ), 8825 (LIN7A), 8938 (BA-
IAP3), 9211 (LGI1), 9223 (MAGI1), 9369 (NRXN3), 9378 (NRXN1), 9379 (NRXN2),
9615 (GDA), 9754 (STARD8), 9973 (CCS), 10125 (RASGRP1), 10203 (CALCRL),
10207 (PATJ), 10276 (NET1), 11336 (EXOC3), 22871 (NLGN1), 23037 (PDZD2),
23109 (DDN), 23209 (MLC1), 23237 (ARC), 23265 (EXOC7), 23513 (SCRIB), 25960
(ADGRA2), 26154 (ABCA12), 29919 (C18orf8), 53616 (ADAM22), 53919 (SLCO1C1),
54413 (NLGN3), 55083 (KIF26B), 55327 (LIN7C), 55914 (ERBIN), 57502 (NLGN4X),
57524 (CASKIN1), 57554 (LRRC7), 57555 (NLGN2), 57575 (PCDH10),
60412 (EXOC4), 64130 (LIN7B), 64398 (MPP5), 84435 (ADGRA1), 84448 (ABLIM2),
85445 (CNTNAP4), 140735 (DYNLL2), 143098 (MPP7), 148753 (FAM163A), 166647
(ADGRA3), 221749 (PXDC1), 642968 (FAM163B)
Cluster 2 (sorted by Entrez ID)
213 (ALB), 216 (ALDH1A1), 217 (ALDH2), 272 (AMPD3), 767 (CA8), 335 (APOA1),
337 (APOA4), 345 (APOC3), 714 (C1QC), 1356 (CP), 1471 (CST3), 1608 (DGKG),
2243 (FGA), 2244 (FGB), 2266 (FGG), 3500 (IGHG1), 3502 (IGHG3), 3503 (IGHG4),
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178 Appendix E. Core PD associated gene sets
3514 (IGKC), 3778 (KCNMA1), 4018 (LPA), 4329 (ALDH6A1), 4635 (MYL4), 5136
(PDE1A), 5142 (PDE4B), 7018 (TF), 7579 (ZSCAN20), 8854 (ALDH1A2),
8911 (CACNA1I), 8914 (TIMELESS), 23036 (ZNF292), 23460 (ABCA6),
26049 (FAM169A), 57165 (GJC2), 57722 (IGDCC4), 79183 (TTPAL), 79925 (SPEF2),
128240 (NAXE), 140460 (ASB7), 154664 (ABCA13), 255189 (PLA2G4F), 284161
(GDPD1), 353274 (ZNF445)
Cluster 3 (sorted by Entrez ID)
775 (CACNA1C), 782 (CACNB1), 783 (CACNB2), 784 (CACNB3), 9478 (CABP1),
57019 (CIAPIN1)
Appendix F
Enriched Gene Ontology terms in the
top three PD enriched clusters
Table F.1: GO terms enriched in at least two communities in Cluster 1 (alphabetical
order of GO terms); significance p-value threshold was set to 0.05. The gene sets
of interest were enriched compared to all genes expressed in the synapse. Results
were obtained using the Fisher exact test, elim algorithm and Benjamini and Yekutieli
multiple testing correction. Exact p-values available upon request since different in
distinct enriched clusters).
GO term GO term ID GO term definition
Biological Process
GDP metabolic process GO:0046710 The chemical reactions and pathways involving GDP, guanosine 5’-
diphosphate
gephyrin clustering involved in
postsynaptic density assembly
GO:0097116 The clustering process in which gephyrin molecules are localized
to distinct domains in the postsynaptic density as part of postsynap-
tic density assembly. Gephyrin is a component of the postsynaptic
protein network of inhibitory synapses




GO:0035235 A series of molecular signals initiated by glutamate binding to a
glutamate receptor on the surface of the target cell, followed by the
movement of ions through a channel in the receptor complex. Ends
with regulation of a downstream cellular process, e.g. transcription
maintenance of epithelial cell
apical/basal polarity
GO:0045199 The maintenance of the apicobasal polarity of an epithelial cell
negative regulation of peptidyl-
cystein S-nitrosylation
GO:1902083 ny process that stops, prevents or reduces the frequency, rate or ex-
tent of peptidyl-cysteine S-nitrosylation
neurotransmitter secretion GO:0007269 The regulated release of neurotransmitter from the presynapse into
the synaptic cleft via calcium regualated exocytosis during synaptic
transmission
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positive regulation of excitatory
postsynaptic potential
GO:2000463 Any process that enhances the establishment or increases the extent
of the excitatory postsynaptic potential (EPSP) which is a tempo-
rary increase in postsynaptic potential due to the flow of positively
charged ions into the postsynaptic cell. The flow of ions that causes
an EPSP is an excitatory postsynaptic current (EPSC) and makes it
easier for the neuron to fire an action potential
positive regulation of synapse
assembly
GO:0051965 Any process that activates, maintains or increases the frequency, rate
or extent of synapse assembly, the aggregation, arrangement and
bonding together of a set of components to form a synapse
positive regulation of synaptic
vesicle clustering
GO:2000809 Any process that activates or increases the frequency, rate or extent
of synaptic vesicle clustering
postsynaptic density protein 95
clustering
GO:0097119 The clustering process in which postsynaptic density protein 95
(PSD-95) molecules are localized to distinct domains in the cell
membrane. PSD-95 is mostly located in the post synaptic density
of neurons, and is involved in anchoring synaptic proteins
protein localization to basolat-
eral plasma membrane
GO:1903361 A process in which a protein is transported to, or maintained in, a
location within a basolateral plasma membrane
receptor localization to synapse GO:0097120 Any process in which a receptor is transported to, and/or maintained
at the synapse, the junction between a nerve fiber of one neuron and
another neuron or muscle fiber or glial cell
regulation of grooming be-
haviour
GO:2000821 Any process that modulates the frequency, rate or extent of groom-
ing behavior
regulation of sodium ion trans-
membrane transport
GO:1902305 Any process that modulates the frequency, rate or extent of sodium
ion transmembrane transport
vocalization behaviour GO:0071625 The behavior in which an organism produces sounds by a mecha-
nism involving its respiratory system
Molecular Function




GO:0005234 Enables the transmembrane transfer of an ion by a channel that
opens when extracellular glutamate has been bound by the channel
complex or one of its constituent parts
guanylate kinase activity GO:0004385 Catalysis of the reaction: ATP + GMP = ADP + GDP
ionotropic glutamate receptor
binding
GO:0035255 Interacting selectively and non-covalently with an ionotropic gluta-
mate receptor. Ionotropic glutamate receptors bind glutamate and
exert an effect through the regulation of ion channels
L27 domain binding GO:0097016 Interacting selectively and non-covalently with a L27 domain of a
protein. L27 is composed of conserved negatively charged amino
acids and a conserved aromatic amino acid. L27 domains can as-
semble proteins involved in signaling and establishment and main-
tenance of cell polarity into complexes by interacting in a het-
erodimeric manner
neurexin family protein binding GO:0042043 Interacting selectively and non-covalently with neurexins, synaptic
cell surface proteins related to latrotoxin receptor, laminin and agrin.
Neurexins act as cell recognition molecules at nerve terminals
neuroligin family protein bind-
ing
GO:0097109 Interacting selectively and non-covalently with a member of the neu-
roligin protein family, neuronal cell surface proteins that mediate
synapse formation
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NMDA glutamate receptor ac-
tivity
GO:0004972 An cation channel that opens in response to binding by extracellular
glutmate, but only if glycine is also bound and the membrane is
depolarized. Voltage gating is indirect, due to ejection of bound
magnesium from the pore at permissive voltages
PDZ domain binding GO:0030165 Interacting selectively and non-covalently with a PDZ domain of a
protein, a domain found in diverse signaling proteins
scaffold protein binding GO:0097110 Interacting selectively and non-covalently with a scaffold protein.
Scaffold proteins are crucial regulators of many key signaling path-
ways. Although not strictly defined in function, they are known to
interact and/or bind with multiple members of a signaling pathway,
tethering them into complexes
Cellular Component
basolateral plasma membrane GO:0016323 The region of the plasma membrane that includes the basal end and
sides of the cell. Often used in reference to animal polarized epithe-
lial membranes, where the basal membrane is the part attached to
the extracellular matrix, or in plant cells, where the basal membrane
is defined with respect to the zygotic axis
bicellular tight junction GO:0005923 An occluding cell-cell junction that is composed of a branching net-
work of sealing strands that completely encircles the apical end of
each cell in an epithelial sheet; the outer leaflets of the two interact-
ing plasma membranes are seen to be tightly apposed where sealing
strands are present. Each sealing strand is composed of a long row
of transmembrane adhesion proteins embedded in each of the two
interacting plasma membranes
cell junction GO:0030054 A cellular component that forms a specialized region of connection
between two or more cells or between a cell and the extracellular
matrix. At a cell junction, anchoring proteins extend through the
plasma membrane to link cytoskeletal proteins in one cell to cy-
toskeletal proteins in neighboring cells or to proteins in the extra-
cellular matrix
dendritic spine GO:0043197 A small, membranous protrusion from a dendrite that forms a post-
synaptic compartment - typically receiving input from a single
presynapse. They function as partially isolated biochemical and an
electrical compartments. Spine morphology is variable including
"thin", "stubby", "mushroom", and "branched", with a continuum
of intermediate morphologies. They typically terminate in a bulb
shape, linked to the dendritic shaft by a restriction. Spine remodel-
ing is though to be involved in synaptic plasticity
dystrophin-associated glyco-
protein complex
GO:0016010 A multiprotein complex that forms a strong mechanical link between
the cytoskeleton and extracellular matrix; typical of, but not confined
to, muscle cells. The complex is composed of transmembrane, cyto-
plasmic, and extracellular proteins, including dystrophin, sarcogly-
cans, dystroglycan, dystrobrevins, syntrophins, sarcospan, caveolin-
3, and NO synthase
exocyst GO:0000145 A protein complex peripherally associated with the plasma mem-
brane that determines where vesicles dock and fuse. At least eight
complex components are conserved between yeast and mammals
juxtaparanode region of axon GO:0044224 A region of an axon near a node of Ranvier that is between the para-
node and internode regions
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MPP7-DLG1-LIN7 complex GO:0097025 A heterotrimeric protein complex formed by the association of
MMP7, DLG1 and either LIN7A or LIN7C; regulates the stability
and localization of DLG1 to cell junctions
myelin sheath abaxonal region GO:0035748 The region of the myelin sheath furthest from the axon
neuron projection GO:0043005 A prolongation or process extending from a nerve cell, e.g. an axon
or dendrite
NMDA selective glutamate re-
ceptor complex
GO:0017146 An assembly of four or five subunits which form a structure with an
extracellular N-terminus and a large loop that together form the lig-
and binding domain. The C-terminus is intracellular. The ionotropic
glutamate receptor complex itself acts as a ligand gated ion chan-
nel; on binding glutamate, charged ions pass through a channel in
the center of the receptor complex. NMDA receptors are composed
of assemblies of NR1 subunits (Figure 3) and NR2 subunits, which
can be one of four separate gene products (NR2A-D). Expression
of both subunits are required to form functional channels. The glu-
tamate binding domain is formed at the junction of NR1 and NR2
subunits. NMDA receptors are permeable to calcium ions as well
as being permeable to other ions. Thus NMDA receptor activation
leads to a calcium influx into the post-synaptic cells, a signal thought
to be crucial for the induction of NMDA-receptor dependent LTP
and LTD
postsynaptic density of dendrite GO:0014069 An electron dense network of proteins within and adjacent to the
postsynaptic membrane of the dendrite of asymetric synapses. Its
major components include neurotransmitter receptors and the pro-
teins that spatially and functionally organize them such as anchor-
ing and scaffolding molecules, signaling enzymes and cytoskeletal
components
postsynaptic membrane GO:0045211 A specialized area of membrane facing the presynaptic membrane
on the tip of the nerve ending and separated from it by a minute cleft
(the synaptic cleft). Neurotransmitters cross the synaptic cleft and
transmit the signal to the postsynaptic membrane
presynaptic membrane GO:0042734 A specialized area of membrane of the axon terminal that faces the
plasma membrane of the neuron or muscle fiber with which the axon
terminal establishes a synaptic junction; many synaptic junctions ex-
hibit structural presynaptic characteristics, such as conical, electron-
dense internal protrusions, that distinguish it from the remainder of
the axon plasma membrane
presynapse GO:0098793 The part of a synapse that is part of the presynaptic cell
sarcolemma GO:0042383 The outer membrane of a muscle cell, consisting of the plasma mem-
brane, a covering basement membrane (about 100 nm thick and
sometimes common to more than one fiber), and the associated loose
network of collagen fibers.
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synapse GO:0045202 The junction between a nerve fiber of one neuron and another neu-
ron, muscle fiber or glial cell. As the nerve fiber approaches the
synapse it enlarges into a specialized structure, the presynaptic nerve
ending, which contains mitochondria and synaptic vesicles. At the
tip of the nerve ending is the presynaptic membrane; facing it, and
separated from it by a minute cleft (the synaptic cleft) is a special-
ized area of membrane on the receiving cell, known as the post-
synaptic membrane. In response to the arrival of nerve impulses,
the presynaptic nerve ending secretes molecules of neurotransmit-
ters into the synaptic cleft. These diffuse across the cleft and trans-
mit the signal to the postsynaptic membrane
T-tubule GO:0030315 Invagination of the plasma membrane of a muscle cell that extends
inward from the cell surface around each myofibril. The ends of
T-tubules make contact with the sarcoplasmic reticulum membrane
voltage-gated potassium chan-
nel complex
GO:0008076 A protein complex that forms a transmembrane channel through
which potassium ions may cross a cell membrane in response to
changes in membrane potential
Z disc GO:0030018 Platelike region of a muscle sarcomere to which the plus ends of
actin filaments are attached
184 Appendix F. Enriched Gene Ontology terms in the top three PD enriched clusters
Table F.2: GO terms enriched in at least two communities in Cluster 2 (alphabetical
order of GO terms); significance p-value threshold was set to 0.05. The gene sets
of interest were enriched compared to all genes expressed in the synapse. Results
were obtained using the Fisher exact test, elim algorithm and Benjamini and Yekutieli
multiple testing correction. Exact p-values available upon request since different in
distinct enriched clusters).




GO:0006958 Any process involved in the activation of any of the steps of the
classical pathway of the complement cascade which allows for the
direct killing of microbes, the disposal of immune complexes, and




GO:0034987 Interacting selectively and non-covalently with one or more specific
sites on an immunoglobulin receptor molecule
serine-type endopeptidase ac-
tivity
GO:0004252 Catalysis of the hydrolysis of internal, alpha-peptide bonds in a
polypeptide chain by a catalytic mechanism that involves a catalytic
triad consisting of a serine nucleophile that is activated by a proton
relay involving an acidic residue (e.g. aspartate or glutamate) and a
basic residue (usually histidine)
Cellular Component
blood microparticle GO:0072562 A phospholipid microvesicle that is derived from any of several cell
types, such as platelets, blood cells, endothelial cells, or others, and
contains membrane receptors as well as other proteins characteristic
of the parental cell. Microparticles are heterogeneous in size, and
are characterized as microvesicles free of nucleic acids
external side of plasma mem-
brane
GO:0009897 The leaflet of the plasma membrane that faces away from the cyto-
plasm and any proteins embedded or anchored in it or attached to its
surface
fibrinogen complex GO:0005577 A highly soluble, elongated protein complex found in blood plasma
and involved in clot formation. It is converted into fibrin monomer
by the action of thrombin. In the mouse, fibrinogen is a hexamer,
46 nm long and 9 nm maximal diameter, containing two sets of non-




GO:0042571 An immunoglobulin complex that is secreted into extracellular space
and found in mucosal areas or other tissues or circulating in the
blood or lymph. In its canonical form, a circulating immunoglobulin
complex is composed of two identical heavy chains and two identi-
cal light chains, held together by disulfide bonds. Some forms of are
polymers of the basic structure and contain additional components
such as J-chain and the secretory component
platelet alpha granule lumen GO:0031093 The volume enclosed by the membrane of the platelet alpha granule
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Table F.3: GO terms enriched in at least two communities in Cluster 3 (alphabetical
order of GO terms); significance p-value threshold was set to 0.05. The gene sets
of interest were enriched compared to all genes expressed in the synapse. Results
were obtained using the Fisher exact test, elim algorithm and Benjamini and Yekutieli
multiple testing correction. Exact p-values available upon request since different in
distinct enriched clusters).




GO:0007528 A process that is carried out at the cellular level which results in





GO:0008331 Enables the transmembrane transfer of a calcium ion by a high
voltage-gated channel. A high voltage-gated channel is a channel
whose open state is dependent on high voltage across the membrane




GO:1990454 A type of voltage-dependent calcium channel responsible for
excitation-contraction coupling of skeletal, smooth, and cardiac
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Abstract: 
Polymerisation of clathrin is a key process that underlies clathrin-mediated endocytosis. Clathrin-coated 
vesicles are responsible for cell internalization of external substances required for normal homeostasis and 
life –sustaining activity. There are several hypotheses describing formation of closed clathrin structures. 
According to one of the proposed mechanisms cage formation may start from a flat lattice buildup on the 
cellular membrane, which is later transformed into a curved structure. Creation of the curved surface 
requires rearrangement of the lattice, induced by additional molecular mechanisms. Different potential 
mechanisms require a modeling framework that can be easily modified to compare between them.  
We created an extendable rule-based model that describes polymerisation of clathrin molecules and various 
scenarios of cage formation. Using Global Sensitivity Analysis (GSA) we obtained parameter sets describing 
clathrin pentagon closure and the emergence/production and closure of large-size clathrin cages/vesicles. 
We were able to demonstrate that the model can reproduce budding of the clathrin cage from an initial flat 
array. 
Introduction 
Clathrin is the major protein component of clathrin–mediated endocytosis (CME)1,2. Due to its particular 
shape and (auto-) polymerization capacity, clathrin is believed to induce the cell membrane to adopt a 
vesicular shape. A range of different mechanisms have been proposed for this process3–5, from a few 
minimalistic ones propose that clathrin polymerization alone is sufficient to generate buds in a planar  
membrane6 to the consensus that describe the orchestrated action of additional proteins and signaling 
cascades on the intracellular side of the membrane, so that ~30 proteins directly participate in the various 
steps of endocytosis1,7–9.  
 
The structural properties of clathrin have been extensively investigated with respect to their role in vesicle 
formation. Usually a clathrin molecule is composed of one heavy (~190 kDa) as well as one light chain (~25 
kD) and is about 475 Ångström (Å) in length10. Within the cell clathrin exists in a form of trimers (triskelia), 
consisting of three clathrin molecules (three heavy and three light chains respectively), where individual 
clathrin monomers are referred to as “legs”. Deviating from the normal 1:1 ratio between light and heavy 
 
 
chain several studies have also revealed the existence of triskelia with fewer light chains. Triskelia formation 
itself does not seem to be influenced by a loss of light chain molecules11, but regulatory control of vesicle 
formation and cargo selection have been proposed. 
 
Due to its internal trimeric structure every single clathrin molecule in the triskelia complex can polymerize 
with another clathrin molecule from a different clathrin triskelia. Hence every triskelia is able to undergo 
interactions with three further triskelia. This leads to the formation of dimers and trimers, which can grow to 
construct large polymers. However, in a normal biological context, hexagonal and pentagonal shapes are 
among the most frequently observed12,13. Specific combinations of these shapes induce the formation of the 
typical vesicle closed spherical structure. Normally, closed structures contain 12 pentagonal faces and (N-
20)/2 hexagonal faces. The fixed relative numbers between pentagonal and hexagonal faces are based on 
geometric constraints, given the clathrin structure and minimal flexibility of the trimer legs. Based on the 
number (N) of triskelia different sphere sizes can emerge, three of which are well defined: The mini-coat, 
hexagonal-barrel and soccer ball13. 
 
Since its discovery in 197514, significant attention has been focused on the mechanism of clathrin 
polymerisation.  It was highlighted in1 that understanding CME is not possible without proper knowledge of 
its key process, the clathrin cage formation. Although it was experimentally shown that clathrin self-
assembles following pH decrease from 8 to 6.515 or under bivalent cation administration16, to obtain 
biologically realistic vesicle shapes the participation of external regulatory proteins is likely critical1.  
 
A range of computational models for clathrin self-assembly exists that describes the formation of clathrin 
cages12,13,17–19, or pits and vesicles13,15,20. Early models considered the association of 3-valent polymers with 
equi-reactive binding sites from the Flori’s theory point of view with20 or without21 allowance for 
intramolecular loop formation. These studies dissected the dependence of the solution/gel phase transition 
linked to the critical concentration of the monomer on the equilibrium constants of different steps of the 
polymerisation process. In the early theoretical models of multivalent condensation, the term “gel” was used 
to describe the situation when the majority of agents participate in one global complex. There are two phases 
in such system: a solution consisting of many small complexes and monomers, and a gel, composed of one 
global complex and a few free monomers. The formation of the global complex is a key phase transition in 
the systems dynamics. Prior to gel formation, the dynamics of the system are driven by bi-molecular 
reactions (when two complexes form a bigger one, or a monomer attaches to the complex). After gel 
formation, the dynamics are driven by uni-molecular reactions within the complex. The key finding of Falk 
and Thomas20  is that before the transition to the gel phase, uni-molecular reactions are negligible. 
 
In particular, it was shown by Pastan and Willingham15, that the critical concentration of clathrin, sufficient for 
the phase transition was 30 mg/ml. Taking into account that the triskelia molecular mass is about 640kDa, 
this value corresponds to the molar concentration of 46µM, or approximately 55000 triskelia per eukaryotic 
cell.  
 
More recent studies examined the assembly of 5- and 6- member rings in parallel with investigation of how 
different physical triskelia characteristics might impact on cage formation. These characteristics include 
 
 
triskelia rigidity21, their asymmetry17, emergent tension during cage closure22 and the effects of superficial 
membrane tension23. These studies provide approximations of binding energy between the chains of the 
neighbouring clathin triskelia17.  
 
The polymerisation process alone presents a significant challenge for mechanistic modeling, as the number 
of molecular species, which have to be described, grows exponentially with the number of available 
monomers. Rule-based modeling24–26 provides a viable solution allowing a network–free simulation 
technique27–29. It uses ‘lumped’ reaction rules to concisely represent molecule interactions. One can assume 
the rules as implicit combinations of different reactions into classes, where all the members of the same 
class perform a common transformation. This modeling approach is generally exploited for large-scale 
biochemical systems to overcome combinatorial complexity and it has previously demonstrated its 
effectiveness in simulations of ligand-receptor complex polymerization25. 
  
Here we present a suite of rule-based models of clathrin polymerisation with increasing complexity, starting 
from a very basic model where the molecule has three equally reactive binding sites to a more advanced 
model reproducing realistic triskelia clathrin structure. We examined the correspondence of each model’s 
behavior with the existing theoretical models while sampling from a wide range of parameter values. 
 
We found that although the basic model exactly reproduces Flory’s findings, it is unable to provide the 
amounts of 5- and 6- member rings required for cage formation and, therefore, it fails to reproduce clathrin 
vesicle formation. A revised model with a more realistic clathrin structure that explicitly supports predominant 
closure of pentagons and hexagons allows 3D cage formation and permits the evolution of flat 2D clathrin 
patches into a 3D cage structures by shifting the ratio of the pentagon/hexagon dissociation constants. 
 
Methods 
Models and simulation 
We used the Kappa language30, a member of the family of rule-based modeling languages, for building the 
models. All models were simulated by KaSim3.5 (http://dev.executableknowledge.org/). We used Kappa 
extensions where appropriate, e.g the MetaKappa (https://github.com/kappamodeler/metakappa) extension 
for building the first model to handle the combinatorial explosion caused by three equal binding sites (see 
Appendix for details). Also, we use the RKappa extension31 for sampling the large parameter space, 
statistical analysis of simulation results, global sensitivity analysis (GSA) and visualization of the Kappa 
molecular structures as more comprehensible 2D and 3D graphs. 
We first investigated the capability of rule-based models to reproduce clathrin cage structures based on 
random self-assembly processes. For this we assume that clathrin triskelia interact in 3D, in a well-mixed 
solution and all binding sites of the clathrin triskelia are assumed to be identical. Due to the combinatorial 
nature of the clathrin molecule association, the size of aggregates is unbounded and limited only by the 
amount of available substrate. 
We started with a reduced model of triskelia monomers similar to Perelson and Goldstein’s equilibrium and 
continuous model21, in which monomers carry three identical equally reactive binding sites. Two variants of 
this model were implemented in the rule-based Kappa language to investigate the polymerization of 
 
 
branched complexes from a single class of trivalent agents under ‘rings allowed’ and ‘rings forbidden’ 
conditions similar to that proposed by20 (Model 1). 
We then developed a more elaborate model, based on clathrin monomers, that considers triskelia as a 
predefined complex of three monomers. This model more accurately reproduces the structure of clathrin with 
distinct legs and binding sites along with specified defined steric and chirality constraints (Model 2). It also 
contains explicit rules describing formation of penta- and hexagonal rings and demonstrates the dynamics of 
closed cage structure formation. All the models presented here are kinetic and do not include notions of 
space. However these could be added by use of existing extensions like SpatialKappa26 or Geometric 
Kappa32 if required later.  
1.Equireactive trivalent agent model 
In the first model (Model 1) we simplify the realistic triskelia structure of clathrin to the trivalent agent Cl3 with 
three identical binding sites. This is effectively a kinetic version of the model described by Perelson and 
Goldstein in 198516,21 (Figure 1A, Supplementary Data). As clathrin is known to aggregate on the membrane, 
we assume that with complex growth its ability to diffuse would decrease. Thus, in our configuration complex 
growth happens preferentially via addition of new monomers rather than merging of existing complexes, in 
the same way as in Perelson and Goldstein. 
The (kappa) rule looks as follows: 
 
'proximal binding' a(A,A,A),a(A) -> a(A!1,A,A),a(A!1) #@ 'pbk' (0),           
where ‘pbk’ is the rate of binding. 
 
To ensure stability of the rings in clathrin complexes we make an assumption that molecules with three 
occupied binding sites cannot dissociate. Thus, dissociation is only possible at the periphery of the complex 
when at least one binding site is/remains free. 
 
'proximal dissociation' a(A!1,A),a(A!1) -> a(A,A),a(A) #@ 'pdk',                
where ‘pdk’ is the rate of dissociation. 
 
This rule partially contradicts the work of Perelson and Goldstein, where the dissociation is possible only at 
the monomer level. However, the rule includes the dissociation of terminal monomers as a special case. 
We studied the random polymerisation of trivalent monomers under two traditional Flory- Stockmayer 
assumptions: ‘ring forbidden’ (Model 1A) and ‘rings allowed (Model 1B).  
In the case of Model 1A (‘rings forbidden’), the intramolecular bonds between the binding sites of the same 
polymers are not allowed as the only free agent (with all three sites non-occupied) can bind the polymer. The 
detailed models for the original Perelson’s model and its two Kappa implementations: Model 1A and Model 
1B are presented in Supplementary Data. 
In the case of Model 1B (‘ring allowed’) intra-molecular reactions are allowed, so that rings of different sizes 
may occur. As in20,21,33 reactions occur with an equal probability for each of the free binding site to react until 
the reaction extent Rext = 1, which means that all binding sites are fully occupied. Although cubical structures 
of clathrin were observed experimentally under special conditions34, the formation of rings of size 4 and less 
 
 
is not reported under conditions approximating intracellular environments. Hence we set a specific constraint 
on the polymer chain ability to make intramolecular bonds only when ring size (nring) exceeds 5 bonds in 
length. 
 
'ring closure' a(A),a(A) -> a(A!1),a(A!1) #@ 'pring' (0.0:'nring')                 
 
In the rule above ‘pring’ is a rate of ring closure, while ‘nring’ refers to the minimal number of bonds in the 
ring (set to 5 in this case). The constraints enforce limitations on the condition of equal reactivity to be always 
fulfilled; yet the probability to close a short ring within a large complex is quite small. We also assume the 
equilibrium constants for initiation, elongation and branching are equal. 
2.Triskelia model 
To generate a more realistic model we next considered clathrin monomers and their structural properties. 
Each monomer consists of a proximal region (“P”, light green in Figure 1B), which contains a binding domain 
on its “right”, long part (“r”) and “left”, short part (“l”), and the distal region (“d”, dark green in Figure 1B). 
Domains in the proximal region facilitate the internal binding of monomers to form trimers. The additional 
binding sites “Pp” and “Pd” in the proximal region allow binding amongst different triskelia. Binding rules 
presume the ‘right’ part of one monomer can only bind to the “left” part of another, and so forth to make 
correct triskelia structures (Figure 1C). 
In kappa language this is expressed in the following way: 
 
Cl(l!1,r!2),Cl(r!1,l!3),Cl(r!3,l!2)                                                                      
 
“Cl” refers to a single clathrin molecule with proximal right (“r”) and left (“l”) binding site. All distal parts of the 
long legs are oriented in one direction, showing a clockwise drift/turn (Figure 1C). 
 
Once assembled, triskelia form the structural unit for the polymerisation process, which is governed by the 
interaction of domains localised on the right, long leg of each monomer. These are: a proximal (Pp), a distal 
“receiving” (Pd) and distal “giving” (d) domain. Based on the given clathrin triskelia structure, formation of 
one bond utilizes four triskelia simultaneously: two monomers bind with their proximal parts, and two form 
additional bonds with their distal parts (see Supplementary Data for triskelia binding code and a 
visualization). As was shown by den Otter et al.17 and Fotin et al.35, the proper orientation of all four legs is 
vital for formation of closed structures. Initial polymerization steps along with the model rules are presented 
in detail in Supplementary Data. 
In addition to the binding rule, a few specific rules enforce the closure/formation of pentagons and hexagons. 
Dissociation is implemented as follows. Closed rings cannot be reopened. At least one monomer needs to 
be unbound for dissociation to happen. Details can be seen in the model code in the Supplementary Data, 
which shows the rules used in the current model version. 
Data Availability 





We investigated the ability of rule-based models to reproduce the clathrin cage structures based on a 
random self-assembly process. Specifically, two traditional Flory- Stockmayer conditions: “rings forbidden” 
and “rings allowed“ were applied separately, similar to20. All models were simulated 5000 times with 
parameter ranges shown in Table 1. 
1.Trivalent model. 
In the first model we used a simplified triskelia structure of clathrin with a trivalent agent Cl3 containing three 
identical binding sites with equal reactivity, similar to the Perelson and Goldstain model in 198521. 
 
The key parameters that have been analyzed are (see also21): 
 
                                           
       (1) 
         
   (2) 
 
 
where Rext - reaction extent,  - nondimensional equilubrium constant,  Nbond - the number of bonds in the 
polymer, and K – the equilibrium constant. Ct and Nt describe the total concentration and total number of 
monomers (respectively), amount – amount of available triskelia. 
 
We showed that in the “ring forbidden” setup, the distribution of free clathrin with dependence on Rext exactly 
followed the prediction of Perelson’s theory (Fig 2 A and B). The vast majority of parameter sets in "ring 
forbidden" are grouped around Rext = 0.5, and the dependency between Rext and Nbond/Nt is linear. We found 
that Rext never exceeded the theoretical limit of gel formation (Figure 2B) while in most of the “ring allowed” 
instances, reactions stopped only when the available binding sites were saturated (Figure 2 B and D).  
 
To explore the types of complexes our simulations produced, we calculated the size of the largest aggregate 
( ) and the number of the rings in the system. The latter was estimated as the cyclomatic number of the 
clathrin graph, which is the number of bonds that need to be removed to form an acyclic graph: 
 
                                                                       (3) 
 
with Eg number of edges and Vg number of nodes in the graph. Cg is the number of connected components 
in the graph. We found that the number of rings in the system ( ) almost always reached the theoretical 
 
 
limit (Fig 2D), where the total number of monomers was equal to the size of the largest aggregate ( ) in 
agreement with analysis from Falk et al.20 
 
In agreement with20, when intramolecular bonds are allowed (Model 1b) ring formation only starts after gel 
structure formation (Fig 2D), when the reaction extent reaches the 0.5 threshold. This means that in the 
simple agent model closed cages would be formed only when 7/8 of the available clathrins form a large 
single complex. 
 
Further analysis (Supplementary Data) shows that probability of the ring closure grows with the size of the 
ring. Therefore, the number of short rings (pentagons and hexagons) is quite low even when we set the rate 
of the ring closure reactions to infinity (Supplementary Data and Figure 3). Therefore we conclude that the 
simple model is not able to describe the closed cage structures, as the clathrin geometry provides the 
optimal mutual disposition of the monomers only when 5- and 6-membered rings are formed. To resolve this 
we developed a more plausible model as follows. 
2.Triskelia model. 
Model 2 described above corresponds to a more realistic structure of clathrin with distinct regions within the 
monomer and respective binding sites that reflect the experimental literature10,12. We also introduced a 
specific rule for orientation of the monomers to ensure that the “right” site of one monomer binds the “left” 
side of another. This preserves the correct geometry of triskelia and chirality of the monomers. To ensure we 
obtain realistic clathrin complexes, 5- and 6- ring closure reactions were explicitly specified. 
 
We started with parameter sampling for the model. To ensure comparability between simulations we used 
the same parameter sets as before by assigning the ring closure rate the value of “pring” to both hexagons 
and pentagons. Again, the two cases  - “ring forbidden” and “ring allowed” were investigated.  
 
The behavior of the “ring forbidden” version of Model 2 is clearly similar to the behavior of the Model 1 and 
theoretical predictions of Perelson (Figure 4A). The number of free triskelia monotonically decreases towards 
zero at Rext = 0.6. The difference between the theoretical prediction of 0.5 and the observed value is 
explained by the association rule in the Model 2, which does not prevent associations of clusters and 
therefore does not follow the monomer attachment mechanisms considered in Perelson21. Association 
between clusters results in a higher numbers of triskelia with all their legs involved in the complex formation, 
which in turn prevents their dissociation.  
 
The “ring allowed” version of the Model 2 (Figure 4B) follows the same scenario as Model 1 (Figure 2D) and 
behaves as predicted by theory20. Ring formation starts only after solution to gel transition at Rext = 0.6. 
Contrary to the Model 1, the number of rings does not grow linearly with the size of the complex (Figure 2C). 
Instead, due to the system not being allowed to form rings of arbitrary size, we obtain many small complexes 




For simplicity of simulation and comparison with Model 1 we did not introduce separate kinetic constants for 
5- and 6-ring closure. As a result, the vast majority of the rings in our simulations are pentagons. 
Nevertheless we observed a number of hexagons as well. The relatively high number of octagons observed 
is a consequence of high number of 5-rings, as hull of two adjacent pentagons can form an octagon (Figure 
5С). 
 
To explore the geometry of complexes, which contain 5- and 6-rings we used a set of all possible 
combinations of pentagons and hexagons as described in22. Table 2 shows that pentagons tend to form 
adjacent dodecahedron-like structures (see g551, Figure 5A, Supplementary Figure 5), while hexagons are 
most often surrounded by pentagons as visualized in structure g661 (Figure 5B). We found no clear 
distinction between ring forming and ring preventing values in parameter sets (Supplementary Figure 3). To 
further investigate which parameters influence the ring formation the most we performed GSA on Model 2 
with the “ring allowed” condition (Supplementary Table 1). We thus concluded that Model 2 is able to 
produce various structures of different shapes (Figure 5) without the initial constraints, but that they do not all 
necessarily end up being cage-like structures.  
 
The type of clathrin cage formed in vivo is known to depend on the ratio of pentagons and hexagons3,22. 
Moreover, planar clathrin consists of just hexagons. As an example we tested to see whether our model 
could be reconciled wit the invagination mechanism (e.g. described in Avinoam et. al.5). Avinoam’s (2015) 
mechanism requires the presence of pentagons. To reproduce this we tuned the rate constants for pentagon 
and hexagon closure and changed the equilibrium of association and dissociation rates for them. First we 
simulated the model where only 6-rings were allowed by setting the 5-ring closure reaction to 0 to form a 
planar structure (Figure 6A and Supplementary movie 1). When the reaction extent was close to 1, 5-ring 
closure was allowed by adjusting rate constant to non-zero value. With a rate of closure for 5- and 6-ring 
close to each other we observed invaginations, but they never reached the scissing stage so that the 
completely closed structure never occurred (Supplementary movie 2). At this point we set the rate of closure 
for 5-rings to infinite and after 104 events we obtained the structures shown in Figure 6B and Supplementary 
Movie 3. 
To evaluate the influence of rates of pentagon and hexagon closure/disruption we performed GSA on the 
model starting with a flat hexagonal mesh (Supplementary Table 2). Here, b and d are the coefficients 
defining the extent to which pentagon closure is faster than hexagon closure (b), and hexagon compared to 
pentagon dissociation (d); rng5 and rng6 are the ratios of ring closure to ring disruption for pentagons and 
hexagons, respectively. For each parameter the significance level is calculated as described in36. The rate of 
the pentagon closure did not significantly influence any property of the system, while the rate of hexagon 
dissociation appeared important for the size of the most frequent complex (wNmax) and the presence of 
hexagon-containing subgraphs (g501, g511, g521, g522, g601, g611, g621, g622, g631, g632, g633, g641, 
g642, g643 in Supplementary Tables 1 and 2)22. During the course of a simulation we were able to obtain 
different numbers of closed cages in almost half of the parameter sets, which indicates that the formation of 





Computational models describing formation of clathrin-coated vesicles (CCVs)2,17,23,37 mostly focus on 
clathrin self-association or its association with the membrane. However, vesicle recycling is regulated via a 
large number of signalling processes2,38. Existing computational models struggle to incorporate these 
regulatory elements either because of high computational cost, which becomes prohibitive in case of 
incorporation of all involved protein types, or because the structure/type of the model can/does not include 
the reactions controlled by regulatory systems. For example, the equilibrium model21 considered growth of 
pits as a linear set of reactions, assuming that all three legs of the new triskelia in the pit assemble using the 
best possible free sites in the net. As shown by simulations in17 and confirmed in our Models 1A and B this is 
not the case. 
As was proposed in39, these signaling processes can be incorporated into models as a modification of 
clathrin association/dissociation rates. With these factors in mind we have developed a model capable of 
describing the formation of CCVs, avoiding the more resource expensive computational algorithms and using 
a modeling format familiar to the signal transduction modelling community. 
 
Our first version of the model, which described clathrin as a trivalent agent demonstrated that formation of 
closed structures required an additional manual closure to achieve 5- and 6- rings. With the flexibility of the 
clathrin molecule and no evidence for energy differences between penta- and hexameric rings we saw no 
preferences towards either specific ring composition. Weak interactions, which have been proposed to have 
a major effect on the association of clathrin legs39, and comparatively low bending energy of the clathrin 
lattice suggest that when on the flat part of the membrane, clathrin will create a flat hexagonal lattice. That 
process was considered in3, where clathrin was modeled as hexagonal lattice with 5- and 7-sided rings 
occurring as defects, but the study only considered the equilibrium state, whereas in our analysis we were 
able to investigate the kinetics of the process. Although the “canonic” mechanism of clathrin pits formation 
proposes constant curvature growth as a function of clathrin polymerization40, the evolution of curved clathrin 
structures from flat plaque has also some supporting experimental evidence 5,38. The recent study of Leyton-
Puig et al.7 reports the ability of clathrin plaques to act as hubs for CME and proposes actin polymerisation 
and actin-based adhesion are major regulating factors for their remodeling7. 
Our model shows that switching pentagon ring formation on/off allows the process to switch between planar 
patches and closed cages. In vivo, this switching could be driven by changes in physical properties of the 
membrane or by additional regulatory mechanisms1,37,41. 
 
In our model we assume the size and the shape of the clathrin lattice to be controlled by three processes: i) 
the association/dissociation of triskelia; ii) the 5-ring formation/dissociation and iii) the 6-ring 
formation/dissociation. Several other factors are known to influence the cage and coat formation and 
dissociation42,43. For example in44, the main difference in pentagon and hexagon closure is attributed to the 
stiffness of the underlying membrane, while in41 the rigidity variation of the clathrin net itself is explained by 
binding to an adaptor protein (AP2, AP3, AP180)8,45. Their influence on clathrin coat formation has been 
studied in distinct experimental setups and binding to clathrin has been confirmed. Due to their influence on 
clathrin triskelia structure and hence their ability to influence coat formation it might be debatable if their main 
 
 
role is in maintaining a flat structure or “forcing”/inducing the formation of vesicles. This mechanism could be 
easily embedded into the model (see the example in Supplementary Data).  
 
The clathrin light chain is an additional part of the triskelia, which connects to the heavy chain in the region 
extending from the self-association domain to the knee39. One of the possible conformations can force the 
knee to bend in a direction that inhibits cage formation. This inhibitory effect is thought to be regulated 
(inhibited) by interaction with Ca ions or by lowering the pH39. The light chain also influences the rigidity of 
the clathrin lattice and its ability to bend the lipid membrane at low temperature4. The light chain contains 19 
serines that are potential kinase targets (GRK2) and phosphorylation of the light chain has been proposed as 
a discriminator for different cargo inclusion in the vesicle46. An example of how the model can be extended to 
incorporate the above mechanism is presented in Supplementary Data. 
 
The rule-based approach we have used allows us to build and compare kinetic models that describe different 
possible mechanisms of clathrin cage formation, from direct assembly from monomers at the vesicle budding 
site to the invagination of flat membrane plaque. More in depth functional details such as the role of N-WASP 
through Arp2/37 can help to expand models and gain deeper insights. Hence, our implementation is easily 
extendable allowing the future inclusion of more detailed mechanistic models of CME regulation. 
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Figure 1. Structure of agents for Model 1  and Model 2. Three identical binding sites in a simple agent (A) 
interact with each other to form a lattice  (Model1). Monomer (B) of detailed Model 2 has two sites to form 
the triskelia hub (l,r) and three sites to interact with other triskelia (d, Pd,Pp)(C). 
Figure 2. Simulation (5000 parameter sets) of the trivalent model with “ring forbidden” (A) and “ring 
allowed” (C, D) assumptions. A. The number of free agents Nfree decreases with Rext and trends to 0 at 
Rext = 0.5 B. The relationship of alfa and Rext under different experimental conditions: “no ring”, “ring” and 
“infinite ring” С. The dependency between the size of the largest aggregate and cyclomatic number under 
“ring allowed” condition D. Relationship between reaction extent and loop structure under “rings allowed”. 
Figure 3. Distribution of different cyclic structures obtained from 5000 simulations. A. 5-membered 
rings B. 6-membered rings C. 7-membered rings D.8-membered rings. 
Figure 4. Results of simulation of “ring forbidden” and “ring allowed” models. A. The number of free 
agents Nfree decreases with Rext towards 0 at Rext = 0.6 for “rind forbidden” model. B. The number of rings 
(cyclomatic number of the graph) per triskelia in the “ring allowed” model. 
 
Figure 5. Most populated structures obtained in 5000 simulations of the unconstrained model. A. 
Most populated pentagon structure. B. Most populated hexagon structure C. An 8-ring formed by two 
pentagons. 
Figure 6. Results of model simulation with different Kd for 5 and 6-membered rings. A. Only hexagons 
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Abstract
The desire to explain how synaptic plasticity arises from interactions between ions,
proteins and other signalling molecules has propelled the development of biophysical
models of molecular pathways in hippocampal, striatal and cerebellar synapses. The
experimental data underpinning such models is typically obtained from low-throughput,
hypothesis-driven experiments. We used high-throughput proteomic data and
bioinformatics datasets to assess the coverage of biophysical models.
To determine which molecules have been modelled, we surveyed biophysical models
of synaptic plasticity, identifying which proteins are involved in each model. We were
able to map 4.2% of previously reported synaptic proteins to entities in biophysical
models. Linking the modelled protein list to Gene Ontology terms shows that modelled
proteins are focused on functions such as calmodulin binding, cellular responses to
glucagon stimulus, G-alpha signalling and DARPP-32 events.
We cross-linked the set of modelled proteins to sets of genes associated with common
neurological diseases. We found some examples of disease-associated proteins that are
well represented in models, such as voltage-dependent calcium channel family
(CACNA1C ), dopamine D1 receptor, and glutamate ionotropic NMDA type 2A and 2B
receptors. Many other disease-associated genes have not been included in models of
synaptic plasticity, for example COMT and MAOA. To determine targets to include in
future models, we incorporated pathway enrichment results, and identified LAMTOR, a
gene uniquely associated with Schizophrenia, which is closely linked to the MAPK
pathway found in some models.
Our analysis provides a map of how molecular pathways underpinning neurological
diseases relate to synaptic biophysical models which can, in turn, be used to explore
how these molecular events might bridge scales into cellular processes and beyond. The
map illustrates disease areas where biophysical models have good coverage, as well as
domain gaps that require significant further research.
Author summary
The 100 billion neurons in the human brain are connected by a billion trillion structures
called synapses. Each synapse contains hundreds of different proteins. Some proteins
sense the activity of the neurons connected by the synapse. Depending on what they
1/36
sense, the proteins in the synapse are rearranged and new proteins are synthesised. This
changes how strongly the synapse influences its target neuron, and underlies learning
and memory. Scientists build computational models to reason about the complex
interactions between proteins. Here we list the proteins that have been included in
computational models to date. For good reasons, models do not always specify proteins
precisely, so to make the list we had to translate the names used for proteins in models
to gene names, which are used to identify proteins. We found that the list of modelled
proteins contains only 4.2% of proteins associated with synapses, suggesting more
proteins should be added to models. We used lists of genes associated with neurological
diseases to suggest proteins to include in future models.
Introduction 1
Activity-dependent synaptic plasticity is necessary for learning and memory [1]. Since 2
the discovery of long term potentiation (LTP) and long term depression (LTD) [2,3], it 3
has been shown that synaptic plasticity can depend strongly on patterns of pre-and 4
post-synaptic firing [4] and neuromodulators [5]. Forms of plasticity vary between types 5
of synapses and brain region [4], which could be explained by the local proteome, 6
i.e. the expressed proteins and their abundances. PSD-95 knock-outs demonstrate the 7
influence of the proteome on synaptic plasticity [6]. Synaptic plasticity underlies 8
behaviour, as evidenced by the effect of antagonising NMDA receptors [1], and synaptic 9
proteins underlie disease [7]. 10
Computational models of synaptic plasticity are important tools for understanding 11
synaptic and neural function. Models at a phenomenological level, such as spike-timing 12
dependent plasticity (STDP) models, link firing patterns in the pre- and postsynaptic 13
neurons to changes in synaptic strength with little or no reference to the underlying 14
molecules [8]. Biophysical models refer to at least some known molecular actors in 15
synaptic plasticity. In 2009 there were at least 117 biophysical postsynaptic signal 16
transduction models [9] and the number is growing [10,11]. When they include 17
molecular entities and phenomena they can also be used to study dysfunction, and 18
potentially model pharmacological interventions. 19
Recent advances in tissue and cell extraction techniques and sample processing allow 20
localised proteomes to be determined, e.g. the synapse including the smaller presynaptic 21
or postsynaptic proteomes [12,13]. Our recent analysis of 37 published synaptic 22
proteomic datasets (in preparation; data from July 2017 in S1 Table) contains 1,867 23
presynaptic genes, 5,053 postsynaptic genes and 5,862 synaptic genes (with human 24
EntrezID identifiers) respectively. These numbers are large compared to results from 25
individual studies. Nevertheless, data inclusion was highly restrictive and the 26
augmented numbers can be partly explained by higher experimental sensitivity and the 27
broad use of high-throughput techniques. 28
These synaptic protein lists make it possible to compare systematically proteins 29
contained in computational models of synapses with those proteins likely to be in the 30
synapse. In this paper we: (1) survey a selection of biophysical models of synaptic 31
plasticity, identifying which proteins are involved in each model, and describing the 32
complexity and detail of description of signalling pathways within the models; 33
(2) compare the proteins in models with synaptic protein lists, thus showing what 34
fraction of synaptic proteins have been considered in models; (3) identify the functional 35
classes of proteins in models; and (4) compare the proteins in models with those 36
involved in neurological diseases. Clearly the coverage of synaptic molecules found in 37
the existing ‘model space’ is going to be very incomplete given the intense amount of 38
effort required to develop each model but here we sought to explore systematically 39
molecular coverage to identify significant gaps that might offer new opportunities. 40
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Analysis of proteins in synaptic models 41
Before outlining our analysis, we first address a fundamental issue we encountered. 42
Computational models contain a diverse cast of players, including proteins, second 43
messengers, reporters, ions and others. Models vary in how precisely they specify 44
proteins; for example Bhalla and Iyengar [14] specify AC1, AC2 and AC8, whereas 45
Castellani et al. [15] and Oliveira et al. [16] specify AC, which could, in principle, map 46
to any of the adenylate cyclases expressed in the synapse. This presents a problem when 47
mapping models to molecular identifiers, which we addressed by developing a mapping 48
from what we refer to as model “entities” to gene families. For example a protein such 49
as Calmodulin 1 can be mapped onto a single gene (CALM1 ), but a family of proteins 50
such as metabotropic glutamate receptors maps onto more than one gene 51
(GRM1–GRM8 ). By definition, second messengers or ions do not map onto gene 52
symbols. 53
The concept of entities allowed each model’s constituents to be catalogued faithfully 54
and then mapped onto identifiers according to the steps shown in Fig 1: (1) select 55
models to analyse; (2) determine all entities (e.g. proteins, protein multimers or families, 56
ions and second messengers) that are contained in each model; (3) map these entities 57
onto gene identifiers and higher level families; and (4) use the lists of entities in each 58
model and the mappings to undertake comparative analyses. These analyses include: 59
comparison of modelled proteins with pre- and postsynaptic proteomic datasets; 60
identification of properties of modelled genes, in particular cellular pathways, gene 61
ontology terms and disease; and comparison of models with each other. 62
Selection of models 63
We selected 30 published computational, biophysical models of plasticity or related 64
pathways in hippocampal, striatal, cerebellar or generic synapses (Table 1). Models that 65
we regarded as phenomenological or descriptive, i.e. models describing a function with 66
no explicit reference to an underlying mechanism, were excluded. For example, models 67
of spike-timing dependent synaptic plasticity are phenomenological, since they contain 68
an empirical function that maps spike times onto changes in plasticity with no reference 69
to proteins. 70
The process of identifying the model constituents can be time-consuming, especially 71
when machine-readable descriptions are not available. In order to address our questions 72
regarding the molecular coverage of synaptic models, it sufficed to select a set of models 73
that we were reasonably confident gave good coverage of modelled proteins, rather than 74
to identify entities in all published models. We assessed molecular coverage of pre-2010 75
models from the tables in Manninen et al. [9] and we screened models published 76
between 2010 and December 31st 2015. 77
Sources of models 78
A number of the models we selected are written in standardised modelling languages 79
and hosted in large scale repositories such as ModelDB [44], BioModels [45], 80
DOQCS [46] and the CellML repository [47]. ModelDB is a curated database of 81
computational neuroscience models at the molecular and electrophysiological levels, 82
written in a number of languages. BioModels hosts models which focus on biochemical 83
and cellular systems at the physiological and biochemical levels, unrestricted by the 84
biological subject [45,48]. In the curated branch of BioModels, models have to be 85
annotated according to the Minimal Information Requested in the Annotation of 86
Biochemical Models (MIRIAM) standard [49], thus meaning that model constituents 87
are mapped to external identifiers. CellML is both a model format and a repository. 88
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List of entities in model
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Fig 1. Overview of the modelling paper analysis process. Sets of data are shown in boxes with black rectangular
borders. Processes are shown in boxes with blue backgrounds and curved corners. Final analyses are shown in boxes with
dashed borders. “ID” refers to the modelled entity. Boldface type refers to column headers.
The CellML repository hosts a wide range of biological models, which have 89
documentation pages generated from the meta-data supplied by model authors. 90
DOQCS (Database of Quantitative Cell Signalling) is a database tailored for storing 91
chemical kinetics and reaction level information [46]. The chemical-level description of 92
each model corresponds to the GENESIS/Kinetikit simulator and reflects reaction 93
diagrams or ordinary differential equation (ODE) equations. 94
Table 2 summarises the numbers of models we analysed that are stored in 95
repositories and other locations, and the format of the model descriptions. Three of the 96
7 models deposited in the BioModels database were curated to MIRIAM standards. 97
Around half of all catalogued models (14) had non-machine readable descriptions. 98
Models in this group were generally difficult to explore and extracting information from 99
them proved challenging. There were 18 machine-readable models available from 100
publication attachments, on institute or lab servers and the four public modelling 101
databases; some models were deposited in more than one database. With two 102
exceptions models were not duplicated in ModelDB and BioModels; the Bhalla and 103
Iyengar [14] model was present in all four public modelling databases, and the Nakano 104
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Table 1. Summary of models.
Paper Vars./comp. Entities Vars./comp./
Entities
Region
Antunes and De Schutter (2012) [17] 103 19 5.4 Cereb. Purk.
Antunes et al. (2016) [18] 17 Cereb. Purk.
Bhalla and Iyengar (1999) [14] 100 42 2.4 Hipp. CA1 Pyr.
Byrne et al. (2009) [19] 82 3 27.3 Hipp. CA1 Pyr.
Castellani et al. (2001) [20] 36 5 7.2 Cortex**
Castellani et al. (2005) [15] 33 13 2.5 Ex. glut. syn.**
Graupner and Brunel (2007) [21] 16 5 3.2 Hipp. CA1 Pyr.
Gutierrez-Arenas et al. (2014) [22] 188 34 5.5 Striatal MSPN, D1R expressing
Hernjak et al. (2005) [23] 9 5 1.8 Cereb. Purk.
Khan et al. (2011) [24] 12 1 12.0 Hipp. CA1 Pyr.
Kim et al. (2010) [25] 54 18 3.0 Hipp. CA1 Pyr.
Kim et al. (2011) [26] 16 17 1.0 Hipp. CA1 Pyr.
Kim et al. (2013) [27] 10 18 0.6 Striatal MSPN, mGluR1
expressing
Kötter (1994) [28] 12 striatal MSPN
Kuroda et al. (2001) [29] 20 Cereb. Purk.
Li et al. (2012) [30] 95 8 11.9 Generic excitatory spine
Mattioni and Le Novère (2013) [31] 13 9 1.4 Striatal MSPN
Miller et al. (2005) [32] 58 4 14.5 **
Nair et al. (2015) [33] 80 16 5.0 Striatal MSPN, D1R and D2R
expressing*
Nakano et al. (2010) [34] 189 28 6.8 Striatal MSPN, D1R expressing
Oliveira et al. (2010) [16] 31 9 3.4 HEK293 cells
Oliveira et al. (2012) [35] 113 28 4.0 Stratial MSPN
Pepke et al. (2010) [36] 156 3 52.0 **
Qi et al. (2010) [37] 115 13 8.8 Stratial MSPN
Smolen et al. (2006) [38] 23 9 2.6 Hipp. CA1 Pyr.
Smolen et al. (2012) [39] 14 6 2.4 Hipp. CA1 Pyr.
Sorokina et al. (2011) [40] 1, 000, 000 55 18, 181.8 Ext. glut. syn.
Stefan et al. (2008) [41] 49 3 16.3 **
Zeng and Holmes (2010) [42] 14, 296, 081 6 2, 382, 680.2 Hipp. DG
Zhabotinsky et al. (2006) [43] 58 11 5.3 Hipp. CA1 Pyr.
“Paper” refers to the analysed model. “Vars/comp.” is the number of molecular variables per compartment, a measure of the
complexity of the model; this was not assessed for all papers. “Entities” is the number of entities in the model, and
“Vars./Enties” is the ratio between the number of variables per compartment and the number of entities. This roughly
corresponds to the level of detail of the model. “Region” refers to the brain region or cell type where the model is situated (**
– no cell specified). Abbreviation: Cereb. Purk., cerebellar Purkinje cell; Ex. glut. syn., excitatory glutamatergic synapse;
Hipp. CA1 Pyr., hippocampal CA1 pyramidal cells; Hipp. DG, hippocampal dentate gyrus cell; MSPN, medium spiny
projection neuron; * – denotes that there is more than one model presented in a study and numbers in this table refer to the
one with the larger number of “Entities”.
et al. [34] model was found in ModelDB and BioModels. We did not test the 105
functionality or reproducibility of models; only the availability and relative ease of 106
exploration were examined. 107
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Table 2. Overview of locations of models and their formats.

































Fractions refer to the number of models in the category relative to the total of
annotated models. Each machine-readable model can be part of several categories. See
text for details.
Features of models 108
We extracted a number of features from each model to highlight their similarities and 109
differences (Table 1). To quantify the model size, we counted the number of entities 110
that appear in the model. We also extracted information on numbers of dynamic 111
variables per compartment (“Vars/comp.”). Variables are values describing quantities 112
that change in the model. A compartment is defined as a spatial subsection within the 113
model. Since the number of compartments varies with the fineness of the spatial mesh 114
used, the number of variables scales with the number of compartments, but the number 115
of variables per compartment will be a constant, independent of the spatial 116
discretisation used to simulate the model. To provide a measure of model complexity, 117
we used the ratio of the number of variables per compartment and the number of 118
entities (“Vars./Comp./Entities”, Table 1). 119
For example, in a model of calcium binding to a buffer in a single compartment, 120
there are two entities: calcium (an ion) and the buffer (a protein). There are three 121
variables, namely the concentrations of free calcium, free buffer and calcium-buffer 122
complex. To model diffusion of calcium, buffer and calcium-buffer complex, space could 123
be divided into 100 compartments. The number of variables would then be 300, but the 124
number of variables per compartment would be 3. There would still only be two entities 125
in this model – calcium and the buffer – and the variables per compartment per entity 126
ratio would be 1.5. 127
A high ratio of variables per compartment to entities reflects a detailed description 128
of a small pathway. For example the model of Byrne et al. [19] – whose stochastic model 129
describes binding of calcium, calmodulin (CaM) and calcium/calmodulin dependent 130
kinase II (CaMKII) – has 82 variables per compartment and 3 entities, making a ratio 131
of 27.3. The 82 variables correspond to the combinations of calcium bound to the N and 132
C lobes of calmodulin and whether or not these complexes are bound to CaMKII. 133
Dealing with this complexity in the simulation is achieved by using an agent-based 134
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Table 3. Frequency of entity types found in models.
Type Frequency Examples
Ion 2 Magnesium, Calcium
Neurotransmitter 5 Adenosine, Dopamine
Others 2 ATP and PIP2, intermediates in the IP3/DAG pathway
Protein 95 Neurogranin
Protein family 52 calmodulin, which may correspond to one of calmodulin-1, calmodulin-2 or
calmodulin-3
Protein multimer 8 AMPA receptor, which comprises a tetramer of GluR1, GluR2, GluR3 and GluR4
proteins.
Reporter 1 AKAR3
Second messenger 8 GTP (Guanosine triphosphate) or cAMP (cyclic AMP).
Total 173
Gillespie method in which the states of individual molecules rather than populations of 135
molecules are followed through the simulation [50]. Agent-based simulation also allows 136
the more extreme example of Zeng and Holmes [42], who modelled the 137
Ca2+-CaM-CaMKII pathway and the binding of Ca2+-CaM to calcineurin, which for 138
consistency with genetic nomenclature we refer to as PP3 rather than PP2B (see 139
Discussion). Along with calbindin and neurogranin, the model has 6 entities in total 140
and 14,296,081 possible states (i.e. variables), making a ratio of 2,382,680 variables per 141
compartment per entity. In this case the large number of states arises because each of 142
the 6 subunits of CaMKII can be in one of 21 states, which gives rise to 14,296,051 143
configurations according to the necklace function [51]. Notes on this and other 144
calculations are contained in the “Model classification” spreadsheet in S1 File. 145
At the other end of the spectrum, a low variable to entity ratio indicates larger 146
pathways with each interaction modelled in less detail. For example, the ODE-based 147
model of Bhalla and Iyengar [14], with 44 entities and approximately 100 variables per 148
compartment, has a ratio of 2.3 variables per compartment per entity. 149
Identifying entities in models 150
To identify the entities in each model, the publication describing the model and, if 151
available, an electronic description of the model were examined by one of the authors. 152
For each entity, we recorded the name used in the model publication and our standard 153
entity identifier. Models do not always specify the entities involved precisely. We 154
discussed ambiguous cases together and erred on the side of not imputing the identity of 155
a protein; for example a “Plasticity related protein” [39] was not mapped to an entity 156
identifier. 157
We identified 178 distinct entities across the 30 catalogued models (see S2 Table for 158
full list). As well as an identifier, each entity has a long name and a type which can be 159
one of: “ion”, “neurotransmitter”, “others”, “protein”, “protein family”, “protein 160
multimer”, “reporter” or “second messenger”. Table 3 shows how many of each type of 161
entity were identified, and gives examples. The most frequent entity type is “protein”, 162
followed by “protein family” and then “protein multimer”. 163
The rationale for having three protein types – “proteins”, “protein families” and 164
“protein multimers” – was to allow us to record as precisely as possible what was meant 165
in each computational model. A “protein” is a specific protein e.g. neurogranin, 166
encoded by a specific gene (NRGN ), so it is unambiguous as to which gene is implied by 167
the model. The same gene may produce multiple isoforms due to gene duplicates or 168
alternate splicing. For example PRKCZ produces two isoforms, atypical protein kinase 169
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C, ζ (PKCζ) and autonomously active isoform of atypical protein kinase C, 170
ζ (PKMζ) [52]. A “protein multimer” is a multiprotein complex, e.g. an 171
α-amino-3-hydroxy-5-methyl-4-isoxalone propionic acid receptor (AMPAR), which 172
comprises a tetramer of a selection of GluR1, GluR2, GluR3 and GluR4 proteins. In 173
this example, if the model only specified “AMPAR” there would be ambiguity about 174
which of the GluR1–4 subunits are implied by the model. Coding AMPAR as a 175
“protein multimer” allows this ambiguity to be recorded and resolved as desired. A 176
“protein family” is a protein from a family of proteins, e.g. calmodulin, which may 177
correspond to one of calmodulin-1, calmodulin-2 or calmodulin-3. Again, it is not clear 178
which protein is implied by the model, though later we will use information about the 179
synaptic proteome to narrow down the possibilities. 180
“Ions”, “neurotransmitters” and “second messengers” were assigned to individual 181
classes. AKAR3 is the only entity that was classified as a “reporter” [33]. The 182
FLIM-AKAR reporter was included in the model to reflect the experimental setup 183
where it is used to measure PKA dynamics. ATP and PIP2, both intermediates in the 184
IP3/DAG pathway were classified as “other”. ATP itself can produce a second 185
messenger and is often referred to as a precursor or “coenzyme”. Similarly, PIP2 is 186
frequently acting as a precursor of a second messenger [27]. 187
The full catalogue of all model entities for all models is shown as a binary matrix in 188
Fig 2. The models are ordered according to the results of Ward’s 2D hierarchical 189
clustering applied to the matrix (as implemented in R’s hclust function with the 190
Ward.2D method). This catalogue is the basis for the rest of the analysis. 191
Mapping entities to gene identifiers 192
In order to compare synaptic models with the synaptic proteome, we needed to map 193
each protein entity onto the proteins to which it might correspond. The construction of 194
this mapping is shown in Fig 3. Based on common practice in bioinformatics we decided 195
to use HUGO Gene Nomenclature Committee (HGNC) gene symbols and NCBI Entrez 196
Gene IDs to identify proteins/genes. The one-to-one mapping from HGNC gene 197
symbols to NCBI human Entrez Gene IDs [53] allowed this approach. 198
As presented in Fig 3, entities of type “protein” were mapped directly to HGNC 199
gene symbols. Entities classified as “protein family” and “protein multimer” required an 200
intermediate mapping step. We searched for ontologies that could be used to identify as 201
many of these entities as possible and map them to HGNC gene symbols. After 202
thorough analysis of available bioinformatic resources (see Methods) we decided to use 203
HGNC gene families to map entities of type “protein family” and “protein multimer” to 204
genes. For each such entity, we tried to identify a corresponding HGNC gene family, 205
and used manual NCBI mapping (see Methods) to check if the genes contained in this 206
family seemed likely to be what was meant in the models. For example, we mapped the 207
entity “Dopamine receptors” (DRD) to the HGNC family “Dopamine receptors”, which 208
contains the genes DRD1, DRD2, DRD3, DRD4 and DRD5. Since this seemed a 209
reasonable set, we accepted the mapping. 210
For some entities no one HGNC family gave a reasonable set of proteins, but the 211
intersection between two or more families did. For example the genes corresponding to 212
SHANK, by which we mean the family of proteins encoded by SHANK1, SHANK2 and 213
SHANK3, may be selected from the gene families list by choosing all genes that are in 214
the “Ankyrin repeat domain containing” (ANKRD) and “PDZ domain containing” 215
(PDZ) gene families. When we could not find a corresponding HGNC family or a 216
combination of HGNC families, we constructed our own mapping (see Methods). Since 217
“ions”, “neurotransmitters”, “others”, “reporters” and “second messengers” are not 218





















































































































































































































































































































































































































































































































































































































































































































































































































































Fig 2. Matrix of entities in models. The occurrence of an entity in a model is
indicated by open circles. Entity IDs are staggered for readability.
Once gene families corresponding to 61 ”protein families” and “protein multimers” 220
were identified we could map each family or multimer onto a set of genes (S3 Table and 221
S4 Table). 331 unique HGNC gene symbols were identified based on protein families 222
and multimers. The union of this set of symbols with the 96 genes mapped directly 223
from type “protein” forms the “full set of HGNC gene symbols in models” dataset, 224
which contains a total of 386 HGNC gene symbols. A number of “protein families” 225
mapped onto the same genes; for example the families PDE and PDE1 both contain 226
PDE1A and PDE1B. 227
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Tabs. 6, 7, 8 & 10)
Full set of HGNC 
gene symbols in 
models
Fig 3. Overview of entity to Gene Symbol mapping process. Sets of data are shown in boxes with black rectangular
borders. Mappings are shown in boxes with blue backgrounds and curved corners. Dashed lines indicate additional
information, and the key outcome is highlighted in a box with green background. Bold font refers to column headers.
Comparison with proteomic data 228
HGNC families are general gene classes and do not contain information about tissue 229
specificity or expression patterns. To identify proteins found in the synapse, we used a 230
meta-analysis of published proteomic datasets of the presynapse, postsynapse and 231
synaptosome (in preparation). The individual references, as of July 2017, can be found 232
in S1 Table. 233
The synaptosome is the largest data subset extracted from brain homogenate. The 234
term synaptosome refers to the complete presynaptic terminal including mitochondria, 235
synaptic vesicles and the postsynaptic membrane together with the postsynaptic 236
density (PSD) [54,55]. The PSD is a tightly connected, dense region of the postsynaptic 237
membrane which hosts a number of different receptors and regulatory units. The 238
presynapse and postsynapse are subsets of the synaptosome, and can be separated 239
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through experimental steps [56,57]. 240
The union of these three datasets, which we refer to as the “synaptic proteome”, 241
comprises 6,706 genes and is based on data obtained from 37 publications and 39 242
datasets (data as of July 2017). The extracted proteome was used to filter the “full set 243
of HGNC Gene symbols in models” (see Fig 3 and Identifying entities in models). We 244
found that every “protein family” (S3 Table) and “protein multimer” (S4 Table) in our 245
list contains at least one gene overlapping with the synaptic proteome. Genes not 246
expressed in the synapse (“OUT SYNAPSE” in S3 Table and S4 Table) were excluded 247
from further analysis. This filtering step reduces the 331 genes in families to 239 HGNC 248
gene symbols. Together with directly mapped proteins this leaves 294 unique HGNC 249
gene symbols describing all mapped genes in models, where families and multimers were 250
screened for the presence in the synapse. From now on we refer to this gene set as 251
“genes in models” (see green box, Fig 3). 252
The overlap between the final set of “genes in models” and the synaptic proteome, 253
as well as its subsets (presynaptic, postsynaptic, and synaptosome), is visualised in the 254
Venn diagram in Fig 4. It can be seen that 46% of “genes in models” (135 genes) are 255
found in all three synaptic proteome datasets. Significantly lower numbers are expressed 256
in individual sub-datasets. These are 3, 14 and 21 genes for the presynapse, postsynapse 257
and synaptosome respectively (representing 1.0%, 4.7% and 7.1% of genes in models). 258
When disregarding “genes in models” present in the intersection of all three datasets, 259
more modelled genes are found in the postsynapse or synaptosome (143 genes) than the 260
presynapse or synaptosome (27 genes). Thus, postsynaptic genes appear to be the most 261
highly modelled subset. However, relative to the total size of the respective proteomes, 262
only 5.1% of postsynaptic genes (258 “genes in models” out of 5,053 postsynaptic genes) 263
versus 7.6% of presynaptic genes (142 “genes in models” out of 1,867 presynaptic genes) 264
are represented in the models. 265
Nine modelled genes, all of type “protein” are not present in the synaptic proteome 266
datasets (see lower right of the circle in Fig 4). Further investigation uncovered evidence 267
for all of them being expressed in the synapse (Table 4), so these 9 genes remained in 268
the set of “genes in models”. These cases illustrate that, despite the number of proteins 269
found in recent publications, proteomic datasets are still incomplete. 270
Table 4. Proteins in models and not to be found in synaptic datasets.
Entity ID Gene Reason for inclusion
ADORA2A ADORA2A Adenosine A2a receptors (A2aR) are expressed with D2R receptors
[33]
CALM2 CALM2 Unpublished dataset
CHRM4 CHRM4 Muscarinic cholinergic receptor shown to be expressed in go-
nadotropin releasing hormone neurons [58]
CRH CRH Corticotropin-releasing factor, regulating the release of adrenocorti-
cotropin in synapses [59]
DRD1 DRD1 D1 subtype of the G-protein coupled dopamine receptor – the
most abundant in the central nervous system; presence in neurons
confirmed [60]
DRD2 DRD2 D2 subtype of the G-protein coupled dopamine receptor; prescence
in neurons confirmed [60]
DUSP1 DUSP1 Model specifies that DUSP1 feedback loop occurs in the dendritic
shaft, the soma and the nucleus [22]
I-1 PPP1R1A Unpublished dataset
PPP2R3A PPP2R3A Preliminary studies suggest PPP2R3A is present in both cytoplasm
and nucleus of cells in the striatum [61]. PPP2R3A mediates Ca2-





















Fig 4. Relationships between the sets of genes in postsynaptic, presynaptic,
synaptosome datasets and the sets of genes possibly present in models.
Postsynaptic genes in red, presynaptic in blue, the synaptosome in purple and genes in
models in green. Numbers refer to the number of genes in each subset and shading
shows how many sets a region belongs to (white – none; red – all four). It can be seen
that the number of genes in the proteome but not included in models is an order of
magnitude bigger than the number of proteins included in models and the proteomic
datasets. There are only 9 genes (listed in Table 4) found in models and none of the
proteomic datasets.
Enrichment analysis of modelled genes 271
After compiling the “genes in models” list, we related it to existing biological knowledge, 272
in the form of gene sets annotated with various biological categories, supplied through a 273
number of databases. Depending on each database’s focus, structured, controlled, and 274
descriptive terms are associated to each gene. In this study, we chose to use the 275
following ontologies: Gene Ontology (GO) [62], REACTOME Pathway 276
Database (REACTOME) [63] and Disease Ontology (DO) [64]. Amongst these GO is 277
the largest and most commonly used ontology, classifying genes within domains 278
including Molecular Function, Biological Process and Cellular Compartment. We also 279
used REACTOME, a free and manually curated database in which genes are tagged 280
with terms representing biochemical reactions and pathways they are involved in. A 281
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pathway is composed of one or more reactions or reaction-like events, such as binding, 282
complex formation, transport or polymerisation. 283
To relate “genes in models” to their associated diseases, we used the DO to provide 284
disease classifications. Multiple sources contain gene disease information. We used 285
annotations retrieved from the GeneRif [65], OMIM [66,67] and Ensemble Variation [68] 286
databases. Based on annotations in the different ontologies we aimed to identify 287
functionalities shared by the “genes in models”. The topONTO package implemented in 288
R [69] was used to undertake enrichment analysis (see Methods). 289
The results are summarised using word clouds to show significantly enriched terms, 290
based on GO annotations, describing Molecular Functions (Fig 5A) and Biological 291
Processs (Fig 5B) for our “genes in models”. It can be seen that a high number of 292
modelled genes are involved in molecular functions such as “G-protein 293
beta/gamma-subunit complex binding”, “G-protein beta/gamma-subunit complex 294
binding”, “GTPase activity”, “calmodulin binding”, “3’,5’-cyclic-AMP 295
phosphodiesterase activity”, “high voltage-gated calcium channel activity”, “signal 296
transducer activity” and “calcium-transporting ATPase activity” amongst others. The 297
most common biological processes are “cellular response to glucagon stimulus”, “platelet 298
activation”, “calcium ion transmembrane transport”, and “activation of protein kinase 299
A activity”. 300
A B
Fig 5. GO enrichment analysis results for “genes in models”. A: Molecular
Function ontology terms enriched for “genes in models”. B: Biological Process ontology
terms enriched for “genes in models”. The synaptic proteome was used as a background
dataset. The list of significant terms was obtained with the Fisher’s exact test and the
elim algorithm, followed by Benjamini and Yekutieli multiple testing correction. The
terms shown in clouds scored less than 0.01 p-value after the correction. Font size is
proportional to the term significance.
The identified molecular functions show that genes included in annotated models 301
cover key synaptic processes mainly centred around energy production, synaptic 302
signalling and information transmission. Identified biological processes are slightly more 303
diverse. Fairly generic processes were identified, showing that the set of modelled genes 304
covers these functions in the synapse. More unique processes appear indicating the 305
synapse specific biological processes described by genes in models. 306
Fig 6 shows results of the REACTOME enrichment analysis that identified “G 307
alpha (s) signalling events”, “G alpha (z) signalling events” and “DARPP-32 events” as 308
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the top enriched pathways. The first two terms are parallel to each other on the 309
pathway hierarchy and have a common parent term of “GPCR downstream signalling”. 310
A comparison of the remaining members of this pathway with the enrichment results 311
shows that they are all significantly enriched in terms of our “genes in models”. The 312
identification of signalling pathways highlights a focus of the analysed models indicating 313
the central role of G-protein signalling. 314
Fig 6. REACTOME enrichment analysis results for “genes in models”. The
synaptic proteome was used as background dataset. The list of significant terms was
obtained with the Fisher’s exact test and the elim algorithm, followed by Benjamini and
Yekutieli multiple testing correction. The terms shown in clouds scored less than 0.01
p-value after the correction.
When considering genes annotated with common diseases, Fig 7A shows a significant 315
enrichment of schizophrenia associated genes in the set of “genes in models”, followed 316
by bipolar disorder, Huntington’s disease and Alzheimer’s disease. The order of results 317
is slightly rearranged when considering the whole cell as a background dataset (Fig 7B). 318
For instance, Alzheimer’s disease becomes more prominent, showing the second highest 319
significance for enrichment in our dataset of interest. On the other hand, bipolar 320
disorders drops down the list to the fifth position and autistic disorder appears in the 321
results. This shows how different diseases not only affect specific tissues but can affect a 322
larger number of body regions inducing their effect. 323
Modelled genes and their overlap with disease genes 324
Based on the preceding enrichment analyses we wanted to test for specific associations 325
of modelled genes with disease. Since synapses play a crucial role in signal transduction 326
and are affected in many neurological diseases, these were addressed in more detail. We 327
picked seven representative examples of neurological disorders, 6 of which were based on 328
a list published by the Genes 2 Cognition online initiative: Attention Deficit 329
Hyperactivity Disorder (ADHD), Alzheimer’s Disease (AD), Autism, Bipolar Disorder 330
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Fig 7. DO enrichment analysis results of “genes in models”. Two background
datasets were used: synaptic proteome (A) and all human protein coding genes (B).
The list of significant terms was obtained with the Fisher’s exact test and the elim
algorithm, followed by Benjamini and Yekutieli multiple testing correction. The terms
shown in clouds scored less than 0.01 p-value after the correction.
(BD), Depression and Schizophrenia. The seventh example was Parkinson’s Disease 331
(PD), motivated by our research interests. The list is a representative rather than 332
exhaustive sample of diseases affecting synapses, including diseases of mental health, 333
developmental disorders, as well as diseases of anatomical entity, such as 334
neurodegenerative diseases. Table 5 gives the DO identifiers and short descriptions of 335
each disease. 336
Table 5. Diseases of Interest and short descriptions.
Disease DOID Description
Alzheimer’s Disease (AD) DOID:10652 Tauopathy, characterized by memory lapses, emotional instability
and progressive loss of mental ability. It results in progressive
memory loss, impaired thinking, changes in personality and mood,
up to profound decline in cognitive and physical functioning.
Attention Deficit Hyperac-
tivity Disorder (ADHD)
DOID:1094 Specific developmental disorder, characterized by co-existence of
attentional problems and hyperactivity.
Autistic Disorder DOID:12849 An autism spectrum disorder, characterized by symptoms across
three symptom domains (communication, social, restricted repeti-
tive interests and behaviors) and delayed language development.




DOID:1470 An endogenous depression that is characterized by an all-
encompassing low mood accompanied by low self-esteem, and by
loss of interest or pleasure in normally enjoyable activities.
Parkinson’s Disease (PD) DOID:14330 Synucleinopathy, based on the degeneration of the central nervous
system that often impairs motor skills, speech, and other functions.
Schizophrenia DOID:5419 Psychotic disorder, characterized by a disintegration of thought
processes and of emotional responsiveness.
Onto Suite Miner [70] was used to obtain all genes linked to the DO IDs from the 337
databases supplying gene–disease association information (GeneRIF, OMIM and 338
EnsemblVariation). The various databases have different approaches to disease-gene 339
annotations. EnsemblVariation relies on genetic mutations (mostly Single Nucleotide 340
Polymorphisms, SNPs), whereas OMIM and GeneRIF contain curated text annotations 341
describing disease–gene associations from which data can be extracted using text-mining 342
tools. The different sources were considered individually and jointly. All results refer to 343
the full set of disease associated genes irrespective of the original data source. The 344
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number of genes linked to each of the diseases can be seen in the “Disease Genes” row 345
in Table 6. 346
Table 6. Overlap of modelled and disease genes.









Disease Genes 1511 665 575 1140 616 620 1844
Disease Genes in the Synapse 645 (43%) 233 (35%) 255 (44%) 379 (33%) 202 (33%) 262 (42%) 828 (45%)
Disease Genes in Synapse and
in modelled Genes








Overlap of modelled and disease genes and their presence in the synapse and our modelled gene set. Disease information is
based on GeneRif, OMIM and EnsemblVariation database data. “AD” stands for Alzheimer’s Disease, “ADHD” for Attention
Deficit Hyperactivity Disorder and “PD” for Parkinson’s Disease. Numbers in brackets refer to the percentages. Percentages
in the “Disease Genes in the Synapse” column are relative to the total of “Disease Genes” and “Disease Genes in Synapse and
in Modelled Genes” is relative to the number of “Disease Genes in Synapse”.
Since not all disease genes are expressed in the synapse, we used the synaptic 347
proteome (see Comparison with proteomic data) to filter the disease associated genes 348
for genes that are expressed in the synapse (see the “Disease genes in the synapse” row, 349
Table 6). Since almost all modelled genes are expressed in the synapse we only present 350
numbers describing the overlap between disease proteins found in the synapse and 351
modelled genes (see the “Disease Genes in Synapse and in Modelled Genes” row, 352
Table 6). 353
The number of genes associated with diseases varies over a threefold range, from 575 354
for autistic disorder to 1844 for schizophrenia. However, the proportions of genes 355
associated with a disease and expressed in the synapse range between 33% (Bipolar 356
Disorder and Major Depressive Disorder) and 45% (Schizophrenia). The number of 357
overlapping modelled genes and disease-associated genes (in the synapse) varies between 358
diseases. Schizophrenia has the highest net overlap (92 genes), but also shows the 359
highest number of total associated genes (1844). In total, between 6.1% (Parkinson’s 360
Disease) and 11.8% (Autistic Disorder) of disease genes associated with any of the 361
selected diseases expressed in the synapse appeared in at least one model. 362
If a gene is associated with many neurodegenerative diseases, its overall function is 363
likely to be generic, leading to a synaptic dysfunction that is not specific to a certain 364
disease. Including such genes in models might explain mechanisms underlying multiple 365
diseases but will not help to model specific diseases. We therefore searched for synaptic 366
genes common to a number of diseases. Table 7 shows the 32 synaptic genes linked to 367
three or more of the diseases included in the analysis. Seven genes are associated to six 368
or all seven tested diseases. The top coverage disease associated genes, found in models 369
annotated, include the protein family voltage-dependent calcium channel family 370
CACNA1C and CACNB2 and dopamine D1 and D2 receptors (DRD1, DRD2 ), the 371
inotropic glutamate NMDA receptors, type subunit 2A and 2B (GRIN2A, GRIN2B) as 372
well as the glutamate metabotropic receptor 5 (GRM5). Of the set of modelled genes, 373
130 (around 50% of the total) are not associated with any of the seven diseases. 374
In summary, the fraction of genes modelled is relatively small and might indicate 375
that it is challenging to use existing models to make disease predictions. On the other 376
hand the modelled genes can be starting points to extend models to obtain better 377
disease insights, as will be considered in the Discussion (Approaches to including 378
non-modelled disease genes in models). 379
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Table 7. Modelled genes associated with three or more of the selected diseases.










CACNA1C, DRD2, GRIN2A, GRIN2B 1 1 1 1 1 1 1
GRM5 1 1 1 1 0 1 1
CACNB2, DRD1 1 1 1 1 1 1 0
HOMER1 0 1 1 0 1 1 1
CACNA1S, GRM7 1 0 1 1 1 1 0
NOS1 1 1 0 1 0 1 1
GNB3, GRM2 0 1 0 1 1 1 0
GRIA2 0 1 1 0 1 1 0
GNAL 1 0 0 1 1 1 0
PLA2G6 0 0 0 1 0 1 1
ATP2A3, CACNA2D1, GRM3 0 0 0 1 1 1 0
GRIK2, GRM8, GRIP1, PPP1R1B 0 0 1 1 0 1 0
DLG4, NRGN 0 1 0 0 0 1 1
GRIA4 0 1 0 0 1 1 0
FYN, GRIA1, GRIN1, GRM1, GNB2L1 0 1 0 1 0 1 0
SHANK3 1 0 1 0 0 1 0
The number in each cell indicates whether the genes in the Gene Names column are associated (1) or not associated (0) with
the diseases indicated in the column headings.
Family trees of entities 380
Our identification of entities in models makes it possible to query in which models a 381
particular entity is contained. The mapping of entities to genes allows querying models 382
by genes that are, or may be, modelled. It is also desirable to query models by families 383
of molecules, such as PDE4. For example Gutierrez-Arenas et al. [22] and Nair et 384
al. [33] include PDE4A, whereas Kim et al. [26] and Oliveira et al. [16] include PDE4B 385
in their models, and Kim et al. [25] and Qi et al. [37] specify PDE4. 386
To enable query by class or family, we determined 29 hierarchical family trees of 387
“proteins”, “protein families” and “protein multimers” implied by the sets of genes 388
corresponding to each (Fig 8). Each “protein family” or “protein multimer” entity is 389
the parent to one or more “proteins” or “protein families”. Each child corresponds to a 390
subset of the proteins in the parent. Tree structures were generated for all “protein 391
multimers” and for “protein families” where a member of that family has been modelled 392
explicitly in at least one of our analysed models. This meant that, for example, PP1 is 393
not represented, since none of its children PPP1CA, PPP1CB and PPP1CC appear in 394
any model explicitly. Individual proteins appear only if they are part of a family or 395
multimer, and they appear in a model – thus, for example, GRIA4 and GRIN3 do not 396
appear. Proteins that do not belong to a family, e.g. PSD95 (DLG4 ), are not shown. 397
Any entity that is part of a family can be mapped to the root node of its tree. 398
Entities that do not belong to a family are implicitly their own root. This mapping of 399
“entities to entity families” (Fig 1) can be applied to the model-entity catalogue (Fig 2) 400
to give the simplified summary mapping of models to 104 family roots shown in Fig 9. 401
This facilitates comparison of entities across models trying to address the differences in 402










































































Fig 8. Family trees of “protein families” and “protein multimers”. “Proteins” are shown in italics; “protein
families” and “protein multimers” in roman. “Proteins” that do not belong to any family are not shown. Only proteins that
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Fig 9. Summary mapping of entities in models. The occurrence of a root entity
in a model is indicated by open circles. Lower-level entities are folded into their root
entity.
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Frequency of modelling 404
Table 8. Numbers of entities or entity families found in models.
Entity family Models Frequency % Frequency
2AG, actin, ACTN, Adn, AKAP, AKAR3, CaMKIV, CaMKK,
cGMP, CHRM4, cortactin, CRH, CRHR, CSK, DAGL, DGK, DNM,
GKAP, GRIK2, Homer, IRSP53, KALRN, LYN, NO, NOS, PAK1,
PEBP1, PICK1, PSD93, PSD95, PTPN11, PTPRA, RAC1, RAC2,
RACK1, RAP1GAP, RHOC, RHOG, SAP102, Shank, SHC, SOS,
Spectrin, SRC, STEP, SYNGAP1
1 46 47.4
APC, CK1, FYN, GRB2, IP3R, PI3K, PIP2, PVALB, RASA1,
RASGRF, SAP97, SERCA
2 12 12.4
AA, DAG, GRIP1, Mg, Ng, RAS, VGCC 3 7 7.2
CDK5, DUSP, Glu, GTP, IP3, PLA2 4 6 6.2
DA, DRD, mGluR, NCX, PLC, PMCA 5 6 6.2
CB, NMDAR 6 2 2.1
ATP, MAP2K, MAPK, Raf 7 4 4.1
cAMP, Gabg, PKC, PP2 9 4 4.1
AC 10 1 1.0
AMPAR, PDE 12 2 2.1
PPP1R 14 1 1.0
PKA 15 1 1.0
PP1 16 1 1.0
PP3 17 1 1.0
CaM 18 1 1.0
CaMKII 22 1 1.0
Ca 23 1 1.0
“Models” is the number of models containing the entity or at least one member of the family. “Frequency” is the number of
appearances of the family or entity in the given number of models, and “% Frequnecy” is the frequency expressed as a
percentage.
To give an indication of which are the frequently modelled entities and families of 405
entities, we determined the number of models in which each of the root entities in Fig 10 406
appears (Table 8). About 50% of root entities appear only in one model. In total, 26 407
(about 25%) of the entity roots were included in five models or more. The three most 408
frequently modelled entities and families are CaM, CaMKII and Ca, which are included 409
in 18, 22 and 23 out of 30 analysed models respectively. This is due to a number of 410
models focusing specifically on the Ca2+–CaM–CaMKII pathway or including it as a 411
model part, reflecting the central role of phosphorylation of CaMKII by Ca2+-bound 412
CaM in synaptic biology. These top coverage families are followed by families such as 413
calcineurin (PP3) and protein phosphatase 1 (PP1), cAMP-dependent protein 414
kinase (PKA) and PPP1R (the receptor subunit of PP1), which are included in the 415
models that model dephosphorylation of CaMKII via the Ca2+–PP3–I1–PP1 pathway. 416
Receptor related families such as AMPAR appear with lower frequency, reflecting the 417
fact that, while crucial for synaptic physiology, not all models include them as a readout 418
mechanism for LTP and LTD. Even though our coverage of models is not complete, it 419
seems likely that cataloguing further models will not change the order much. 420
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Comparing models based on their entities 421
Having annotated the models with entities enabled us to compare models with each 422
other by applying a hierarchical clustering approach to the model-entity root mapping 423
(Fig 9). Ward’s 2D method, as implemented in R’s hclust function was used to give the 424
dendrogram shown in Fig 10. The dendrogram splits into 4 clusters, each of which 425
contains a majority of models from one brain region (cerebellum, hippocampus, 426
striatum) or contains only a generic model. 427
Gutierrez−Arenas et al. (2014)
Nakano et al. (2010)
Nair et al. (2015)
Qi et al. (2010)
Oliveira et al. (2010)
Kim et al. (2010)
Kötter (1994)
Oliveira et al. (2012)
Castellani et al. (2005)
Kim et al. (2011)
Sorokina et al. (2011)
Zhabotinsky et al. (2006)
Mattioni and Le Novère (2013)
Graupner and Brunel (2007)
Li et al. (2012)
Smolen et al. (2006)
Smolen et al. (2012)
Castellani et al. (2001)
Hernjak et al. (2005)
Zeng and Holmes (2010)
Stefan et al. (2008)
Byrne et al. (2009)
Pepke et al. (2010)
Khan et al. (2011)
Miller et al. (2005)
Antunes and De Schutter (2012)
Antunes et al. (2016)
Bhalla and Iyengar (1999)
Kim et al. (2013)
Kuroda et al. (2001)
Fig 10. Clustering of the model-entity family root matrix. Clustering of the matrix in Fig 9 as implemented in R’s
hclust function with the Ward.2D method. The colour of the citation indicates the brain region modelled: hippocampus
(blue), striatum (red), cerebellum (olive), generic (black). Clusters referred to in the text are indicated by the circled numbers.
The cluster labelled 1 is dominated by 3 cerebellar models [17,18,29] (olive text), 428
and also contains the hippocampal model (blue text) of Bhalla and Iyengar [14] and the 429
striatal model (red text) of Kim et al. [27]. It can be seen in the matrix of root entities 430
(Fig 9) that distinctive proteins and families in this cluster are PKC (shared by all 5 431
models), PLA2 (in 4 of 5 models), DAG and PMCA (in 3 of 5 models), and the 432
Raf–MAP2K–MAPK pathway (4 of 5 models). 433
Most of the 14 models belonging to cluster 2 are hippocampal (7) or generic (5), 434
along with the cerebellar model of Hernjak et al. (2005) [23] and the striatal model of 435
Mattioni and Le Novère [31]. Three models (Byrne et al. [19], Pepke et al. [36] and 436
Stefan et al. [41]) are clustered together as they all contain the identical set of entities: 437
Ca, CaM and CaMKII. The closely related model of Zeng and Holmes [42] includes 438
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calbindin (CB) as well, and the closely related models of Miller et al. [32] and Khan et 439
al. [24] are also centred on CaMKII. The related models of Smolen et al. (2006) [38] and 440
Smolen et al. (2012) [39] feature the MAPK pathway, in addition to CaMKII. The 441
group of models containing Li et al. [30], Graupner and Brunel [21], and Zhabotinsky et 442
al. [43] are all variations on the CaMKII phosphorylation-dephosphorylation circuit, all 443
adding PP1 and PP3 (calcineurin) to the Ca2+–CaM–CaMKII pathway. 444
The sole member of cluster 3, the model of Sorokina et al. [40], is dissimilar to other 445
models, reflecting the large number of entities, particularly scaffolding proteins, which 446
are contained in this model but not in others. 447
Cluster 4 mostly contains striatal models [22,25, 26,33, 34,37], with the exceptions of 448
the generic model of Castellani et al. [15] and the hippocampal models of Kim et 449
al. [25, 26]. These models are some of the few non-striatal models to contain the 450
adenylate cyclase (AC)–cyclic adenosine monophosphate (cAMP)–PKA pathway as well 451
as hydrolisation of cAMP to adenosine monophosphate (AMP) by 452
phosphodiesterase (PDE). Dopamine and G-coupled protein receptors also feature in 453
this cluster. 454
The bias of each cluster towards a particular brain region indicates that the 455
clustering is meaningful. However, the bias may arise more from choices modellers have 456
made about which pathways to include in models of the various regions. For example, 457
dopamine receptors are included in most striatal models and are only included in a few 458
hippocampal models. Nevertheless, the clustering provides a different view of the 459
landscape of models, and could be used to identify models with similar composition, 460
whose behaviour it might be insightful to compare. We also applied the clustering to 461
the full model-entity matrix (Fig 2), with similar results, though slightly less meaningful 462
groupings. 463
Approaches to including non-modelled disease genes in models 464
Knowing which disease associated genes are included in models helps models with high 465
potential to explain disease impact on the synapse to be identified (Modelled genes and 466
their overlap with disease genes). It also allows us to identify disease associated proteins 467
which do not appear in the models we analysed. Of all disease associated genes, 1,248 468
are found in the synaptic proteome but not in any of the analysed models. Table 9 469
shows the 32 genes that are associated with 5, 6 or all 7 diseases, and which do not 470
appear in any of the investigated models. Of these, COMT and SLC6A3 are associated 471
with all 7 diseases of interest. Since these genes are associated with all or many studied 472
diseases, they could be of interest when it comes to gaining a better understanding of 473
generic disease dysfunctions. 474
Supporting the idea that genes implicated in many diseases could be potentially 475
targets for modelling, we identified two genes, COMT and MAOA, that have been 476
included in metabolic models [71,72]. Functionally, the catechol O-methyltransferase 477
(COMT ) degrades catechols, such as dopamine, by catalysing their methylation. This 478
methylation results in one of the major degradative pathways of the catecholamine 479
transmitters [73]. Dopamine is included in a number of analysed models [74,75], and it 480
could be possible to explore what happens in these models if there is an excess of 481
dopamine due to COMT malfunction. 482
Genes associated with all studied diseases could represent generic disease 483
mechanisms, in which case exploring the role of COMT in dopaminergic models would 484
indicate the possible influence of the gene in many diseases. An alternative approach is 485
to consider disease specific genes not appearing in models and associated with only one 486
of the selected diseases. Integrating such proteins into pre-existing models could thus 487
help to gain disease-specific insights. 824 of the disease associated genes are specific to 488
one disease only. To identify genes that can be integrated into existing models, the list 489
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Table 9. Disease associated genes not appearing in any of the annotated models.










COMT, SLC6A3 1 1 1 1 1 1 1
GIGYF2 1 0 1 1 1 1 1
GSK3B, ABCB1 1 1 0 1 1 1 1
ANK3, ENO1, KIF5C, MAOA, PRNP,
SLC17A6, CSMD1
1 1 1 1 1 0 1
ACE, GAD1 0 1 1 1 1 1 0
DDC, FMR1 1 0 1 1 0 1 1
APAF1, DFNA5, ELAVL2, GRIK1, HINT1,
ITIH1, ITIH3, ITIH4, STT3A, LIG4, ND-
UFAB1, NDUFB7, NPY, NTRK3, GATB,
SMARCA2, MAD1L1, PRPF3, SH3PXD2A,
TRANK1, PPIF, NT5C2, KIF21B, RPRD2,
SYNE1, NGEF, TENM4, GNL3, MPP6,
MRPS21, RAB39A, CNNM2, OXR1, ANKS1B,
VARS2, AS3MT, PALB2, DCTN5, PPP1R21,
MTPN, SLC39A12, CHSY3
1 0 1 1 1 0 1
CNR1 1 1 0 0 1 1 1
YWHAZ 1 1 1 0 0 1 1
SNAP25 1 1 1 0 1 0 1
CNTNAP2 1 1 1 1 0 0 1
The number in each cell indicates whether the genes in the Gene Names column are associated (1) or not associated (0) with
the diseases indicated in the column headings. The table only lists genes that are associated with four or more diseases.
of non-modelled disease associated genes was compared with genes in pathways enriched 490
in the modelled genes. 491
For example, all disease genes unique to Schizophrenia were compared with the list 492
of genes in pathways significantly enriched in the modelled genes, giving a list of 8 493
genes, each of which is found in one or more pathways (Table 10). One of these genes is 494
LAMTOR2. The LAMTOR2:LAMTOR3 complex binds MAPK components [76], 495
together with other members of the mitogen-activated protein kinase kinase (MAP2K) 496
and mitogen-activated protein kinase (MAPK) activation pathway, such as RAF1, 497
MAPK1, MAPK3 and MAP2K2. In this role it contributes to the activation of the 498
MAPK pathway which has a central role in striatal and cerebellar synapses. Including 499
the influence of LAMTOR2 on the activity of MAPK in a pre-existing model could 500
hence help to better understand its role in and effects on schizophrenia. Integrating 501
LAMTOR2 activity in the model could be done mechanistically, or functionally, for 502
example by influencing the MAPK concentration. 503
Discussion 504
We have developed a catalogue of genes whose corresponding proteins correspond to 505
entities in computational models of synaptic plasticity. To achieve this we developed a 506
new set of standard identifiers for entities in computational models, and mapped those 507
entities corresponding to proteins and protein families onto genes. Although time and 508
lack of machine-readable model descriptions constrained the number of models we could 509
analyse, by selecting models from three brain regions (hippocampus, striatum and 510
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Table 10. Schizophrenia specific genes not found in models and appearing in pathways that are enriched in
annotated models.
Gene Name Gene Name (long) REACTOME pathway Pathway ID





MAP2K and MAPK activation, FCERI
mediated MAPK activation, VEGFR2 me-






PSMB1 proteasome subunit beta
1
FCERI mediated MAPK activation,





PSMB4 proteasome subunit beta
4
FCERI mediated MAPK activation,





PSMC1 proteasome 26S subunit
and ATPase 1
FCERI mediated MAPK activation,





PSMC4 proteasome 26S subunit
and ATPase 4
FCERI mediated MAPK activation,





PSMD2 proteasome 26S subunit
and non-ATPase 2 and
FCERI mediated MAPK activation,





TUBB3 tubulin beta 3 class III Chaperonin-mediated protein folding R-HSA-390466
cerebellum) we are confident that we have covered the bulk of proteins in models. 511
We were able to identify 294 genes that could be mapped to entities in 512
computational models. This corresponds to 4.2% of the 6,706 known genes in the 513
synaptic proteome. Enrichment analysis showed that, compared to the set of proteins 514
found in the synapse, the genes in models tended to have more signalling functions, 515
which reflects the focus on signalling pathways in such models. This suggests 516
considerable scope for including new molecules in models. However, models of synapses 517
at the molecular level are already complex and are beset by problems of determining 518
parameters. One strategy to prioritise molecules to add to models is to chose those most 519
relevant for disease. Our comparison of the list of genes in models with databases of 520
gene-disease association shows that many disease-associated genes are not currently 521
included in synaptic models, and suggests targets for future modelling. 522
Targeting disease-relevant proteins for modelling 523
The genes in models are more associated with neurological diseases, such as 524
Schizophrenia, Alzheimer’s, Huntington’s disease and bipolar disorder, than randomly 525
selected genes in the synaptic proteome or the whole genome. Nevertheless, depending 526
on the disease, the number of disease-associated genes included in models range between 527
6% and 12% of the disease-associated genes in the synapse. This suggests that there is 528
considerable potential to include disease-related genes in models. Including these 529
molecules could make these models more useful in helping elucidate disease mechanisms 530
and helping to identify new drug targets. 531
We identified two un-modelled genes associated with 7 neurological diseases, COMT 532
and MAOA and we found they have close functional links with existing models. By 533
incorporating pathway enrichment results, we identified LAMTOR, a gene uniquely 534
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associated with Schizophrenia. LAMTOR is linked to the MAPK pathway, which 535
features in a number of existing models. This demonstrates the utility of our approach 536
for identifying which proteins to incorporate in existing models so that they can make 537
disease-associated predictions. Further investigation using this approach could indicate 538
other target proteins to add to existing synaptic pathway models to make them more 539
informative about the influence of diseases on the synapse. 540
A new ontology for computational neuroscience models 541
The challenge we faced mapping model entities to genes highlighted a gap between 542
bioinformatics, where each gene is well-defined and has a commonly used identifier, and 543
computational neuroscience, where the elements of models are defined at varying levels 544
of precision: for example they may be proteins, protein families or multimers of proteins. 545
Even within the same model, one element may be specified precisely, for example a 546
particular isoform (PKMζ), and another element may be generic, for example 547
“plasticity related proteins” [39]. From a bioinformatics perspective this may seem 548
offensive, but from the viewpoint of computational neuroscience it is entirely valid: a 549
computational model can be seen as a means to reasoning about a hypothesis; the 550
formulation of the model is the hypothesis and the simulations embody the reasoning 551
that generates the predictions arising from the hypothesis [77]. The modelling process 552
sometimes even requires hypothetical elements, which have no existing identifier. For 553
example, one seminal computational neuroscience model [78] contained hypothetical 554
elements (“gating particles”) that predicted essential features of ion channels function. 555
The problem of mapping model constituents onto biological entities was noted by the 556
originators of the MIRIAM standard [49]. This standard suggests solving the problem 557
of mapping entities at different levels of abstraction by using a “HasVersion” qualifier to 558
map reactants in models to multiple entities, e.g. to map IP3R to Inositol 559
1,4,5-triphosphate receoptors type 1, 2 and 3. Most of the models we investigated had 560
not been annotated to MIRIAM standards, and we found it more efficient to define our 561
own ontology containing proteins and protein families. We found that existing 562
ontologies such as UniProt, HGNC gene families [79] and Neurolex [80] were not 563
extensive enough to map proteins specified at different levels of precision (e.g. PDE4A, 564
PDE4) to common families (e.g. PDE), though HGNC gene families covered about half 565
of the protein families we identified. 566
In the absence of a suitable ontology, we used HGNC gene families and curated other 567
family relationships manually to give a full list of entities (see S2 Table) and mappings 568
of proteins to families and multimers in which they occur (see S3 Table and S4 Table). 569
These tables form the kernel of an ontology, and we have demonstrated that it can be 570
used to determine the potential genes underlying the proteins in computational models, 571
and to cross-link these genes with expression data. Furthermore, we have demonstrated 572
that the ontology can be used to compare models, for example using hierarchical 573
clustering, and to summarise of how often various protein families have been modelled. 574
By annotating models with identifiers of brain region or neuron type, the set of possible 575
proteins belonging to a model could be narrowed down according to the genes that are 576
expressed in a given region. The same procedure could be used to link the genetic 577
content of synaptic models with other types of data, for example spatial expression data 578
from the Allen Brain atlas. This would make it possible to check that a particular 579
model was valid in the brain region it is supposed to represent, or, conversely, could be 580
used to find brain regions for which a particular model might be valid. 581
The number of models analysed in this paper was limited by the time it took us to 582
annotate models we had not constructed. While some repositories, such as the curated 583
branch of BioModels, enforce curation of models to MIRIAM standards [49], it would be 584
desirable for all models to be annotated consistently at the time of publication or 585
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deposition in a repository. Annotation would be a fairly quick process for authors 586
familiar with the models, and the quality of the information would be higher than if 587
annotated by third parties. Three of the 30 models we investigated were annotated to 588
MIRIAM standards. We did not use the MIRIAM annotations of these models, partly so 589
that our annotation of models was consistent and partly because the MIRIAM standard 590
suggests mapping to external identifiers that are often at a finer level of granularity 591
than we needed to compare models to proteomic data. Were more models curated to 592
MIRIAM standards, it would be worthwhile developing a mapping to our identifiers. 593
As discussed above, some models are of necessity not precise about which protein is 594
specified. To address this, one option would be for the computational neuroscience and 595
bioinformatics communities to adopt an ontology along the lines of the ones we have 596
generated here. If the ontology were stored in the Interlex dynamic lexicon of 597
biomedical terms, a development of Neurolex [80], it would be straightforward for 598
authors to suggest new terms or relationships. The model metadata could be stored by 599
adding fields to existing repository schema, or our data could be converted to a 600
standalone, API-enabled database. 601
Nomenclature 602
The nomenclature we have used for entities has been decided by the authors. We have 603
been guided by gene names, and some of our choices might be controversial, for example 604
naming PP2B (calcineurin) PP3. Our rationale for using identifiers related to gene 605
names is so there is more consistency between the names of members in a family. For 606
example, in Fig 8, PP3 is the parent of the catalytic and regulatory subunits PPP3C 607
and PPP3R; having PP2B as a parent would not be equally consistent. It would be 608
desirable for the computational neuroscience and bioinformatics communities to agree a 609
common nomenclature. 610
New directions in modelling 611
We have demonstrated the potential of our method of identifying entities in models and 612
mapping them to genes to suggest new, disease-relevant directions for modelling. We 613
believe there is considerable potential for the work to be adopted to suit the needs of 614
the community. Our data and mapping tables and code to reproduce the results in this 615
paper are available (S1 File) and suggestions for additions or amendments are welcome. 616
[We will also be making our files available via github.] 617
More speculatively, despite the challenge of expanding the number and relevant 618
proteins in models of synaptic plasticity, we believe that the time has come to 619
incrementally increase the number of proteins involved in models, especially those 620
involved in disease mechanisms. 621
Methods 622
Identifying entities in models 623
The question of what entities mean is outlined in Analysis of proteins in synaptic models, 624
subsection Identifying entities in models. The constituent entities of each model were 625
identified by one of the authors (EMW, KFH or DCS) reading the paper, or extracting 626
elements from a machine-readable representation of the model, for example CellML [14] 627
or Kappa [40] descriptions. The name used to identify the entity in the model was then 628
mapped to the standardised list of entities that we built up as we looked through the 629
models. In some cases model entities were not specified enough to allow us to map them 630
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unambiguously onto a model entity – for example “Plasticity Related Protein” [39]. We 631
did not consider a complex as an entity – for example a Ca-CaM-CaMKII complex 632
would give rise to Ca (ion), CaM (“protein”) and CaMKII (“protein multimer”). In 633
naming our standard entities, we have tried to use names commonly used in models, but 634
for entities that have not appeared in many models we have tended to use the newer 635
standard names that appear in the NCBI or UniProt databases. 636
Mapping entities to a unique gene identifier 637
To obtain a common identifier for all entities we searched for an ontology that could be 638
used to identify our entities, especially “protein families” and “protein multimers”. We 639
considered a number of potential ontologies: 640
The Computational Neuroscience Ontology 641
(http://bioportal.bioontology.org/ontologies/CNO) This ontology covers 642
the description of the modelling technique (e.g. Integrate-and-fire neurons) rather 643
than the components of the model. 644
HGNC Gene families (http://www.genenames.org/) The Human Gene 645
Organisation Gene Nomenclature Committee (HGNC) approves unique symbols 646
and names for human genes, and also places genes in families, based on 647
characteristics such as function, homology, domains and phenotype [79]. Placing 648
genes into families is a manual process, often involving specialists who are expert 649
in that family of genes. Often, but not always, genes in the same family have a 650
common root symbol. The process of defining families is ongoing. 651
InterPro protein families (http://www.ebi.ac.uk/interpro) The InterPro 652
Consortium is a federation amalgamating protein signature databases (Gene3D, 653
Conserved Domain Database, HAMAP, PANTHER, Pfam, PIRSF, PRINTS, 654
ProDom, PROSITE, SMART, SUPERFAMILY, Structure-Function Linkage 655
Database and TIGRFAMs) [81]. Protein signatures are predictive models build on 656
fragments of amino acid sequences that share local features (e.g. conservation at 657
different positions) known to be associated with a function or structure [82]. 658
There are multiple computational approaches that are detecting such patterns and 659
define types of signatures [83]. The similarity in signature matches between 660
proteins is used to define a hierarchy of families. 661
Manual NCBI search (www.ncbi.nlm.nih.gov/gene/) The National Center for 662
Biotechnology Information (NCBI) provides access to biomedical and genomic 663
information. We used their searchable database of genes, which can be queried 664
with a number of different identifiers. 665
We intended to map out entities using information supplied by one of these 666
ontologies, but no one source proved sufficient. In InterPro, there are a number of 667
families that correspond exactly to proteins, for example Phospholipase A2 (IPR001211) 668
and Phosphoinositide phospholipase C (IPR001192). However, some proteins, including 669
SOS1 and SOS2, belong to very broad families. 670
In the HGNC database we identified a relatively large number of our entities that 671
correspond to existing HGNC gene families. For example the HGNC Homer family 672
(short for “Homer scaffolding proteins”) comprises the genes HOMER1, HOMER2 and 673
HOMER3 and the genes PPP3CA, PPP3CB, PPP3CC, PPP3R1 and PPP3R2 belong 674
to the HGNC PP3 family. Other entities do not correspond to a single gene family, but 675
can be extracted from the database by selecting multiple families. For example SHANK, 676
by which we mean the family of proteins encoded by SHANK1, SHANK2 and SHANK3 677
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may be selected from the gene families list by selecting all genes that are in the 678
“Ankyrin repeat domain containing” (ANKRD) and “PDZ domain containing” (PDZ) 679
gene families. Some of our entities cannot be recovered by searching for families. For 680
example SOS (by which we mean the proteins encoded by SOS1 and SOS2 ) are in both 681
the “Rho guanine nucleotide exchange factors” and “Pleckstrin homology domain 682
containing” families, but so are 35 other proteins. 683
We also curated our own mappings by manually querying the NCBI portal by 684
searching for human genes matching a full protein name and a common gene prefix, 685
suffix or infix, if available. For example, Entrez IDs for a “protein family” of 686
Voltage-dependent calcium channel were obtained with the following query: 687
‘Voltage-dependent calcium channel[All Fields] AND CACN*[All Fields] AND ”Homo 688
sapiens”[Organism]’. The top 20 results were considered and only entries with the 689
closest description and gene summary to the search term were extracted. 690
Although we were not able to map all our entities by relying on only one ontology, 691
we found that HGNC families covered more of our entities than Interpro, so we used 692
this as a basis for developing an ontology to describe the molecular components of 693
computational neuroscience models. We tried to map all entities of type “protein family” 694
and “protein multimer” to HGNC families. Manual NCBI mappings were used to check 695
and verify that HGNC families represented the modelled group of genes. 696
In situations where we were unable to find a corresponding HGNC family we (1) 697
suggested some protein groups to be added to the list of HGNC families and await 698
approval of the request; (2) we had no choice but to fall back on our manual NCBI 699
mapping. The combination of the above lead us to our final mappings. S3 Table and S4 700
Table show identified HGNC families as well as the genes belonging to them. The 701
superscript given with the HGNC family name indicates its origin, the official HGNC 702
mapping vs. custom mapping. The columns “IN SYNAPSE” and “OUT SYNAPSE” 703
are explained in Analysis of proteins in synaptic models, Comparison with proteomic 704
data. 705
Enrichment Analysis 706
A commonly used method to find statistically significant commonalities between large 707
gene lists is enrichment analysis, also known as over-representation analysis. Based on 708
information contained in ontological databases, enrichment analysis can show if a set of 709
“genes of interest” contains a significantly high number of genes with the same 710
annotation. This approach allows us to gain a better understanding of underlying 711
common themes in our “genes in models” list. 712
The underlying principle of such an enrichment analysis is to estimate, for each 713
specific category annotated in the database of interest, if the number of genes in our 714
genes of interest set associated with a certain category is larger than expected by chance. 715
To test this relationship statistically, the hypergeometric distribution or one-tailed 716
Fisher’s exact test is commonly applied. Both are known to be equivalent [84]. 717
The four key numbers required to carry out the statistical calculations are: 718
1. The number of elements in the full dataset, also considered as the background 719
dataset, N . In our case these are all proteins part of the synaptic proteome. 720
2. The number of elements n in the subset of the full dataset which is tested for 721
enrichment. This is the number of genes in the “genes in models” list. 722
3. The number of elements associated to a certain trait in the full dataset, T . It 723
corresponds to the set of genes annotated to any term in one of the databases, e.g. 724
“Schizophrenia”, which describes a disease in the DO database. 725
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4. The subset of n shared by the elements found in T , denoted as t. This refers to 726
the number of genes within a category that are also present in our “genes in 727
models” list. 728
The probability of encountering the exact number of hits t of interest given N , n and T 729
is calculated with the hypergeometric probability h(t;N,n, T ): 730












To describe the probability of finding greater than or equal to the number of items of 731
interest t, we use the cumulative hypergeometric probability: 732
p(t;N,n, T ) =
T∑
x=t














If this probability is less than a criterion (e.g. p < 0.01), the dataset is regarded as 733
enriched [84] for the tested category. 734
For the analysis, ontology terms for all genes in the background dataset N were 735
obtained. Initially two background sets were considered, containing (1) all genes in the 736
genome and (2) all proteins found in the synapse. Since results were quite similar and 737
the focus of this study is on the synaptic region rather than the whole organism, we 738
only present results obtained with the second dataset as the background set of genes. 739
We analysed all terms that had at least one gene associated to our “genes in models”. 740
For each such term, the p-value was calculated, indicating potential enrichment, and 741
then corrected for multiple comparison, using the Benjamini and Yekutieli [85] method. 742
Terms with adjusted p-values smaller than 0.01 are presented in the final results. 743
topONTO and topGO 744
Ontologies that supply functional annotation information are organised in a hierarchical 745
structure, with the most generic terms at the top, and the most specific ones at the 746
bottom. The higher the term is located in the hierarchy, the more genes are associated 747
with it as it aggregates all genes from its child terms. Hence, a single gene can be found 748
at different levels of annotation specificity. Depending on the purpose of the analysis it 749
is important to be able to choose the level of retrieved terms. 750
To retrieve the most specific and refined terms among significantly enriched ones, we 751
used an algorithm proposed by Alexa et al. [86] and implemented for the GO database 752
by the R topGO package. Since GO is represented as a Directed Acyclic Graph (DAG), 753
the authors incorporated the underlying GO graph topology in the term scoring 754
approach, removing strong correlations commonly occurring between high level terms. 755
This allows the enrichment of a very generic term to be ignored, and less frequent but 756
more specific and potentially more interesting low level ones to be identified. 757
Assuming that a child term is potentially more interesting than its more generic 758
ancestors, significance of a term is calculated depending on its child terms. Out of 759
multiple versions implementing this idea, we used the elim algorithm paired with 760
Fisher’s exact test. The decision was based on the clear number of comparisons 761
conducted by the algorithm. This number was further used to correct for the false 762
discovery rate. 763
In the elim approach [86], enrichment analysis starts at the bottom of the ontology 764
graph. If a child term is significantly enriched amongst the genes of interest, this 765
influences the number of genes annotated with its ancestor terms. All genes associated 766
with the enriched child term are removed from the ancestor terms leaving most specific 767
ones with the minimal indicated significance. 768
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We discovered that the algorithm leads to more refined results than a set-based 769
enrichment analysis that ignores the ontology structure. Therefore, we were interested 770
in applying a same approach to other gene annotation sets. This can be achieved with 771
the topOnto R package [69]. It extends the advantage of the Alexa et al. method [86] to 772
any hierarchically structured dataset. Since both REACTOME and DO satisfy this 773
requirement, we were able to apply the same approach to all chosen annotation sets. 774
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